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ABSTRACT 
Immunological stressors, in the form of clinical and sub-clinical disease are currently 
controlled using both prophylactic antibiotics in-feed, and therapeutic antibiotic 
treatment.  Respiratory disease, primarily Actinobacillus pleuropneumoniae (App) 
infection, is recognised as a major factor causing reduced productivity in pigs.  This 
thesis reports investigations into the use of novel immunomodulators in particular 
Interleukin 4 (IL-4) and Interleukin 1 receptor antagonist (IL-1ra) as alternatives to 
antibiotics to treat App infection. Immunological and molecular biological assays 
were used to investigate and accumulate data.  An in vitro study undertaken to find 
potential anti-inflammatory substances, revealed that Interleukin 8 (IL-8) mRNA 
production stimulated by PMA or LPS in whole pigs’ blood was suppressed by IL-4.  
IL-1ra also suppressed stimulated IL-8 mRNA production by heat killed App bacteria 
(KB) in vitro.  An acute LPS challenge in pigs in vivo however, showed no variation 
in illness or weight loss between pigs treated prophylactically with anti-inflammatory 
substance (IL-4 and IL-1ra) and saline treated pigs.  The use of plasmids as a delivery 
system for anti-inflammatory substance did not show promise since it did not enhance 
growth or prolong the expression of the substances in the pigs.  However, in the 
chronic App challenge model IL-4 and IL-1ra administered prophylactically in vivo 
showed an ability to improve growth.  The therapeutic administration of IL-4 and IL-
1ra to App challenged pigs showed no difference in pigs’ growth, regardless of the 
treatment or control administered.  To conclude, IL-4 and IL-1ra showed promise 
when administered prophylactically and improved growth and abrogated disease 
under conditions of App challenge. However when IL-4 and IL-1ra where 
administered therapeutically they did not perform as well. Moreover these compounds 
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have potential as a commercial application to reduce the growth reduction caused by 
disease such as App. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1  Introduction 
What is stress? Stress is defined as “a disturbing physiological or psychological 
influence which produces a state of severe tension in an individual” (Macquarie 
Dictionary, 1998). 
The effects of stress can manifest as a range of illnesses such as increased 
susceptibility, infection, eating disorders and mental breakdown (Bartrop et al., 1977).  
Furthermore, Solomons et al., (1993) implicated environmental stress, particularly 
that caused by recurring infections, in the poor growth rates of children in 
underdeveloped countries and their inability to reach genetic adult stature. 
Stress can be referred to as physiological or psychological disturbances, which can 
originate primarily from the environment.  In this Chapter the environmental stress 
factors that reduce growth in animals (pigs) will be examined, this will aim to give 
some perspective on the relationship between different types of stress factors and their 
influence on growth.  In particular the immunological mechanisms of infection and 
methods of reducing its inhibiting effect on growth will be examined. 
Chapter 1 examines the relationship of different environmental stress factors and their 
influence on growth in pigs. 
1.2  Stress and its impact on growth 
Previous studies have shown that stress factors, which have a deleterious effect on 
growth and/or health, are mainly environmental. The most significant environmental 
factors relating to pigs are group housing (Hyun et al., 1998),  
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temperature and climate changes (Scheepens et al., 1994), air quality (Torremorell et 
al., 1997) and infection (Bartrop et al., 1977; Perez et al., 1995; Solomons et al., 
1993). 
1.2.1  Group housing 
Group housing (an environmental stress) is a consequence of the industrialisation of 
animal production.  In recent years, pigs have been penned from weaning to market 
weight in groups of 10-30 (McGlone et al., 1994).  However the escalating pressure to 
increase the output of stock has caused pig group sizes to increase 50, 100 or even 
more (McGlone et al., 1994).  Bustamante et al., (1996) found that there was no 
difference in the performance of pigs who were fed and housed individually or in 
groups.  This allowed farmers to maximise housing use and minimise housing cost, 
with increased overall profitability. 
Contrary to this, many experiments have reported a negative outcome on growth due 
to group housing (Hyun et al., 1998).  For example, Tonn et al., (1985) observed a 
higher growth rate in boars (male pigs) individually penned as compared to those in 
group pens.  Hyun et al., (1998) examined the effect of crowding on growth rate and 
also found that crowding decreased growth by 9.6%.  Randolph et al., (1993) 
similarly demonstrated that as floor space decreased the daily feed intake of the pigs 
reduced and in turn daily live weight gain was also reduced. 
In addition Edwards et al., (1988) illustrated that when floor space was decreased to 
less than 0.034m2 per kg body weight, the pigs’ wellbeing and growth was affected.  
The different findings between Bustamante et al., (1996) and Edwards et al., (1988) 
may be the result of different floor space allowances per animal. 
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Growth is influenced by group size because as group size increases the incidence of 
respiratory infection also increases.  Studies have found the risk of respiratory disease 
can be controlled by depopulation, segregation of cohorts (a group of pigs at the same 
stage of life) and the use of an “all-in/all-out system”.  All-in/all-out production refers 
to a housing strategy whereby an entire group of pigs enter an empty shed at the same 
time.  Later, they exit the shed together for the next phase of production.  Torremorell 
et al., (1997) and Ekkel et al., (1995) showed that mixing of pigs, in addition to 
crowding, increased the transmission of respiratory infection.  Straw et al., (1999) 
found that the greater the number of pigs housed together, the higher the risk of 
respiratory disease.  It seems large herds with increased levels of mixing between 
individuals are more prone to respiratory disease outbreaks than smaller herds.  
Infectious bacteria can be spread by nose rubbing, coughing, sneezing and vomiting. 
Lack of space means the infection can be transmitted through the herd quickly 
decreasing the chance to isolate or quarantine the sick animals before the disease is 
spread.  Age and site segregation in rearing has been used to control Actinobacillus 
pleuropneumoniae (App) (Straw et al., 1999).  Management strategies have positive 
effects by reducing the risk of respiratory disease, especially if pigs are weaned at or 
before 21 days of age (Veenhuizen, 1998; Leman et al., 1992). 
A system of all-in/all-out has also shown positive results for reducing infectious 
outbreaks from overcrowding (Straw et al., 1999). Torremorell et al., (1997) 
confirmed that a reduction in airborne bacterial load can be achieved when the “all-
in/all-out system” is applied. However, the “all-in/all-out system” can cause a loss of 
important bloodlines.  The opposite system to all-in/all-out is a “continuous-flow 
management system”.  Here, animals at different stages of life are moved in and out 
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of the pens accordingly.  This system maintains the bloodlines of animals, however 
the sheds are not cleaned completely since they are never empty. 
It would appear that stress from overcrowding has a greater negative implication on 
the pigs and outweighs the benefits.  Respiratory infection seems to be perpetuated by 
overcrowding. 
1.2.2  Temperature and climate 
Temperature and climate can exert stress upon animals in various ways. For example 
Schoenbaum et al., (1990) found that a low humidity of 55% and a low temperature 
of 4oC increased the spread of airborne particles.  Therefore climatic conditions and 
the risk of respiratory illness seem to be related.  Scheepens et al., (1994) explored the 
effect of unpredictable draughts daily or intermittent on weaners and found that their 
health status was reduced and their growth was impaired. 
A reduction in Tumor necrosis factor α (TNF-α) and Interleukin-6 (IL-6) cytokine 
production in the whole blood of humans stimulated with LPS was observed in 
autumn as compared to the other seasons.  Anti-inflammatory cytokine Interleukin-10 
(IL-10), Tumor necrosis factor receptor 1 (TNF-RI) and Tumor necrosis factor 
receptor 2 (TNF-RII) production was also reduced in human whole blood during 
summer and autumn (Myrianthefs et al., 2003) 
Studies on pigs exposed to hot and cold temperature fluctuations show negative 
immune response both in vivo and in vitro (Kelly 1980; Scheepens et al., 1994). 
Minton et al., (1988) observed that a 3 to 4 week nursery phase of pigs exposed to 
fluctuating temperatures increased significantly in insulin levels (>3.35µU/mL), 
neutrophils (>100 cells/µl) and eosinophils (>338 cells/µl) as compared to those pigs 
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exposed to constant ambient temperature.  Studies by Creshaw et al., (1986) showed 
no effect on immune system by fluctuating temperatures, but an effect reduction on 
growth as observed.  That being so, it could be concluded that cold draughts, humidity 
and large temperature fluctuations increase susceptibility to disease, and reduce 
growth rate (Kelly, 1980). 
1.2.3  Air quality 
Poor air quality is a further aspect implicated in growth rate and reduced health in 
livestock (pigs).  Curtis et al., (1975) and Leman et al., (1992) found that as ammonia 
levels increased, normal mucocilliary function was damaged immunocompromising 
the animal.  Some studies found that recycling air within an animal housing facility 
could contribute to the spread of disease (Straw et al., 1999).  In addition, this 
recirculation coupled with insufficient ventilation contributes to a high concentration 
of microbes, dust and dander, chronically stimulating the immune system to produce 
Interleukin-1 (IL-1) (Straw et al., 1999).  Similarly, Jobert et al., (2000) found 
recirculation of air detrimental to pigs.  His experiment contained 2 housing units; one 
with pigs infected with Actinobacillus pleuropneumoniae (App) and one with 
uninfected pigs.  Six days post infection the units were connected, by a rectangular 
opening and the air was circulated from the infected pigs’ unit to the uninfected pigs’ 
unit.  The infection spread rapidly and App was isolated from the pigs’ tonsils and 
lungs.  It was also isolated from the experimental unit’s air. This concluded that over 
a distance of at least 2.5m App was readily transmitted through aerosol, thereby 
impeding the health and growth of the pigs.  Solomons et al., (1993) and Roura et al., 
(1992) found that dirty environments with poor air quality suppressed the growth of 
chickens and increased plasma IL-1 production.  Since IL-1 producing lymphocytes 
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were found in vitro this showed the chickens’ immune system was stimulated.  Under 
commercial conditions (dirty environment) infectious disease was found to be spread 
from animal to animal or from farm personnel to animal via aerosols, and airborne 
droplets (Straw et al., 1999).  Torremorell et al., (1997) similarly showed that App 
was transmitted by air over a distance of 1m.  Healthy pigs were exposed to air from a 
pen containing App infected pigs for 2 to 7 weeks (Torremorell et al., 1997).  Most 
pigs died 12 days after initiation of the experiment from the airborne exposure to App 
infection.  Therefore an unsanitary environment, in this case pathogen contaminated 
air, can cause health and growth problems and even pig mortality.  The “all-in/all-out 
system” may reduce the problems associated with poor air quality, as can be seen with 
Davos et al., (1981) who found a 53% decrease in airborne bacteria in the “all-in/all-
out system” compared to the “continuous-flow management system”. 
1.2.4  Viral disease and Opportunistic pathogens  
The final deleterious effect on health and growth discussed in this Chapter is 
microbial infection (viral disease and pathogens).  These are obviously considered a 
major problem in the farming community.  According to Leman et al., (1992) pigs 
seldom reach slaughter weight without contracting a respiratory lesion. 
Nutritional problems related to diet and feed intake have often been assumed to be the 
cause of poor growth.  However, Solomons et al., (1993) found environmental factors 
such as airborne pathogens and airborne microbes to strongly influence growth. 
Poultry reared in unsanitary conditions (high number of airborne microbes, high 
levels of ammonia and seldom cleaned living areas) were examined.  Results showed 
that chickens did not achieve maximum growth potential.  Unsanitary conditions 
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mimic commercial conditions or environments where livestock are raised under 
intensive farming conditions. 
Similarly, Hill et al., (1952) found that chickens raised in sanitary environments 
attained a higher growth rate (15%) and greater skeletal muscle accretion than those 
raised in unsanitary environments. In-feed antibiotics made no difference to the 
weight gain of those chicks in ideal conditions.  Whereas antibiotic-assisted chickens 
in the unsanitary environment reached a similar growth status as those raised in the 
ideal environment (Hill et al., 1952).  Furthermore, Solomons et al., (1993) stated that 
“antibiotics are often considered growth permitters or promoters in that they permit 
birds (chickens) kept under practical husbandry conditions to realise the rate of 
growth that occurs normally when sanitation is excellent.” The literature shows that 
by decreasing a stress factor such respiratory disease, normal growth rate will return. 
Solomons et al., (1993) refer to recurrent infection of respiratory and gastrointestinal 
tracts of people as not only a problem but also as a factor in reducing animal growth.  
Solomons et al., (1993) demonstrated a relationship between frequency of respiratory 
infection in children and growth reduction in epidemiological studies, confirming the 
association. 
Respiratory disease, primarily App infection, is a major immunological stress in the 
form of clinical and sub-clinical disease in pigs.  Immunological, environmental and 
social stressors negatively influence growth performance of commercially housed 
pigs. 
It has been argued that a possible reason for growth reduction is that infection 
redirects nutrients towards host defences instead of physiological processes 
(Solomons et al., 1993).  Metabolic changes in response to immunological stresses 
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such as disease, cause partitioning of dietary nutrients away from growth and skeletal 
muscle accretion in favor of metabolic processes that support immune response and 
disease resistance (Solomons et al., 1993). 
The mechanics of the so-called metabolic changes requires further scrutiny. Studies 
have found that TNF-α (Beutler et al., 1988), primary monokines IL-1 and 
Interleukin-6 (IL-6) are produced during infection (Baarsch et al., 1995).  
Accumulated data from chickens, rats and mice showing that these cytokines are 
involved in infection will be discussed in Section 1.4.2 ‘Over-Production of Pro-
inflammatory cytokines’. 
 
1.3  Respiratory disease caused by opportunistic pathogens like 
Actinobacillus pleuropneumoniae (App) 
App respiratory disease is one of the most important diseases in swine production 
with a large impact on animal welfare and production economics (Angen et al., 2001).  
App bacterium produces an immunological stress in the form of clinical and sub-
clinical disease which negatively influences growth. 
App respiratory disease is a contagious, fibrinous haemorrhagic and necrotizing 
disease, which causes septicemia, lung lesions, poor growth performance and even 
mortality (Straw et al., 1999; Goethe et al., 2000).  This disease is most commonly 
known as pleuropneumonia.  App is a gram negative capsulated rod (Pohl et al., 
1983) with coccibacillary morphology, with haemolytic activity on sheep blood agar 
and a negative result for urease (Goethe et al., 2000).  Clinical signs include fever, 
anorexia, diarrhoea, vomiting, increase in pulse rates, cardiac and circulatory failure, 
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coughing, blueness, pleurisy, mouth breathing and loss of appetite (Sebunya, et al., 
1983; Jobert et al., 2000; Straw et al., 1999). 
Wallgren et al., (1994) and Beskow et al., (1989) found that at slaughter 8% of pigs 
showed signs of pleuritis.  Most lesions were found in the respiratory tract.  They are 
caused by the infiltration of neutrophils, macrophages and platelet activation (Liggett 
et al., 1987; Bertram, 1986 and 1985,) which are linked to pigs’ inflammatory 
responses to the invading bacteria (reviewed by Standiford 2000). 
The App bacterium lives for a short time outside its former host. However, if the 
bacterium is encompassed in mucus or other organic matter the survival period and 
potential for re-infection is increased (Straw et al., 1999).  Sebunya et al., (1983) 
found that pigs that survived had a reduced growth rate and became asymptomatic 
carriers with the infection found in necrotic lung lesions, tonsils and the nasal cavity.  
These carriers play a major role in the initiation of App respiratory disease outbreaks 
resulting in respiratory disease.  Furthermore, the impact of subclinical infection on 
growth productivity is not currently addressed in farming practice.  Researchers have 
isolated App bacterium from seemingly healthy looking pigs (ie. no clinical signs), 
(Heidt et al., 1982; Kielstein et al., 2001) which demonstrates that as long as the herd 
is in good health the disease may not manifest itself.  These findings conflict with 
Leman et al., (1992) who only found App bacteria in sick or compromised animals.  
However, Heidt et al., (1982) also isolated App bacteria from lung lesions of pigs 
suffering pneumonia.  Therefore, it is possible that Heidt et al., (1982) isolated the 
App microbe from carrier pigs with subclinical infection rather than truly healthy pigs 
(Heidt et al., 1982). 
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1.3.1  The implications of App 
As earlier stated (reviewed by Solomons et al., (1993); Hill et al., (1952)) viral 
disease and opportunistic pathogens may contribute to reduced growth productivity in 
animals such as chickens and humans, due to respiratory disease. Most clinically 
significant diseases are seldom from one infection alone.  During the early fattening 
period Wallgren et al., (1994) found that Mycoplasma hyopneumoniae was gained 
which causes lesions containing App.  This is an example of a pathogen reducing the 
animals’ defences thereby allowing another pathogen, such as App bacteria, to infect 
the host. 
App respiratory disease has been referred to as the most common cause of respiratory 
disease in pigs (Angen et al., 2001; Wallgren et al., 1994).  Healthy pigs are colonised 
by Mycoplasma flocculare, Mycoplasma hyorhinis, Haemophilus parasuis and other 
microbes.  These bacteria live as commensals while respiratory defences neutralise 
their pathogenicity (Leman et al., 1992). However, at the first sign of reduction in the 
host’s wellbeing the microbe reproduces and makes the animal sick. Respiratory tract 
infections by these pathogens may help the development of diseases such as 
pleuropneumonia.  
The pathogen App causes respiratory disease and is one of the most significant 
environmental factors affecting growth of pigs (Beskow, et al., 1989).   
App is a bacterium with high pathogenicity.  It is inhaled from the environment, and 
typically infects the host after influenza or Aujeszky’s disease (Straw et al., 1999). 
App and M. hypopneumoniae were only found in compromised pigs; it is usually 
associated with a subclinical infection (Straw et al., 1999). The presence of M. 
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hypopneumoniae decreases the host’s resistance against App bacteria (Leman, et al., 
1992), which explains why they commonly occur together. Therefore App seems to 
be implicated in respiratory disease which is mainly caused by another stress factor 
such as another pathogen. These pathogens are acquired through the host suffering 
environmental stresses eg. group housing, temperature fluctuations and bad air 
quality. All these factors seem to work synergistically to reduce the host’s defences 
and increase susceptibility to the App bacteria and hence cause respiratory disease 
suffered by the pigs. 
1.3.2  Treatment of App 
In the past Ampicillin, and Sulfonamisde have been used to treat App respiratory 
infection. However, due to prolonged use of antibiotics, the App bacteria has 
developed resistance to Ampicillin and Sulfonamisdes (Straw et al., 1999). These 
antibiotics do not affect serovar 1, 3, 5, and 7 greatly (Straw et al., 1999; Hirsh et al., 
1982).  Antibiotics kill the App bacteria but have no effect on the toxins released by 
the App bacteria (Straw et al., 1999; Hirsh et al., 1982; Veenhuizen 1998).  The 
success of therapy depends on early detection of clinical signs and rapid therapeutic 
intervention (Straw et al., 1999; Veenhuizen 1998). Antibiotics must be given in high 
dosages, subcutaneously or intramuscularly, and in repeated treatments to ensure 
effectiveness. (Straw et al., 1999). 
Veenhuizen, (1998) showed that in-feed medication such as antibiotics reduced 
porcine respiratory disease complex (PRDC) and improved growth performance of 
pigs. PRDC is produced by a combination of factors including; viruses, bacteria and 
environmental stresses. Mycoplasma hyopneumoniae, Pasteurella multocida, and 
Actinobacillus pleuropneumonia are the three most important bacterial respiratory 
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pathogens that contribute to PRDC (Veenhuizen 1998).  However, Veenhuizen (1998) 
did not do follow-up experiments regarding in-feed medication or observed if the 
disease recurred and if the antibiotics were still able to control the disease.  Huang et 
al., (1998) found current vaccines and bacterins from commercial sources contained 
one or a combination of secreted toxins.  In the experiments of Huang et al., (1998) 
the severity of lung lesions and clinical disease were reduced. However, some 
vaccinated animals still suffered acute and chronic disease from serovars that they 
were not vaccinated against and therefore became carriers of App. 
Fenwick et al., (1994) established that various purified and partially purified antigens 
of App used as a potential vaccine reduced mortality but did not prevent the initial 
infection and therefore gave only part protection.   
Huang et al., (1998) showed that secreted components from host cell surfaces act 
synergistically in the pathogenesis of porcine App.  Huang et al., (1998) found 
animals that recovered from natural infection became immune to subsequent 
infections.  Therefore more focus is needed on host defences as a treatment or 
preventative of this disease since the defences do not change but disease strains do. 
In contrast, antigens from outer membrane lipoproteins of App (serotype 2 and 9) 
grown under iron restriction conditions showed an effective protection against clinical 
signs of App (serotype 2) disease.  Unfortunately large-scale production of this as a 
vaccine is problematic and may not provide cross protection from serotype to serotype 
(Goethe et al., 2000). 
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1.3.3  Pathology 
Rioux, (2000) set out to show that capsular polysaccharides of App play a role in the 
pathogenicity of the disease.  However, a mutant strain was found without capsular 
polysaccharides and which adhered better to the lungs but was more susceptible to 
host defences.  It was concluded that outer membrane components were masked by 
the capsular polysaccharides. The capsular polysaccharides protect the bacterium 
from the host defences.  Similarly, Dimango (1995) found binding specific genes 
(pillin and flagellin) produced by Pseudomonus aeruginosa were necessary for the 
host to produce cytokines.  Dimango (1995) found non-pilated and non-adherent 
isogenic mutants produced less cytokines in lung epithelial cells. Therefore the host 
did not have to produce a vigorous attack since these mutants were more susceptible 
to host defences.  Therefore the host defences may play a role in the disease outcome.  
The immunological mechanisms of the infection needs further investigation, 
especially the disease relationship to the host defences, so to reduce the negative 
effect of the disease on growth and health.  
 
1.4  Immunological response to infection with App  
As mentioned at the beginning of this review, environmental factors primarily cause 
stress and stimulate physiological disturbances such as loss of weight, muscle protein 
degradation, fever, lipolysis, infection and possibly death (Straw et al., 1999).  
Microbial infection (an environmental stress factor) produces an immunological 
response, which then produces a physiological response.  The physiological response 
to App respiratory disease in pigs was discussed earlier when the clinical signs of the 
disease were described. 
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App respiratory infection, as stated earlier, is a secondary infection which may occur 
as a result of another stress (eg. mycoplasma) (Caruson and Ross 1990).  Once the 
mycoplasma infection is established it allows the App bacteria to take hold by gaining 
entry as airborne particles.  The moist warm conditions in the lungs allow rapid 
multiplication (Veenhuizen 1998) and production of toxins (cytotoxic factors) and 
waste product (Huang et al., 1999).  App bacteria have many secreted and non-
secreted cytotoxic factors such Apx I, II and III (Huang et al., 1998) and LPS (Idris et 
al., 1993; Udeze et al., 1987) which stimulate host responses.  Resting monocytes, 
macrophages and eosinophils are activated to aggregate to the infected area (reviewed 
by Hazlett 2002).  The inability of pulmonary alveolar monocytes to kill App bacteria 
is believed to lead to rapid neutrophil infiltration. The App toxins degenerate 
neutrophils, which release lysosomal components, which damage vascular tissue, 
cause necrosis and pleural adhesions (Veenhuizen 1998).  Macrophages become 
phagocytic, release lysosomal enzymes to counter the bacteria and therefore the 
macrophages produce cytokines (Tizard 1996; Brostoff 1991).  The death of the 
pulmonary alveolar monocytes may increase the inflammatory response which causes 
the influx of neutrophils to the infection site leading to necrosis and lesion formation 
(Liggett et al., 1987).  In response to infection with App bacteria and the subsequent 
activation and infiltration of immune cells, a cascade of cytokines is produced with 
profound effects on the pig.  In particular the influx of neutrophils produces IL-8 and 
thereby has a feedback in recruiting more neutrophils (Strieter et al., 1992) causing 
further necrosis and lesion formation.  Of concern are the pro-inflammatory 
cytokines, implicated in the pathology of App and poor growth of livestock. 
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1.4.1  Cytokines 
Cytokines are a heterogeneous group of unrelated molecules unified by their ability to 
influence the behavior of other cells (Klein et al., 1997; Tizard 1996).  In other words 
they are immune messangers and act via cell receptors on target cells to influence 
local or systemic effects.  Cytokines can interact with other systems such as the 
endocrine axis and the central nervous system. 
Pro-inflammatory cytokines mobilise host defences and are responsible for 
recruitment of immune cells to inflammatory sites (Khair 1996). The cytokines 
produced by the activated monocytes and macrophages are IL-1, IL-6, Interleukin-8 
(IL-8) and TNF-α (Klein 1997; Tizard 1996).  These pro-inflammatory cytokines are 
present at various levels in an inflamed or injured area. 
The need for pro-inflammatory cytokines has been demonstrated by Laichalk et al., 
(1996) and Standiford et al., (2000).  They showed that TNF-α present in the lung of 
mice has antibacterial properties (Laichalk et al., 1996; Standiford et al., 1999), which 
have been overlooked due to the damage it (TNF-α) can cause when over produced.  
Another pro-inflammatory, MIP-2 (homolog of human IL-8), is needed by the host 
(mouse) to recruit neutrophils (reviewed by Standiford et al., 2000) and to isolate 
invading bacteria (Brostoff et al., 1991; Tizard 1996). 
TNF-α on the other hand induces lipolysis and affects serum triglycerides which after 
chronic exposure may cause weight loss and body protein depletion (Mullin 1990). 
IL-1 enhances fatty acid synthesis and secretes very low density lipoproteins. 
(reviewed by Johnson 1997).  Lipoproteins are detrimental to the modern meat 
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industry since increased fat is now considered undesirable because of links between 
dietary fat in-take and cardiovascular disease in humans. 
Cytokines play an essential role in the development of humoral immune responses to 
infection.  Epithelial cells in the respiratory tract produce cytokines such as IL-8, IL-
6, TNF-α and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) (Khair 
et al., (1996); Levine 1997) for protection in response to bacterial challenge. 
Hakansson et al., (1996) showed that IL-6 and IL-8 were produced by airway 
epithelial cells in response to the attachment of Haemophilus influenzae.  In addition, 
DiMango et al., (1995) and Massion et al., (1994) reported an increase in cytokines 
secreted by bronchial epithelia in vitro exposed to Pseudomonus aeruginosa.  These 
studies showed that pro-inflammatory cytokines like IL-6, IL-8 and TNF-α in 
mucosal tissue are essential for host defences against pathogen stresses. 
The first cytokine released into the circulation 4-6 hours after an antigen is detected 
by macrophages is IL-1 (Tizard 1996; reviewed by Johnson 1997). IL-1 binds to 
receptors on T helper lymphocytes and activates a cascade of immune responses 
(Tizard 1996). 
Kroemer et al., (1993) stated that monocytes and macrophages play a major role in 
the activation of lymphocytes through the cytokines that they secrete. 
Antibodies are produced as a result of the cytokine cascade (within 10-14 days post-
infection) to recognise the infection and help in recovery and protection against re-
infection.  Cytokines such as IL-6 and IL-1 stimulate T helper 2 lymphocytes to 
secrete Interleukin 4 (IL-4) and Interleukin 5 (IL-5), which stimulate eosinophils and 
B cells to produce immunoglobulins (reviewed by Johnson 1997; Tizard 1996; 
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Saleem et al., 1998).  IL-6 promotes the production of IL-4 (an anti-inflammatory 
cytokine), and enhances the production of Immunoglobulin A (IgA). 
IL-8 recruits neutrophils at the site of infection (reviewed by Murtaugh et al., 1996).  
Since neutrophils and eosinophils are most mobile of the blood leukocytes they arrive 
at the damaged or infected area first (Brostoff et al., 1991).  The function of 
neutrophils is to capture and destroy foreign material through phagocytosis (Brostoff 
et al., 1991; Klein et al., 1997). When an antigen or foreign matter is too large for one 
cell (macrophages or neutrophils) to ingest, cells aggregate and surround the antigen.  
The same occurs when an antigen persists (Roitt 1994; Brostoff et al., 1991).  This 
behavior (infiltration) stops the antigen from spreading but it is detrimental to the 
surrounding tissue as it causes the development of lesions when this occurs in the 
lung.  Lesions can lead to breathing difficulties and lethargy.  The aggregation of cells 
is not desirable since the lung is a soft, spongy and filtering organ (Tizard 1996) and 
cellular infiltration inhibits oxygen exchange.  Morrison et al., (2000) found that IL-1 
and TNF-α were implicated in massive lung injury. 
As alluded to earlier, pro-inflammatory cytokines mediate immunological responses 
and inflammation but over-production can exacerbate the inflammation or disease and 
end in death (reviewed by Sharma et al., 1997).  An optimal outcome of 
immunological activation depends on the balance between inflammatory cytokines 
and the release of immunosuppressors or anti-inflammatory activity. 
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1.4.2  Over Production of Pro-inflammatory cytokines 
The over-expression of pro-inflammatory cytokines such as IL-1, IL-8 and TNF-α 
can be detrimental to the (pig) host (Baarsch et al., 1995).  The detrimental effects of 
pro-inflammatory cytokines occurs in most animals not just pigs.  Olsson (1995) 
realised that elevated levels of TNF-α play a role in Multiple Sclerosis (humans), and 
since levels of IL-1α, IL-1β and IL-6 were elevated in systemic juvenile chronic 
arthritis (humans). Arend et al., (1990), came to a similar conclusion that elevated 
pro-inflammatory cytokines are detrimental.  Overproduction of IL-6 is known to 
cause toxic shock/endotoxic shock (Mire-sluis and Thorpe 1998; Tizard 1996).  IL-6 
also has been found at an elevated level in patients suffering Crohns disease (Mire-
Sluis and Thorpe 1998).  This pro-inflammatory cytokine (IL-6) has been associated 
with fever (Tizard 1996) and is implicated in auto immune conditions (Mire-Sluis and 
Thorpe 1998).  IL-6 when not over-produced can be protective against Listeria 
bacteria in the mouse (Lui and Cheers 1992) and protective against Pseudomonas 
aeruginosa corneal infection in the mouse (Cole 2001). 
Huang et al., (1999) recorded an elevation in TNF-α and IL-1 in the serum, which 
coincided with the onset of acute clinical disease (App) in pigs.  Neutrophil 
chemoattractants (IL-8) rather than the App bacterial components are the major 
factors causing acute lung inflammation (Huang et al., 1999). 
The detrimental effect of the over production of pro-inflammatory cytokines, such as 
TNF-α or IL-1β, exacerbate disease caused by bacterial infection (Morrison et al., 
2000).  Further studies (Baarsch 1995) showed the presence of IL-8 and IL-1 in the 
pigs’ lungs after App infection, and concluded that these inflammatory cytokines are 
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associated with the development of pleuropneumonia and contribute to the severity of 
the disease.  Over production of pro-inflammatory cytokines can exacerbate the 
inflammation or disease and end in death (reviewed by Sharma et al., 1997). 
 
1.5  Prevention of (App) Pathogen stress in Pigs 
Factors which contribute negatively to the physiological state of the pigs should be 
removed in order to prevent or reduce poor growth.  From this review and others 
(reviewed by Johnson 1997) it can be seen that all stress factors contribute to the poor 
growth of animals such as pigs, chickens and humans.  In fact, these stress factors, 
(i.e. large group size, temperature and climate fluctuation, poor air quality and 
pathogens) act synergistically to activate the endocrine-immune axis (reviewed by 
Johnson 1997).  Preventing or decreasing the stress factors will help increase growth.  
Reducing stocking rate and group size in pigs showed a positive effect on growth 
(Tonn et al., 1985).  However, this is not commercially viable and may not be cost 
effective. 
Crowding and air quality are related as overcrowding causes an increase in microbial 
load and an increase in respiratory disease with elevated pig numbers (Curtis et al., 
1975). Increasing ventilation causes a reduction in ammonia, carbon dioxide, 
microbes and dust and thus increases the health and performance (Jobert et al., 2000) 
of pigs; again this is a costly project and calls for the rebuilding of farm sheds. 
Currently, App and similar clinical and sub-clinical diseases are controlled using 
prophylactic antibiotics in-feed and therapeutic antibiotic treatment (Straw et al., 
1999).  Several components of the host immune system (eg. immunosuppressors and 
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anti-inflammatory cytokines) have shown promise as prophylactics and therapeutics 
to abrogate disease under App challenge and hence improve growth. 
1.5.1  Anti-inflammatory cytokines as a therapeutic and/or prophylactic 
The increase in severity of App by pro-inflammatory cytokines could be reduced by 
the use of anti-inflammatory cytokines.  IL-10 is an anti-inflammatory which usually 
down regulates the balance of pro-inflammatory cytokines. For example, Muller 
(1998) found that the absence of IL-10 prolonged and enhanced systemic juvenile 
chronic arthritis (humans).  Morrison et al., (2000) also demonstrated that IL-10 
reduced the acute disease caused by App infection and decreased lung damage 
significantly (pigs).  IL-10 and Transformation growth factor-β (TGF-β) are 
associated with Multiple Sclerosis patients going into remission (Tian et al., 1998).  
IL-10 also suppressed the activity of neutrophils therefore reducing necrosis.  Since 
anti-inflammatory cytokines such as IL-10 have positive effects on disease, it would 
seem to be a good idea to use gene therapy to reduce the over-production of pro-
inflammatory cytokines and thereby reduce the severity of the disease. 
Van Roon et al., (1996) found that IL-4 could reduce the ratio of type 1 and 2 T cells 
by acting as a growth factor for type 2 T cells, causing an increase in anti-
inflammatory cytokines such as IL-10.  IL-4 also reduced cartilage degradation in 
rheumatoid arthritis (humans) and hence IL-4 is another anti-inflammatory cytokine 
which should be observed in an immunocompromised system (Isomaki 1996).  Other 
researchers also observed that IL-4 and IL-10 inhibited the synthesis of pro-
inflammatory cytokines (reviewed by Bendtzen et al., (1994) and reviewed by 
Mosmann (1994)). 
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Although IL-1 is considered a pro-inflammatory cytokine and can intensify 
inflammation, it can be reduced or even inhibited. Arend et al., (1993) found IL-1β 
and α were inhibited by Interleukin 1ra (IL-1ra) which binds to receptor sites of IL-1 
and stops signal transduction.  Morrison et al., (2000) showed upregulation of IL-1ra 
therefore helping in the reduction of pneumonic disease in pigs.  Anti-inflammatory 
cytokines decrease or even inhibit disease. Research showed that Interleukin 13 (IL-
13) inhibited IL-8 release and stimulated IL-1ra synthesis in blood mononuclear cells 
(Seitz et al., 1996). IL-4 was also found to have anti-inflammatory effects on blood 
mononuclear cells.  Zhou et al., (1994) found that IL-4 suppresses inflammatory 
cytokines (IL-1, IL-8, TNF-α) in alveolar macrophages at a transcriptional level in 
pigs. With further study a therapeutic application may be established. 
Saleem et al., (1998) also observed that IL-4 suppresses neutrophil influx and 
therefore limits tissue damage.  IL-4 also suppresses IL-8 production (Hazlett 2002) 
by neutrophils and therefore the feed-back system (Strieter 1992) is halted. 
Inflammatory cells producing pro-inflammatory cytokines (TNF-α, IL-1β and IL-8) 
found in the lungs of App infected pigs (Baarsch et al., 1995) could be reduced or 
halted by anti-inflammatory cytokines such as IL-4.  IL-4 stimulates Interleukin 4 
receptor antagonist (IL-4ra) while inhibiting IL-1 and TNF-α production by 
monocytes. IL-4 inhibits Intercellular Adhesion Molecule 1 (ICAM-1) mRNA in mice 
and therefore blocks neutrophils from adhering to lung endothelium or epithelium 
(Saleem et al., 1998). 
The exacerbation of App respiratory disease by pro-inflammatory cytokines, eg. IL-8, 
can be reduced by anti-inflammatory cytokines, such as IL-4 and IL-1ra as stated 
earlier, restoring the immunological activity balance.  Neutrophil infiltration produced 
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by IL-8 over-production causes pathogenic lesions which can be reduced or stopped 
by stimulating the production of IL-4 or IL-1ra.  The potential of IL-1ra and IL-4 as 
therapeutic or prophylactic alternatives to antibiotics, needs further investigation in 
the App model and may have subsequent commercial application. 
The main aim of this thesis is to investigate novel immunomodulators in particular 
Interleukin 4 and Interleukin 1 receptor antagonist as alternatives to antibiotics to treat 
the infectious stress of App respiratory disease which is detrimental to health and 
growth
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
 
2.1  Animals 
Male pigs (Landrace X large white from Westmill Piggery, Young, NSW) were nasal 
swabbed and confirmed to be free of App and mycoplasma by PCR (NSW 
Agriculture). 
Animals were maintained in a piggery with a controlled environment at Elizabeth 
Macarthur Agricultural Institute (EMAI, Menangle, NSW) for the duration of the 
trials. The relative humidity was maintained at 60% with a temperature of 24oC and 
fresh air circulated constantly. The floor was fully slatted concrete and the sub-floor 
area was flushed twice daily.  Pigs were acclimated to their surroundings for at least 2 
weeks before initiation of each experiment.  Pigs were fed a commercial grower diet 
in pellet form and water was provided ad libitum via a nipple dispenser.  Pigs were 
randomly allocated into groups, rooms and pens according to the experimental 
protocols.  Weight was measured using a walk in cage balance, at which time anal 
temperatures were taken as required. 
 
2.2  Blood samples 
Animals were restrained using a nasal snare, and blood was collected by venipuncture 
from the jugular vein.  Blood was collected into Vacutainer™ tubes (Becton 
Dickinson, Franklin Lakes, NJ, USA) and stored on ice for transport. 
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For the collection of serum, blood was collected in Vacutainer™ SST II tubes with a 
clotting accelerant and centrifuged at 2000g for 10 minutes at 4°C.  Serum was 
removed using a pipette and aliquoted into tubes for storage at -20°C. 
For the collection of whole blood, the blood was collected into Vacutainer™ tubes 
lined with lithium heparin.  The blood was stored at 4°C prior to use. 
 
2.3  Infection Protocol 
Pigs were restrained using a nasal snare and injected intravenously with xylazine 
(0.1mL/10kg) and ketamine (1mL/10kg) anaesthetic prior to intra-tracheal 
inoculation.  A laryngoscope was used to enable proper placement of an endotracheal 
tube.  The Actinobacillus pleuropneumoniae was isolated from pig lungs and grown 
on PPLO agar (2%w/v heart infusion, 3%w/v yeast enriched peptone, 1.6%w/vNaCl, 
4.6% Agar, pH7.8) then transferred to PPLO broth and grown to mid log phase. App 
serovar 1, strain Hs54 was maintained, cultured and stored ( -80oC in 70% glycerol) at 
EMAI, and the appropriate dose delivered according to each experimental protocol.  
2.4  RT-PCR 
Preliminary investigations revealed that compared to conventional methods such as 
chloroform extractions, the Promega SV RNA total extraction kit (Promega, Madison, 
USA) yielded a greater amount of RNA over a minimal amount of time.  Therefore it 
was used to extract RNA from porcine blood and tissue samples.  A standard amount 
of RNA between 0.2µg/µL to 0.4µg/µL was used to synthesise cDNA. 
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2.4.1  RNA Extraction Method 
Whole blood was collected in Vacutainer™ tubes and mixed well.  Red blood cells 
interfere with the extraction therefore they were removed using 900µL SV RNA Red 
Blood Lysis solution (Promega, Madison, USA) added to 500µL of whole blood in a 
1.5µL microfuge tube. Samples were left to incubate for 15 minutes at room 
temperature, during which time they were inverted twice. 
The samples were then centrifuged at 20,000g for 20 seconds to produce a white 
pellet.  The supernatant was discarded and the pellet lysed using 175µL SV RNA lysis 
buffer (Promega, Madison, USA) to release nucleotides.  Preparation of tissue 
samples (1cm3 lung and lymph nodes samples) involved crushing them in a 1.5µL 
microfuge tube using a microfuge pestle in 175µL SV RNA lysis buffer (Promega, 
Madison, USA).  The remaining components of the SV RNA kit (Promega, Madison, 
USA) were used according to the manufacturer’s instructions for both blood and 
tissue (Appendix 4).  However, the obtained yield of approximately 0.22µg/µL RNA 
required the use of 50µL of water to elute the RNA from the column, which was an 
exception to the manufacturer’s instructions. 
2.4.2  RT cDNA Synthesis 
The total RNA concentration was determined using a Spectromax 250 plate reader 
(Molecular Devices, Sunnyvale, CA, USA).  A dilution of 1 in 200 for each RNA 
sample was made and 200µL of each sample was aliquoted into a 96 well quartz plate 
(Hellma GMBh & Co KG, Müllheim, Germany) which was placed on ice.  The plate 
was placed in the Spectromax 250 and read at 260nm and 280nm.  The 260nm result 
was used to calculate the concentration of RNA (RNAµg/µL = 
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A260nm/0.025*dilution factor/1000) and the ratio of the 260nm result over the 
280nm result gave the purity of the sample (1.8 to 2.0 optimum). 
Total RNA was reverse transcribed using a reverse transcriptase system (Promega, 
Madison, USA) to produce cDNA; 0.2µg/µL RNA was used for each sample. 
2.4.3  PCR  
The whole procedure was performed on ice to control reactions until all the cDNA 
samples were added, allowing the direct comparison of samples.  A master mix was 
prepared and aliquoted into tube strips or 384 well plates (Nunc, Service Life Science, 
Rockilde, Denmark) adding all components except the cDNA (Appendix 3). 
The master mix was prepared containing 0.05units/µL Taq polymerase (Sigma-
Aldrich, St Louis, USA), 1.5mM MgCl2, 100µM dNTP (Promega, Madison, USA), 
1X reaction buffer (10X reaction buffer; 100mM Tris-HCl, pH 8.3, 500mM KCl, 
11mM MgCl2 and 0.1% gelatin) (Sigma-Aldrich, St Louis, USA) and 10pmol specific 
primers.  Approximately 1µL neat cDNA was used; this volume was previously 
determined to be optimum via titration.  The specific paired primers used were IL-8, 
IL-6, (created by Dr Nicola Kingsford using Primer3 web program (Whitehead 
Institute, Cambridge, MA, USA)) IL-1β, TNF-α; β-actin (Sequences for paired 
primers found in Dozois, et al., 1997). 
The IL-8 primer pair was derived from the porcine IL-8 nucleotide (Genbank 
accession M86923) and the IL-6 primer pair was derived from the porcine IL-6 
nucleotide (Genbank accession M86722). The primer sequences and product sizes are 
listed in Appendix 1. 
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The cycling conditions consisted of initial denaturation at 95°C for 2 minutes, 
followed by 94°C for 5 seconds; annealing was performed at 56°C for 5 seconds and 
extension at 72°C for 24 seconds for 34 cycles and final extension for 2 minutes at 
72°C.  Cycling was performed on a PTC-200 DNA Engine thermal cycler (MJ 
Research Inc. Waltham, MA, USA).  A positive control (master mix plus cloned 
known positive cDNA) and negative control (master mix plus water) were run with 
each plate or strip reaction.  PCR sample (10µL) were migrated on a 1-2% TBE 
(0.089M Tris base, 0.089M Boric acid, 2mM EDTA, pH 8.3) agarose gel.  The gel 
was stained in 250mL TBE containing 5µl EtBr (stock 10mg/mL) and was shaken for 
20 minutes at room temperature.  The gel was transferred to the destaining container, 
which contained milliQ water and was destained by shaking for 20 minutes at room 
temperature.  The gels were photographed using a CCD Kodak digital camera 
(Kodak, Rochester, NY, USA) and the images were subsequently analysed using 
Quantity One (Biorad, California, USA).  For analysis the above staining technique 
provided a clearer gel image rather than incorporation of EtBr into the gel prior to 
running the samples.  The ratio of the density of the cytokine product over the 
corresponding density of the internal standard (β-actin) product was used to calculate 
relative band intensity for individual samples. 
2.5  Cloning 
PCR products were purified and cloned to create positive controls, for running with 
PCR products from porcine samples, on gels.  Approximately 50µl of PCR solution 
was found to be the optimal amount for purification.  A wizard PCR Prep Purification 
Kit (Promega Corporation, Madison, USA) was used to purify the PCR product 
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according to the manufacturers instructions (Appendix 5).  The purified sample was 
stored at –20°C until the next step. 
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2.5.1  DNA Ligation 
Ligation was done overnight according to manufacturer’s instructions using pGEM-T 
easy vector system (Promega Corporation, Madison, USA).  Ligation entailed placing 
the purified PCR product inside a plasmid to enable insertion into a cell for 
replication. 
2.5.2  Transformation 
Transformation was done by inserting a plasmid vector into a cell for replication.  The 
cell in this case was an Escherichia coli cell line JM109 (Gibco, Maryland, USA) 
which was stored at –70°C. 
Ampicillin LB plates (LB medium, 1.5% Agar, 100µg/mL ampicillin) were prepared 
by making LB medium (1% Tryptone, 5% Yeast extract, 0.5% NaCl) (Appendix 7). 
Plates were taken out of the fridge to equilibrate to room temperature; 80µg/mL 5-
bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal) and 0.5mM IPTG were added to 
plates following manufacturer’s instructions for the pGEM-T easy vector system.  The 
white colonies containing the vector were then grown up in Ampicillin LB broth (LB 
medium, 100µg/mL Ampicillin) to obtain one single clone. 
2.6  White Blood Cell counts 
White blood cell (WBC) counts were obtained from heparinised blood samples and 
analysed using a Sysmex analyser (Toa Medical Electronics Co. Ltd., Japan). 
2.7  Differential white blood cell counts 
White blood cell differentials were counted manually.  Heparinised blood was 
inverted in the Vacutainer ™ tubes to obtain a homogeneity of cells.  About 5 drops of 
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blood was smeared on a microscope slide and air-dried overnight.  Slides were stained 
with Diff-Quick, a modified Wright stain (Lab Aids Pty Ltd, NSW, Australia).  A 
total of 200 cells were counted and tallies of each cell type were recorded for the 
determination of cell population percentages. The number of each cell type per 
milliliter was obtained by multiplying the percentage by the total WBC count. 
2.8  Enumeration of Lymphocyte Subsets via Flow Cytometry 
2.8.1  Preparation and Staining of Lymphocytes 
Heparinised blood was dispensed (100µl) into Falcon tubes (Becton Dickinson, 
Franklin Lakes, NJ, USA).  Blood samples to be stained for the B cell marker 
immunoglobulin (Ig) were washed twice, in 2mL Potassium Buffered Saline (PBS) 
(0.8% NaCl, 0.02% KCl, 0.115% Na2HPO4, 0.02% KH2PO4 pH7.5) and centrifuged 
at 850g and 4oC for 5 minutes to remove immunoglobulin in the serum.  Each 
subsequent wash and centrifuge was done using the same parameters as stated above. 
The optimal dilutions of primary antibodies were determined previously by titration. 
The primary antibodies were monoclonal mouse antibodies specific for porcine CD3, 
CD4, CD8 and immunoglobulin (Ig light chain).  Primary antibodies were diluted in 
PBS. Mouse anti-porcine Ig (Serotec, Raleigh, USA) antibody was diluted 1:10, 
mouse anti-porcine CD8 (Serotec, Raleigh, USA) was diluted to 1:20, mouse anti-
porcine CD4 (VMRD, Washington, USA) was diluted to 1:200 and mouse anti-
porcine CD3 (Veterinary Medical Research and Development, Washington, USA) 
diluted to 1:100.  Samples were washed, and incubated at 4oC for 20 minutes with 
FITC-conjugated goat anti-mouse IgG (ICN, Costa Mesa, CA, USA).  Samples were 
mixed and incubated at 4oC for 20 minutes.  Red blood cells were lysed by the 
addition of 2mL of FACS Lyse (Becton Dickinson, Franklin Lakes, NJ, USA). 
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Samples were incubated at room temperature in the dark for 10 minutes.  The tubes 
were centrifuged at 400g at 4oC for 5 minutes and the supernatant was discarded.  The 
remaining pellets of white blood cells were washed and centrifuged at 400g at 4oC for 
5 minutes.  The pellets were resuspended in 1% paraformaldehyde (200µL) and stored 
in the dark at 4oC prior to analysis. 
 
2.8.2  Flow Cytometric Procedure 
The fluorescence in each sample was quantified using a FACScan flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA).  The resulting cell plots were analysed 
using CellQuest software version 3.0.1f (Becton Dickinson, Franklin Lakes, NJ, 
USA).  The lymphocyte population was identified on the basis of their granularity and 
size, and this population was gated to exclude dead cells and other cell types.  The 
fluorescence of the gated population was recorded, from which the background 
fluorescence of a negative control sample containing no primary antibody was 
subtracted.  
 
2.9  Neutrophil function assay 
The phagocytic capacity of neutrophils was adapted from the method of Perticarari et 
al., (1991). 
Heparinised blood was aliquoted (100µL) into Falcon tubes (Becton Dickinson, 
Franklin Lakes, NJ, USA).  Six 100µL aliquots were taken from a randomly chosen 
blood sample and dispensed into the Falcon tubes.  These tubes were numbered 
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Control 1 to 6.  All samples along with controls 2, 4 and 5 received 1µg of HE in 
10µL.  Other controls received an equal volume of PBS.  All tubes were mixed and 
incubated at 37°C for 15 minutes.  Approximately 100µL serum opsonised FITC-
zymosan (Appendix 9) was added to samples and controls 2 and 3.  The remaining 
controls received 100µL PBS.  PMA (Phorbol 12-Myristate 13-Acetate) (10ηg/µL) 
(Sigma-Aldrich, St Louis, USA) was added to samples and controls 5 and 6, with 
other controls again receiving an equal volume (40µL) of PBS (or Killed App bacteria 
(KB) at 1x107cfu/mL was added to appropriate tubes instead of PMA).  Tubes were 
mixed and incubated at 37°C for 45 minutes.  Phagocytosis was then stopped by 
placing the tubes on ice. 
Red blood cells were lysed with FACSlyse (2mL) (Becton Dickinson, Franklin Lakes, 
NJ, USA) and tubes were incubated at room temperature for 10 minutes in the dark.  
The tubes were centrifuged at 300g for 5 minutes and the pellet was resuspended in 
2mL of PBS.  Tubes were centrifuged at 300g for 5 minutes and the pellets were 
resuspended in 500µl PBS.  The tubes were stored on ice and immediately prior to 
analysis, trypan blue (1mg/mL) was added to tubes to quench auto-fluorescence. 
Fluorescence was quantified using a FACScan flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA) and analysed using CellQuest (Becton Dickinson, Franklin 
Lakes, NJ, USA). 
Neutrophils were gated according to their size and granularity on the light scatter plot 
and the fluorescence on the red and green channels recorded.  Green fluorescence 
indicated the amount of FITC-zymosan that had been phagocytosed and internalized.  
Red fluorescence indicated the oxidative burst had commenced. 
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2.10  Lymphocyte proliferation assay in whole blood 
The lymphocyte proliferation assay was adapted from the method of Fletcher et al., 
(1987). 
2.10.1  Preparation of Culture Plates 
Culture media (100mL RPMI (ICN, Australia), 2µg/mL L-glutamine and 0.01unit/mL 
penicillin, 1µg/mL streptomycin) was prepared and added with stimulatant into some 
wells and without stimulants into other wells of a 96 well round bottom plates (Nunc 
Service Life Science, Rockilde, Denmark).  Columns 1-4 were filled with 100µl 
culture media only (controls).  Columns 5-8 were either filled with 100µl of killed 
App bacteria (KB) to a final concentration of 1x107cfu/mL in culture media or with 
100µl Con A at 10ug/mL in culture media. Columns 9-12 were filled with 100µl of 
PHA (8µg/mL) in culture media.  Plates were stored at -20°C.  The optimal 
concentrations of KB, Con A and PMA had previously been determined by titration. 
 
 
2.10.2  Assay 
Prepared plates were thawed prior to use. Heparinised blood was diluted 1:5 with 
culture media then 100µL was aliquoted into 12 wells across 1 entire row of each 
plate and each sample was placed in 4 control wells, 4 KB wells and 4 PHA wells.  
Thus, 8 blood samples filled a pre-prepared plate.  Plates were incubated for 54 hours 
in a tissue culture incubator at 37oC, 85% humidity and 5% CO2. 
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2.10.3  Pulsing 
Tritiated [3H] thymidine (Amersham, Buckinghamshire, England) was diluted 1:100 
with culture media then 25µL was added to each well and plates were incubated for 
18 hours.  Plates were wrapped in aluminium foil and stored at -20oC to stop further 
incorporation of thymidine.  
2.10.4  Harvesting and Analysis 
Cells were harvested from each well using a Skatron combi-harvester (Molecular 
devices, Sunnyvale, CA, USA) and placed onto glass fiber filter paper.  Incorporated 
radioactivity was measured using a liquid scintillation counter (Beckman, Fullerton, 
CA, USA).  Stimulation indices were calculated by dividing the mean counts per 
minute of stimulated wells by the mean counts per minute from non-stimulated 
(control) wells. 
2.11  Enzyme-Linked Immunosorbent Assay (ELISA)  
Antibody levels in pig antisera were determined using a sandwich ELISA. Mouse 
anti-pig IgG light chain antibodies (Serotec, Raleigh, USA) were diluted 1:500 in 
0.6M carbonate buffer, pH 9.6, and applied (100µL/well) to a 96 well flat bottom 
microtitre plate (Nunc, Rockilde, Denmark).  This was incubated at 4°C overnight.  
Unbound antibodies were removed by inverting and flicking the plates.  The plates 
were washed three times with PBS-T (0.15M PBS, pH 7.2, containing 0.05% Tween-
20 (Sigma-Aldrich, St Louis, USA)).  The plates were inverted and flicked to remove 
the excess PBS-T.  Consecutive washes were performed in a similar manner unless 
stated otherwise.  Gelatin (1% in carbonate buffer) was applied (150µL/well) and 
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incubated for 1 hour at 37°C to block reactive sites on the polystyrene.  The plates 
were inverted and flicked before washing to remove unbound gelatin. 
Porcine IgG (Serotec, Raleigh, USA) was used as a standard.  It was titrated from a 
concentration of 500µg/mL in doubling dilutions and applied to the first 2 columns 
(100µL/well) in duplicate.  The serum samples were diluted 1:200 with PBS-T and 
applied in duplicate to each plate (100µL/well).  Plates were incubated for 2 hours at 
37oC, and then washed with PBS-T.  Horse radish peroxidase (HRP) conjugated goat 
anti-porcine IgG heavy and light chain (Serotec, Raleigh, USA) was diluted 1:2500 
with PBS-T and 100µL applied to each well. Plates were incubated for 1 hour at 37oC 
followed by 10 washes with PBS-T.  A working substrate was made using 10mg of 2-
2 azino-di (3-ethyl-benzthiazoline sulphonic acid) (ABTS) (Sigma-Aldrich, St Louis, 
USA) in 33mL 0.05M citric acid, pH 4 plus 125µL 30% hydrogen peroxide 
(100µL/well).  The degree of hydrolysation of the added substrate was measured by 
reading plates at 405nm using a Spectromax 250 plate reader (Molecular Devices, 
Sunnyvale, CA, USA). 
2.12  TNF-α Bioassay 
This method was modified from the methods of Baarsch et al., (1991), Blagosklonny 
et al., (1993), Jeffes et al., (1991) and performed across 3 days. 
Day 1  
Supernatant from the flasks containing L929 cells was removed and 4mL 
trypsin/EDTA (0.25% trypsin/EDTA) (Sigma-Aldrich, St Louis, USA) was added and 
returned to the incubator for a further couple of minutes.  When the cells detached, 
30mL media (RPMI-1640 (ICN, Australia), 100U/mL penicillin, 100µg/mL 
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streptomycin, 2mM L-glutamine, 10% v/v heat inactivated Fetal calf serum (Sigma-
Aldrich, St Louis, USA)) was added to neutralise the trypsin/EDTA.  Cells were 
transferred from the flask into a 50mL centrifuge tube and centrifuged at 500g, for 5 
minutes at room temperature.  Pellet was resuspended in 10mL of media.  Cells were 
stained with trypan blue and counted using a haemocytometer (Sigma-Aldrich, St 
Louis, USA) to determine cells/mL.  Cells were diluted to a final concentration of 
4x106 cells in 10mL.  Approximately a 100µL of cell suspension (ie. 4x104 cells/well) 
was added to each well (96 well plate (Nunc, Rockilde, Denmark)).  The plates were 
then incubated overnight at 37oC, 85% humidity and 5% CO2. 
Day 2 
Plates with L929 cells were removed from the incubator.  Standards were prepared 
using recombinant porcine TNF-α stock (R&D systems Inc. Minneapolis. MN. USA) 
from 1500pg and double diluted to a final contraction of 25pg.  The supernatant was 
removed from the wells of each plate and discard using a multichannel pipette so as 
not to disrupt the monolayer.  Approximately 50µL of each standard from 1500pg to 
25pg was added in duplicate to the first 2 columns of the plates.  Serum from pigs 
(50µL) was applied neat in duplicate.  Actinomycin D (Sigma-Aldrich, St Louis, 
USA) solution at 8µg/mL was prepared in media and 50µL was added to every well.  
The plates were returned to the incubator for a further 18 hours at 37oC, 85% 
humidity and 5% CO2. 
Day 3 
The plates were removed from the incubator and the supernatant was removed using 
multi-channel pipette so as not to disturb the monolayer.  Approximately 50µL of 
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crystal violet solution (0.5%w/v crystal violet, 20%v/v ethanol) was added to each 
well and the plates were left to incubate at room temperature for 10 minutes.  The 
stain was rinsed under tap water without washing cells off the plate.  Water was 
flicked off and the plates were dried by resting on absorbent paper overnight.  
Approximately 100µl of methanol was added to each well. The plates were shaken for 
20 seconds and the read at 595nm absorbance.  Samples were compared with the 
standard curve to determine TNF-α concentration in sample. 
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CHAPTER 3 
DEVELOPMENT OF METHODOLOGIES TO 
MEASURE THE PRODUCTION OF PRO-
INFLAMMATORY CYTOKINES IN VITRO 
3.1  Introduction 
Stimulation of cells with mitogens is a common method to measure non-specific 
responses of immune cells.  A mitogen is a substance or agent that triggers or 
induces mitosis such as lectins, phorbol esters and endotoxins. 
It was necessary to develop a method which demonstrated that the production of 
pro-inflammatory cytokines could be mitogenically stimulated in whole blood, and 
subsequently measured.  Ideally, this method would allow for the selection of the 
most potent mitogens and their optimal concentrations for in vitro stimulation of 
cytokines.  Such a method would provide a useful tool for screening the ability of 
substances to inhibit or reduce the production of pro-inflammatory cytokines, and 
for the selection of potential treatments for future in vivo experiments. 
Such an assay would use whole pig blood instead of a more conventional method 
of separating out the white cells (Polymorphonuclear Cells (PMN), lymphocytes, 
monocytes) before stimulation with mitogen.  Most assays use blood separated by 
centrifugation on density gradient medium such as ficoll-hypaque resolving 
medium (Huang et al., 1998 used ficoll-hypaque resolving medium).  A whole 
blood method was preferable as it permits the processing of large sample numbers.  
Most importantly whole blood may give a more accurate reflection of what could 
occur in vivo since plasma, serum, cells and other components are present.  Such 
components in whole blood may interact when stimulated by mitogens.  
Furthermore, separation techniques are not efficient in obtaining all the white 
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blood cells, which is important for observations of the interactions of pro-
inflammatory cytokines.  A whole blood assay seemed to be the simplest, most 
cost effective and time effective assay to develop. 
From the four pro-inflammatory cytokines of interest; IL-1, IL-6, IL-8 and TNF-α, 
IL-8 was chosen since it has been associated with the pathogenicity of App disease 
(Baarsch et al., 1995) and the mRNA of IL-8 was easily detectable.  The neutrophil 
chemotactic ability of IL-8 is known to be associated with the influx of neutrophils 
(Zhou et al., 1994) leading to the development of lung lesions in pigs infected with 
App (reviewed by Standiford et al., 2000).  The robustness of the IL-8 RT-PCR 
assay was proven in other studies run previously by this Laboratory.  cDNA 
transcription of samples were done according to the methods described in Section 
2.4.2.  IL-8 paired primers were used to perform PCR described in Section 2.4.3. 
The ease of established primers was another reason IL-8 mRNA was detected in 
these in vitro experiments. 
The mitogens to be used included; Phorbol 12-Myristate 13-Acetate (PMA), 
Phytohemagglutinin (PHA), Concanavalin A (Con A), lipopolysaccharides (LPS) 
and Killed Actinobaccillus pleuropneumoniae bacteria (KB).  PHA is a lectin 
which is isolated from kidney beans. It is also a glycoprotein, which binds to 
carbohydrate receptors on the surface of lymphocytes (Di Sabato, et al. 1987).  It 
has the capacity to stimulate proliferation of lymphocytes (B cells, T cells).  Con A 
is a lectin which activates T cells (Gunther, et al. 1973) and has similar properties 
to PHA .  PMA is a phorbol ester which activates T cells and polyclonal B cells. It 
is a direct agonist of protein kinase C which plays a role in B cell activation 
(Schmidt and Hecker 1975).  The rapid expression of cytokines is due to the 
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presence of regulatory sequence elements in the PMA protein (Schmidt and Hecker 
1975). It mimics the effect of various cytokines by inducing the production of 
cytokines (Schmidt and Hecker 1975). 
LPS is an endotoxin found in gram negative bacteria cell walls.  LPS is a B cell 
stimulator and functions as a polyclonal B cell activator.  It also activates 
macrophages and complements cascades.  It is a physiological stimulus for the 
synthesis of pro-inflammatory cytokines. 
KB (heat killed App bacteria) has LPS in the cell wall (Idris et al., 1993 and Udeze 
et al., 1987) and other secreted and non-secreted toxins which may give an 
indication of potential stimulation of pro-inflammatory cascades resulting from 
bacterial infection in vivo. 
The purpose of this Chapter was to develop an assay which could be used to 
estimate the amount of mitogen needed to produce a pro-inflammatory cytokine 
response in whole blood.  A further purpose was to identify substances which 
could inhibit or reduce this inflammatory response. 
3.2  Experiment 1:  Titration of mitogens and killed App for the 
stimulation of IL-8 production in porcine whole blood. 
3.2.1  Objectives 
The aim of this experiment was to discover which of the four mitogens (PMA, 
PHA, Con A and LPS) and KB samples produced the greatest immune response 
measured as the production of pro-inflammatory cytokines.   
Further investigations were required to determine optimal concentrations of 
mitogens for the stimulation of pro-inflammatory cytokines. 
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3.2.2  Experiment 1 Materials and Methods 
3.2.2.1  Experiment 1a Whole blood Stimulation 
The blood was taken by venipuncture from a male pig with no observable illness 
according to the method described in Section 2.2.  The animal was housed at the 
University of Sydney Piggery (May Farm), Camden. Blood was collected into 
lithium heparin Vacutainer TM tubes and put on ice. 
Heparinised blood was then aliquoted (2mL) into 16 sterile plastic Falcon test 
tubes (Becton Dickinson, Franklin Lakes, NJ, USA).  The proliferation method 
using microtitre plates as outlined in Section 2.10 was modified for use in test 
tubes, to enable removal of samples from each test tube over time.  The test tubes 
were separated into 5 groups of 3 test tubes. Saline was added to the 16th test tube 
(control).  Each group was treated with a stimulant at 3 different concentrations 
described as low, medium and high (Table 1).  The tubes were incubated in 5% 
CO2 at 37°C and 85% relative humidity; 300µL aliquots were removed prior to 
stimulation, and 2 hours, 4 hours and 24 hours after stimulation for total RNA 
extraction. 
Table 3.1: The final concentration of mitogens per mL of whole blood, used in the 
test tube based proliferation assay, experiment 1a. 
 
Concentration 
Stimulant Low Medium High 
PMA 1ug/mL 5ug/mL 10ug/mL 
PHA 1ug/mL 5ug/mL 10ug/mL 
ConA 1ug/mL 5ug/mL 10ug/mL 
KB-App 3x105cfu/mL 3x107cfu/mL 3x108cfu/mL 
LPS 1ug/mL 10ug/mL 50ug/mL 
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3.2.2.2  Experiment 1b 
A volume of 1.8mL of blood was aliquoted into 27 sterile plastic Falcon test tubes 
(Becton Dickinson, Franklin Lakes, NJ, USA). Samples were separated into 5 
groups with 5 concentrations of mitogens (Table 3.2) and a control each done in 
duplicate.  The control blood samples were given 200µL sterile injectable saline 
(1.5mMNaCl, AstraZeneca, North Ryde, Australia).  All saline treated blood 
samples in the future had been given 200µL, so as to compare between in vitro 
experiments.  RNA was extracted for cytokine analysis of IL-8, TNF-α and IL-1β. 
Blood was analysed for cytokine production before stimulation to observe any 
baseline constitutive cytokine presence.  Another reason to measure this is that 
individual differences between animals and their baseline cytokine levels may 
occur.  One could easily make an assumption of up-regulation that may only be the 
base level of pro-inflammatory cytokines normally circulating in peripheral blood. 
The 5 mitogen groups used in the first part of this experiment (Table 3.1) were 
expanded in concentration (Table 3.2). After 200µl of mitogen was added, each 
tube contained a final volume of 2mL. The tubes were incubated with shaking in 
5% CO2 at 37°C and 85% relative humidity.  Aliquots of 300µL were removed 
prior to stimulation, 2 hours and 24 hours after stimulation.  The control blood 
samples were stimulated with saline and the un-stimulated blood sample was not 
processed in any way. 
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Table 3.2: Variable concentrations of mitogens used to stimulate whole blood in 
experiment 1b. 
 
PMA Tube 1 
20µg/mL 
Tube 2 
10µg/mL 
Tube 3 
1µg/mL 
Tube 4 
500ηg/mL 
Tube 5 
100ηg/mL 
PHA Tube 6 
20µg/mL 
Tube 7 
10µg/mL 
Tube 8 
1µg/mL 
Tube 9 
500ηg/mL 
Tube 10 
100ηg/mL 
ConA Tube 11 
20µg/mL 
Tube 12 
10µg/mL 
Tube 13 
1µg/mL 
Tube 14 
500ηg/mL 
Tube 15 
100ηg/mL 
KB Tube 16 
2x109cfu/mL 
Tube 17 
1x109cfu/mL 
Tube 18 
1x104cfu/mL 
Tube 19 
1x102cfu/mL 
Tube 20 
1x101cfu/mL 
LPS Tube 21 
20µg/mL 
Tube 22 
10µg/mL 
Tube 23 
1µg/mL 
Tube24 
500ηg/mL 
Tube 25 
100ηg/mL 
 
Total RNA was isolated using SV Total RNA Isolation System (Promega, 
Madison, USA) according to the manufacturer’s instructions, and as outlined in 
Section 2.4.1. 
RNA samples were transcribed to cDNA in a 10µL reaction according to the 
methods described in Section 2.4.2.  PCR was performed using IL-8, TNF-α, and 
IL-1β paired primers as described in Section 2.4.3. 
3.2.3  Experiment 1 Results 
3.2.3.1  Experiment 1a Results  
Saline treatment of porcine whole blood did not stimulate the production of any 
detectable IL-8 mRNA and was therefore considered to be the baseline production 
of IL-8 mRNA for that particular pig, and an appropriate negative control.  
Unfortunately, at 24 hours the blood samples were found to be coagulated, possibly 
due to the plastic tubes used to perform the assay.   
The stimulation of whole blood by the 5 mitogens at all 3 concentrations produced 
IL-8 mRNA above the baseline with the exception of KB at 3x108cfu/mL. 
KB at 3x107cfu/mL stimulated the most IL-8mRNA production at 4 hours. 
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All 3 concentrations of PMA stimulated production of IL-8 mRNA after 2 hours of 
stimulation in a dose dependent manner (Figure 3.1a).  There was little difference 
between IL-8 mRNA stimulation by the different concentrations of PMA at 4 
hours.  It remains to be seen whether IL-8 mRNA production would increase, 
decrease or plateau after 4 hours of stimulation with PMA. 
An IL-8 mRNA response, similar to that produced by PMA, was stimulated by all 
3 concentrations of Con A (Fig 3.1c).  IL-8 mRNA production peaked at 2 hours 
and remained relatively constant until 4 hours.  PMA and Con A stimulation 
showed similar trends for the production of IL-8 mRNA at high (10µg/mL) and 
medium (5µg/mL) concentrations (Figure 3.1a, Figure 3.1c). 
The high concentration (3x108cfu/mL) of KB failed to stimulate production of IL-8 
mRNA (Fig 3.1d).  The medium concentration of KB stimulated IL-8 mRNA 
production at 2 hours and this level was further increased at 4 hours (Figure 3.1d).  
At the low concentration, KB stimulated IL-8 mRNA at 2 hours and again at 4 
hours (Figure 3.1d). 
In the case of LPS stimulation, all 3 concentrations stimulated similar levels of IL-
8 mRNA production after 2 hours (Figure 3.1e).  The low concentration of LPS 
showed no stimulation of IL-8 mRNA production at 4 hours.  Production of mRNA 
for IL-8 increased throughout the study for the high concentration of LPS, while 
there was little change between 2 hours and 4 hours for the medium concentration. 
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Figure 3.1:  The temporal expression of IL-8 mRNA, measured by RT-PCR, in 
porcine whole blood after stimulation with a) PMA, b) PHA, c) Con A, d) KB, and 
e) LPS, applied at low medium and high concentrations. Control whole blood 
sample was stimulated with saline.  Data from Experiment 1a. 
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3.2.3.2  Experiment 1b Results 
Results were only obtained for blood prior to stimulation and at 2 hours after 
stimulation, as the blood coagulated by 24 hours after the addition of mitogens. 
Whole blood samples with saline were found to produce IL-8 mRNA, resulting in a 
relative band intensity of 0.7.  This was considered to be a constitutive level of 
expression in this pig and was presented as a background line in Figure 3.2.  
Therefore, anything above the line was considered to be up regulated. 
All 3 PMA concentrations showed the presence of pro-inflammatory cytokine IL-8 
mRNA prior to stimulation (Figure 3.2a).  PMA concentrations between 0.1µg/mL 
and 20µg/mL showed negligible difference in their ability to stimulate the 
production of IL-8 mRNA in whole blood. 
PHA at the 1µg/mL concentration stimulated the greatest production of IL-8 
mRNA in whole blood (Figure 3.2b).  However, there was little difference in the 
results obtained for concentrations < 0.5 µg/mL.  No production of IL-8 or internal 
standard β-actin was detected when blood was stimulated with PHA at 0.1µg/mL 
(Figure 3.2b). 
Con A at 0.1µg/mL stimulated IL-8 mRNA production with a band intensity of 1.3 
(Figure 3.2c) which was much larger than the mRNA produced at 0.5µg/mL and 
20µg/mL.  Again, there was little difference in the IL-8 mRNA levels stimulated 
by 0.1µg/mL, 1µg/mL and 10µg/mL.  At 20µg/mL Con A did not stimulate any 
IL-8 mRNA production. 
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LPS at 10µg/mL performed very well at stimulating increased levels of IL-8 
mRNA production (Figure 3.2e) in whole blood.  The remaining concentrations of 
LPS also stimulate IL-8 mRNA production but to a lower level than that seen with 
10µg/mL LPS (Figure 3.2e). 
The production of IL-8 mRNA by KB was at the greatest when the blood was 
stimulated with KB at concentrations of 1x109cfu/mL and 2x109cfu/mL (Figure 
3.2d). 
Pro-inflammatory cytokines such as TNF-α mRNA and IL-1β mRNA were also 
produced by the stimulation of whole blood by LPS or PMA (Figure 3.3). 
The production of TNF-α mRNA and IL-1β mRNA in whole blood after 
stimulation with saline resulted in a relative band intensity of ~0.5 (Figure 3.3).  
This was considered existing baseline production of TNF-α and IL-1β mRNA in 
the whole blood obtained from that particular pig.  Therefore anything above 
baseline (~0.5 band intensity) was considered up-regulation. 
PMA stimulation of whole blood at all concentrations produced IL-1β and TNF-α 
mRNA above baseline and therefore was considered to up-regulate these 
cytokines. 
LPS at all concentrations except 1µg/mL stimulated the production of IL-1β 
mRNA in whole blood above baseline.  At 0.5µg/mL to 10µg/mL LPS stimulated 
the production of TNF-α mRNA above baseline. 
In Figure 3.3, PMA at 20µg/mL stimulated the greatest production of TNF-α 
mRNA, however at concentrations between 1µg/mL and 10µg/mL a stable pro-
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inflammatory cytokine production profile was produced.  PMA stimulation of 
whole blood generally produced more IL-1β than TNF-α mRNA. 
LPS at 10µg/mL produced the most stimulation of IL-1β mRNA in whole blood, 
while the highest level of TNF-α occurred at 1µg/mL LPS stimulation.  This level 
was not much higher than the TNFα mRNA level produced by LPS at 10µg/mL 
concentration. 
At 10µg/mL stimulation with both PMA and LPS resulted in considerable 
increases in the production of mRNA for IL-8, TNF-α and IL-1β in porcine whole 
blood in vitro.  It would seem these concentrations of mitogens would produce a 
pro-inflammatory profile which would be sufficient for the testing in assays to 
screen for substances able to inhibit or reduce pro-inflammatory cytokine 
production since up-regulation was achieved above baseline. 
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Figure 3.2: The expression of IL-8 mRNA measured by RT-PCR, in porcine 
whole blood after 2 hours stimulation with a) PMA, b) PHA, c) Con A, d) LPS, 
and e) KB, applied at varying concentrations;  na indicates not assessable. Black 
line in the middle and in the background indicates baseline IL-8 mRNA 
production.  Data from Experiment 1b. 
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Figure 3.3:  The expression of mRNA for IL-1β and TNFα measured by RT-PCR, in 
porcine whole blood after 2 hours stimulation with PMA and LPS at varying concentrations; 
na indicates not assessable. The zero concentration on the x-axis represents saline 
stimulated blood producing IL-1β and TNFα mRNA which was considered baseline. 
Production of cytokines above this level was considered up-regulation.  Data from 
experiment 1b. 
 
3.2.4  Experiment 1 Summary 
• PMA, LPS and KB were the best performing mitogens in terms of 
increasing the production of IL-8 mRNA in these preliminary titration 
studies.   
• PMA was chosen because PMA at all the concentrations stimulated IL-8 
mRNA as compared to PHA and Con A.  Con A stimulation resulted in a 
similar level of IL-8 mRNA as that found for PMA in experiment 1a which 
for this reason Con A was excluded. 
• The optimal concentrations of PMA and LPS were determined to be 10µg 
mitogen/mL whole blood. 
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• Since the next in vitro experiment was a time course to 24 hours and 
3x107cfu/mL stimulated the most IL-8mRNA at 4 hours (1.6 band 
intensity) which was higher than the IL-8mRNA (1.4 band intensity) 
produced by 2x109cfu/mL at 2 hours, the concentration of KB chosen to 
continue with was 1x107cfu/mL. 
• The abovementioned mitogens and their optimal concentrations were 
selected for use in further in vitro assays. 
3.3  Experiment 2:  The temporal effect of selected mitogens on IL-8 
production in porcine whole blood 
3.3.1  Objectives 
The optimal concentrations of KB, PMA and LPS established from the previous 
experiment were used to determine whether stimulation of IL-8 mRNA production 
occurred in a repeatable fashion between individual pigs.  Mitogen stimulation was 
also measured across time to confirm the ideal duration of stimulation for in vitro 
assays. 
3.3.2  Experiment 2 Materials and Methods 
3.3.2.1  Whole Blood Stimulation 
From the results of experiments 1a and 1b, PMA (10µg/mL), LPS (10µg/mL), and 
KB (1x107cfu/mL) were selected for the stimulation of pro-inflammatory cytokines 
in this experiment. The whole blood was treated in a similar manner to Experiment 
1 except glass test tubes were used and blood was collected from 4 different pigs.  
As in Experiment 1a, 1.8mL was aliquoted into 16 sterile glass test-tubes.  Blood 
from each pig was treated with PMA, LPS, KB, saline or left untreated (un-
stimulated control).  The IL-8 mRNA produced by the saline  
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stimulated and un-stimulated whole blood was considered baseline IL-8 mRNA.  
Once again any IL-8 mRNA produced above this level was considered up-
regulation. 
All samples were shaken in 5% CO2 at 37oC and 85% relative humidity.  A volume 
of 300µL blood was removed from each test tube prior to stimulation, and 2 hours, 
4 hours and 24 hours after stimulation for extraction of RNA and subsequent RT-
PCR.  Extraction of RNA and RT-PCR were conducted according to the methods 
outlined in Sections 2.4.2 and 2.4.3 respectively.  
3.3.3  Experiment 2 Results 
Mitogens stimulated IL-8 mRNA production to a similar level at all 3 sampling 
times (Figure 3.4).  
The production of IL-8 mRNA by the saline and un-stimulated blood was 
significantly less (p<0.05) than that produced by the mitogens at 2 hours and 24 
hours post stimulation (Figure 3.4).  The 4 hour time point appeared highly 
variable with high standard errors confounding any trends. 
PMA, LPS and KB stimulation of IL-8 mRNA in whole blood showed no 
significant difference between each other at all time points post stimulation (Figure 
3.4).  KB increased IL-8 mRNA production significantly at 24 hours compared to 4 
hours (1.124 vs 0.953 P< 0.05).  
There was no difference in IL-8 mRNA production between the un-stimulated 
blood and the saline stimulated blood.  Thus, either un-stimulated blood or saline 
stimulated blood were suitable controls demonstrating the constitutive baseline 
levels of IL-8 mRNA expression in pig whole blood samples.  The 24 hour time 
 52
53 
COMMERCIAL IN CONFIDENCE 
point produced little variation between samples stimulated with mitogens (mean ± 
sem) and as such, 24 hours may be considered the optimal stimulation time for in 
vitro cytokine production assays in whole blood. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4:  The temporal expression of mRNA for IL-8 as measured by RT-
PCR, in porcine whole blood after stimulation with PMA (10µg/mL), LPS
(10µg/mL), killed App (KB, 1x107 cfu/mL), saline, and un-stimulated blood 
(control). na indicates not assessable. Bars refer to mean (n=4), and standard 
error. 
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3.3.4  Experiment 2 Summary 
• Stimulation of porcine whole blood with LPS, PMA and KB resulted in 
similar levels of IL-8 mRNA production across individual pigs, as 
illustrated by low variability. 
• Variability between animals producing IL-8 mRNA in response to 
mitogens was the lowest at 24 hours after stimulation, and this time point 
was thus the ideal duration of stimulation for such in vitro assays. 
• These results confirm the robustness of this assay system for producing 
consistent results across individual blood samples. 
 
3.4  Experiment 3.:  Screening of anti-inflammatory agents on 
mitogenic stimulation of pro-inflammatory cytokines, to inhibit the 
production of these cytokines in porcine whole blood 
3.4.1  Objectives 
Results described in the previous 2 experiments showed the optimal concentrations 
of a series of mitogens and KB and the optimal stimulation time for the stimulation 
of pro-inflammatory cytokine production in porcine whole blood.  These 
concentrations have been selected for use in an inhibition assay to examine the 
effect of putative anti-inflammatory compounds on the production of pro-
inflammatory cytokines.  It is envisaged that compounds which inhibit the 
production of pro-inflammatory cytokines in response to mitogens and KB in vitro 
may have potential as therapeutics for the treatment of inflammatory syndromes in 
pigs in vivo. 
 54
55 
COMMERCIAL IN CONFIDENCE 
3.4.2  Experiment 3 Materials and Methods 
PMA, LPS and KB were administered at the confirmed concentrations outlined in 
experiment 2.  Anti-inflammatory cytokines IL-4, IL-1ra and Flunix (a non 
steroidal anti-inflammatory drug (NSAID)) were applied at 3 concentrations; low, 
medium and high in order to reduce the production of pro-inflammatory cytokines. 
The low concentration of anti-inflammatory cytokines and NSAID was applied at 
10µg/mL for all the substances. The medium concentration for Flunix and IL-1ra 
was 50µg/mL, while IL-4 was applied at 25µg/mL.  The high concentration was 
100µg/mL for both Flunix and IL-1ra, and 50µg/mL for IL-4. 
Whole blood (1.7mL) was placed in glass test tubes, to which 100µL of stimulant 
and 200µL of anti-inflammatory compounds was applied to make a final volume of 
1mL. 
Un-stimulated whole blood was also treated with all anti-inflammatory compounds 
all at 50µg/mL. 
Saline controls were again incorporated in order to determine the animal 
constitutive level of IL-8 mRNA.  Tubes were then placed in 5% CO2 and 85% 
relative humidity and agitated for 24 hours at 37oC. 
3.4.3  Experiment 3 Results 
The un-stimulated controls and the saline control samples showed a baseline 
production of IL-8 mRNA at a band intensity of 0.7 indicated by the black lines in 
Figure 3.5.  Once again the lines represent the constitutive amount of IL-8 mRNA 
in the whole blood and any production of IL-8 mRNA exceeding these lines was 
believed to have been caused by immunological stimuli.  Production of IL-8 
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mRNA less than baseline was indicated as a percentage reduction.  Flunix showed 
promising results in limited in vivo tests in pigs for reducing fever (Knowles 
personal communication). 
The production of IL-8 mRNA stimulated by KB was suppressed 100% by a high 
concentration of Flunix (Figure 3.5).  IL-1ra at medium concentration also reduced 
KB stimulated IL-8 mRNA by 100% (Figure 3.5).  However, the production of IL-
8 mRNA in whole blood stimulated by KB was not reduced or inhibited by the 3 
concentrations of IL-4. 
Flunix at all 3 concentrations (low, medium and high) did not reduce the 
production of IL-8 mRNA by the stimulation of PMA (Figure 3.5).  The whole 
blood stimulated with PMA and treated with a high concentration of IL-1ra yielded 
no result since the house keeping gene β-actin could not be detected in this sample.  
Whole blood stimulated by PMA and subsequently treated with IL-4 at a low 
concentration reduced IL-8 mRNA production by 100% (Figure 3.5). 
Whole blood stimulated by LPS and treated with Flunix at a high concentration 
showed a 100% reduction in IL-8 mRNA production.  Unfortunately, LPS 
stimulation of IL-8 mRNA and treatment with IL-1ra at a low concentration did 
not yield any data since the house keeping gene β-actin again could not be 
detected.  However the whole blood stimulated by LPS and subsequently treated 
with a low dose of IL-4 reduced IL-8 mRNA production 100% below baseline 
(Figure 3.5). 
Saline, Flunix, and 2 anti-inflammatory cytokines (IL-1ra and IL-4) were applied 
to un-stimulated blood at the same concentration (Figure 3.6).  The saline 
 56
57 
COMMERCIAL IN CONFIDENCE 
stimulated blood produced IL-8 mRNA at a band intensity of 0.7 consistent with 
baseline IL-8 production from Figure 3.5.  Flunix and IL-1ra reduced baseline 
constitutive IL-8 mRNA to zero.  Conversely IL-4, up-regulated the production of 
IL-8 mRNA in un-stimulated porcine whole blood (Figure 3.6). 
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Figure 3.5:  Mitogenic stimulation of IL-8 mRNA in porcine whole blood, co-
incubated with Flunix, IL-4 and IL-1ra at varying concentrations.  The black lines 
in the middle of the graphs indicate the baseline constitutive IL-8 mRNA for this 
particular pig. 
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Figure 3.6:  The effect of saline, Flunix (50µg/mL), IL-1ra (50µg/mL) and IL-4 
(50µg/mL) on the production of IL-8 mRNA in porcine whole blood which has not 
been stimulated by mitogens. Bars show relative band intensity of IL-8 mRNA 
compared with β-actin mRNA. 
3.4.4  Experiment 3 Summary 
• IL-8 mRNA produced in whole blood stimulated by KB after 24 hours was 
inhibited by the high (100µg/mL) concentration of Flunix.  This 
concentration of Flunix also inhibited the production of IL-8 mRNA 
produced by the stimulation of LPS after 24 hours. 
• The stimulation of IL-8 mRNA by KB was inhibited 100% by the medium 
concentration (50µg/mL) of IL-1ra. 
• The stimulation of IL-8 mRNA by both PMA and LPS was inhibited by the 
low (10µg/mL) concentration of IL-4. 
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• Baseline IL-8 mRNA produced by un-stimulated whole blood was 100% 
inhibited by Flunix and IL-1ra, while IL-4 up-regulated the production of 
IL-8 mRNA. 
 
3. 5.   Discussion 
The main objective of the experiments described in this Chapter was to develop a 
method which demonstrated that the production of mRNA encoding for the pro-
inflammatory cytokines could be mitogenically stimulated in whole blood.  This 
method was developed to provide a useful tool for screening of substances which 
may inhibit or reduce the production of pro-inflammatory cytokines in vitro.  
Larsson et al., (1999) found constitutive levels of IL-8 in epithelial cells while 
Strieter (1992) found constitutive levels of IL-8 produced by neutrophils, it would 
seem reasonable to assume that cells present in whole blood (particularly 
neutrophils and monocytes) also produce a constitutive level of IL-8. 
In Experiment 1, five stimuli (PMA, PHA, Con A, LPS and KB) were tested to 
observe which stimuli delivered at which concentration would produce the greatest 
pro-inflammatory response.  IL-8 was of most interest since it is a neutrophil 
chemotactic factor and is implicated in respiratory disease pathology caused by 
App (Baarsch, et al., 1995).  Baarsch et al., (1995) found pro-inflammatory 
cytokines such as IL-1β and IL-8 were associated with pleuropneumonia and may 
contribute to the severity of the disease. 
The high concentration of KB (Figure 3.1d) used to stimulate the production of IL-
8 mRNA in porcine whole blood may have been too high and instead of 
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stimulating the production of IL-8 mRNA, toxins like LPS present in KB.  (Idris et 
al., 1993 and Udeze et al., 1987) may have killed the cells.  KB may also have 
other toxins present since App has secreted proteins and non-secreted components 
such as ApxI, II and III which act synergistically to cause damage to lung tissue 
(Huang et al., 1998).  However this is mere speculation until this assay is repeated 
with blood from several different pigs which was done in Experiment 2. 
However, assumptions made about KB toxins at high concentrations 
(3x108cfu/mL) damaging or busting the mononuclear cells in Experiment 1a were 
dispelled with the resulting production of IL-8 mRNA by KB at >1x109cfu/mL in 
Experiment 1b.  KB in Experiment 1a stimulated the greatest production of IL-8 
mRNA at 3x105cfu/mL at 2 hours with a resulting band intensity of 1.5.  In 
Experiment 1b an IL-8 mRNA band intensity of 1.4 was produced by the 
stimulation of KB at 2x109cfu/mL (Figure 3.2d). Therefore the best concentration 
of KB for the stimulation of IL-8 mRNA production is somewhere between 
3x105cfu/mL and 2x109cfu/mL, possibly around 7.5x105cfu/mL. 
IL-8 mRNA was not detected when blood was stimulated with PHA at 0.1µg/mL 
(Figure 3.2b).  β-actin (the internal standard) was not detectable.  It can be 
assumed that the RNA extraction failed or the RNA degraded before synthesis to 
cDNA.   
The IL-8 mRNA levels (0.7 band intensity) produced by the saline treated blood 
was much higher than that produced when the whole blood in Experiment 1a was 
treated with saline (zero band intensity), which showed individual differences in 
the pigs constitutive levels of pro-inflammatory cytokines present in peripheral 
blood. 
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From the 5 stimuli (4 mitogens and KB) applied to whole pigs’ blood, PMA, LPS 
and KB produced the most IL-8 mRNA in Experiment 1b. 
Whole blood was stimulated by LPS and PMA in Experiment 1b to produce other 
pro-inflammatory cytokines of interest such as IL-1 and TNF-α above baseline 
levels.  LPS has, in other studies, stimulated the production of IL-1 and TNF-α, in 
white cells, epithelial and endothelial cells (reviewed by Surendran 1999).  Unlike 
Experiment 1a, only the 2 hour time point was sampled due to clotting of the 4 
hour and 24 hour samples.  Clotting was reduced by agitating the tubes and also by 
switching from plastic tubes to glass which was implemented in Experiment 2. 
PMA in Experiment 1a produced a similar IL-8 mRNA profile to Con A, while 
PMA, Con A and PHA showed similar stimulation of IL-8 mRNA profiles in 
experiment 1b. 
Of these 3 mitogens, PMA was selected for future use based on its consistency in 
stimulation of IL-8, TNF-α and IL-1β 
LPS, PMA and KB all stimulated the production of IL-8 mRNA in whole blood to 
a similar level (Figure 3.2) and this stimulation was consistent across time (Figure 
3.4). 
Unstimulated blood and saline stimulated blood produced a constitutive level of 
IL-8 mRNA production which was significantly less than that produced by porcine 
whole blood stimulated with mitogens.  Variation in production of IL-8 mRNA by 
individual animals in response to mitogens was minimal in Experiment 3, 
suggesting the results seen with the animals’ blood in Experiments 1 and 2 are 
repeatable. 
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In Experiment 3 the pro-inflammatory cytokine IL-8 mRNA was up-regulated by 
IL-4 in un-stimulated whole blood.  This up-regulation could have been due to IL-4 
which enhances or activates in some cases the Th 1 cytokine responses 
(Nuntaprasert et al., 2005).  Nuntaprasert et al., 2005 also found that LPS and IL-4 
given at the same time to alveolar macrophages suppressed the secretion of IL-8, 
TNF-α, IL-6 and IL-1α however when IL-4 was given before LPS challenge in an 
in vivo system (pigs) it increased severity of respiratory failure and endotoxic 
shock. 
The ability of IL-4 to inhibit or reduce IL-8 mRNA in LPS stimulated whole blood 
seen in Experiment 3 is supported by the results of Zhou et al., (1994).  He found 
that IL-8 mRNA induced by LPS could be suppressed by IL-4 in vitro in pig 
alveolar macrophages. 
IL-4 performed the best in the in vitro Experiment 3 and reduced the production of 
IL-8 mRNA in pig’s whole blood stimulated by LPS or PMA (Figure 3.5).  IL-1ra 
also performed well in the in vitro Experiment 3 and reduced KB stimulated IL-8 
mRNA production to zero (Figure 3.5). 
It was hoped that the influx of neutrophils and inflammatory cells found by other 
authors in App infection could be reduced or halted by delivery of IL-4 in vivo.  As 
outlined in the data from the experiments in this Chapter IL-4 successfully reduced 
IL-8 mRNA production in LPS stimulated porcine whole blood at a transcriptional 
level, IL-8 recruits and activates cells such as neutrophils to inflammatory sites 
(reviewed by Standiford et al., 2000; Murtaugh et al., 1996).  Furthermore, 
neutrophils, macrophages and platelets make up the lesions found in the respiratory 
tract of pigs suffering App infection (Liggett, et al., 1987).    
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LPS is known to stimulate the production of IL-1β, TNF-α, IL-8 and IFNδ in white 
cells and epithelial cells (reviewed by Surendran et al., 1999, and by Murtaugh et 
al., 1996).  In this Chapter the production of IL-1β and TNF-α mRNA in whole 
blood by the stimulation of LPS established similar results in whole blood.  It was 
observed that IL-1ra suppressed IL-8 mRNA production by KB (Figure 3.5).  Chen 
et al., (1998) also found that IL-1ra inhibited the production of IL-8 by IL-1α 
stimulation in an in vitro system (squamous cell carcinoma human cell line). 
IL-1ra inhibits IL-Iβ and α by binding to receptor sites of IL-1 thereby stopping 
signal transduction (Arend et al., 1993).  IL-1β and IL-8 are associated with the 
severity  of pleuropneumonia (Baarsch et al., 1995) and IL-1β and α also stimulate 
the production of IL-8 by macrophages (Tizard, 1996), thus IL-1ra may be able to 
reduce not only IL-1β, but other over produced pro-inflammatory cytokines such 
as IL-8. 
These in vitro experiments have given an insight into the production of pro-
inflammatory cytokines in response to immunological stimuli, and to what extent 
anti-inflammatory cytokines can inhibit the production of pro-inflammatory 
cytokines. A whole blood model has been established to test the inhibitory 
properties of potential anti-inflammatory substances.  These selected substances 
have potential as treatments for future in vivo experiments to reduce the impact of 
pro-inflammatory cytokines which result from infections with bacterial pathogens 
such as App.  The illness and weight loss experienced by pigs in response to App 
challenge may also be reduced or inhibited by delivery of anti-inflammatory 
substance such as IL-1ra, IL-4 and Flunix.  Chapter 4 executes these investigations. 
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CHAPTER 4 
PROPHYLACTIC DELIVERY OF ANTI-
INFLAMMATORY AGENTS FOR THE PREVENTION 
OF SYMPTOMS CAUSED BY INFLAMMATORY 
EFFECTORS IN PIGS 
4.1  Introduction 
Pro-inflammatory cytokines such as IL-8, IL-6, IL-1 and TNF-α have been implicated 
in the poor growth rate (Morrison et al., 2000 and Baarsch et al., 1995) of livestock 
under commercial conditions. In Chapter 3, I performed in vitro experiments which 
revealed that, a reduction or inhibition at a transcriptional level has been demonstrated 
by anti-inflammatory compounds such as Flunix (non-steroidal anti-inflammatory 
drug), IL-4 (anti-inflammatory cytokine) and IL-1ra (Interleukin 1 receptor 
antagonist).  The experiment in this Chapter was performed to demonstrate whether 
the illness and weight loss experienced by pigs infected with App may be reduced or 
inhibited by the prophylactic delivery of these anti-inflammatory substances.  Two 
challenge models were attempted; an acute challenge model with LPS, followed by a 
chronic infection with App. 
Flunix is used therapeutically in horses to reduce and control fever due to bacterial 
infections. Flunix is a cyclo-oxygenase inhibitor, potent antipyretic and anti-
inflammatory (MIMS 1988, IVS annual).  It inhibits the production of prostaglandins 
and other chemicals which stimulate inflammatory responses in the body. 
IL-4 was selected as it performed the best in the in vitro experiment of Chapter 3 by 
reducing the production of IL-8 mRNA.  IL-4 successfully reduced LPS stimulated 
IL-8 mRNA production in porcine whole blood at a transcriptional level (Chapter 3 
and Zhou et al., 1994). IL-8 recruits and activates cells such as neutrophils to 
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inflammatory sites (reviewed by Standiford et al., 2000 and reviewed by Murtaugh et 
al., 1996). It has been found that lesions in the respiratory tract of pigs suffering the 
App infection consist of neutrophils, macrophages and platelet activation (Bertram 
1986, Bertram 1985, Liggett et al., 1987). Given the activity of IL-4 against IL-8 in 
vitro, it was hoped that the influx of neutrophils and inflammatory cells could be 
reduced or halted by IL-4 in vivo.  
IL-1ra was used since it too performed well in the in vitro experiment of Chapter 3 
and reduced KB stimulated IL-8 mRNA production to zero.  LPS is known to 
stimulate the production of IL-1β, TNF-α, IL-8 and IFN-δ in white cells and 
epithelial cells (reviewed by Surendran et al., 1999, and Murtaugh et al., 1996).  The 
production of IL-1β and TNF-α mRNA in whole blood by the stimulation of LPS in 
Chapter 3 showed the same trends seen in other studies reviewed by Surendran et al., 
1999.  Arend et al., (1993) found IL-1ra to inhibit IL-1β and α by binding to receptor 
sites of IL-1 and stopping signal transduction.  Since IL-1β is associated with the 
severity pleuropneumonia (Baarsch et al., 1995), and IL-1β and α also stimulate the 
production of IL-8 by macrophages (Tizard 1996).  Therefore IL-1ra may be able to 
reduce not only IL-1β, but other over produced pro-inflammatory cytokines such as 
IL-8.  Chen et al., 1998 also found IL-1ra can directly influence the production of IL-
8 since IL-1ra inhibited IL-8 in an in vitro system (squamous cell carcinoma human 
cell line). 
The aim of this Chapter was to examine whether compounds with known anti-
inflammatory activity could reduce the severity of App and the deleterious effects of 
this infection on growth.  In addition investigation into whether deliveries of 
recombinant cytokines or plasmid cytokines were effective was examined.  
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4.2  Experimental Protocol LPS Challenge 
Male pigs at an average weight of 52kg were weighed and were randomly allocated 
into 7 treatment groups as described in table 4.1. 
Table 4.1: Summary of treatment groups and of treatment schedule in relation to LPS 
challenge 
Treatment groups Dose rate Treatment applied 
 (days before challenge) 
Saline 50µL/kg -1 days 
Plasmid control 2µg/kg -7 days 
Flunix 2.2mg/kg  -1 day 
Recombinant IL-4 2µg/kg -1 days  
Recombinant IL-1 ra 2µg/kg -1 days  
Plasmid IL-4 2µg/kg -7 days  
Plasmid IL-1 ra 2µg/kg -7 days  
 
Each pen contained 9 pigs, one pig from each treatment group plus 2 spaces and the 
pen was repeated in 4 replicates.  The plasmid groups were given the corresponding 
plasmid 7 days before LPS challenge.  The recombinant cytokine groups received the 
corresponding cytokine 1 day before LPS challenge. 
Plasmids were given intra-muscularly in the upper hind leg while recombinants and 
saline were given behind the ear subcutaneously.  Flunix was administered as a 2mL 
dose (2.2mg/kg) and according to the manufacturer’s instructions.  Recombinants and 
plasmids were provided by CSIRO laboratories in Geelong by Dr. David Strom. 
The weights of the animals were recorded at allocation, 1 day before challenge, 6 days 
post challenge and finally at the conclusion of the LPS challenge.  The pigs were 
challenged with 5µg/kg LPS intravenously.  Animals were restrained using a nasal 
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snare, and whole blood was collected by venipuncture from the jugular vein as 
described in Section 2.2.  Blood was collected before LPS challenge and 1 day after 
LPS challenge.  Pigs were observed after each challenge and throughout the duration 
of the experiment to obtain clinical scores and to check that the animals were not in 
distress.   
4.2.1  Assays performed 
4.2.1.1  Immunoassays 
Lymphocyte stimulation, neutrophil function, T lymphocytes and B lymphocyte 
stimulation, TNF-α bioassays, differential and white blood cell (WBC) counts were 
performed according to the methods outlined in Chapter 2. 
In order to show a complete set of cluster designation (CD) receptor data, obtained 
from the T lymphocyte assay, data was supplied as both percentage and cells/mL 
(Table 4.4, 4.6-4.7).  Due to unforeseen circumstances (machine error) the WBC 
(Table 4.8) for the App challenge model at 24 hours was not obtained, therefore 
cells/mL for this sample time was not calculated. The missing data is displayed by na 
which indicates not assessable. 
 
4.2.1.2  Measurement of Pro-inflammatory Cytokines and CRP by RT-PCR 
RNA was extracted from whole blood samples as outlined previously in Section 2.4.1.   
RT-PCR was performed as described in Sections 2.4.2 and 2.4.3, using paired primers 
for (IL-8, IL-6, IL-1β, TNF-α and C-reactive protein (CRP)).  Minor modifications to 
the methods included IL-8 and TNF-α PCR increased cDNA template changes to 3µl 
and the remainder IL-6, IL-1β and CRP to 2µl.  
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Additives used with some primers are documented in Appendix 3. Data from all 
assays were analysed using ANOVA. 
4.3  Results of LPS Challenge Model 
4.3.1 Growth, in response to LPS Challenge 
The 3 week LPS challenge was not stringent enough to show a difference between 
administrated treatments and controls in terms of weight gain (Figure 4.1). 
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Figure 4.1: Average weight (kg) gain in pigs at one week prior to LPS 
challenge (week 1), the week of challenge (week 2) and one week after 
challenge.  Pigs were treated with saline, Flunix, recombinant cytokines, 
plasmid cytokines prior to LPS challenge. Bars represent mean±SEM, n=5. 
 
Weight gain was not changed in response to LPS challenge.  All groups showed a 
similar level of weight gain the week after challenge (week 3). 
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4.3.2 Immunological and Molecular Techniques LPS 
Table 4.2: Results from immunoassays on blood from pigs before and after challenge 
with LPS.  Pigs were treated with saline, Flunix, recombinant cytokines or plasmid 
anti-inflammatory cytokines and subsequently challenged with LPS. Data 
represented as mean±SEM, n=5. 
 
Assay saline Plasmid 
control 
Flunix IL-4 IL-1ra IL-4 
plasmid 
IL-1ra 
plasmid 
PHA Lymphocyte 
Proliferation  Pre LPS 
% stimulated cells 
99.02+/-
49.72 
124.80+/-
47.39 
98.33+/- 
14.03 
30.34+/-
11.09 
46.18+/- 
24.45 
72.82+/- 
45.10 
110.71+/-
30.10 
Post LPS 
% stimulated cells 
156.28 
+/- 
29.73 
157.41 
+/- 
36.87 
143.43 
+/- 
25.37^ 
311.34 
+/-
99.93*# 
173.80 
+/- 
74.21+ 
76.09 
+/- 
5.77 
140.87 
+/- 
17.34 
Con A Lymphocyte 
proliferation  Pre LPS 
% stimulated cells 
185.37 
+/- 
89.46 
204.12 
+/- 
72.44 
146.88 
+/- 
40.99 
84.93 
+/- 
8.88 
119.56 
+/- 
25.36 
133.86 
+/- 
63.67 
161.34 
+/- 
38.90 
Post LPS 
% stimulated cells 
345.63 
+/- 
51.13 
544.93 
+/- 
287.13 
259.88 
+/- 
54.13 
492.90 
+/- 
110.56 
387.27 
+/- 
103.53 
198.62 
+/- 
66.89 
149.90+/- 
26.36 
Phagocytosing 
neutrophils  Pre LPS 
% phagocytosis 
18.43+/- 
2.06 
18.99+/- 
0.55 
28.56+/- 
2.36 
19.48+/- 
1.43 
25.58+/- 
2.77 
18.74+/- 
3.34 
19.18+/- 
1.68 
Post LPS 
% phagocytosis 
44.60+/- 
2.70^ 
48.32+/- 
4.26&
37.35+/- 
3.90 
28.92+/- 
0.89 
52.07+/- 
3.47 
36.59+/- 
3.85 
33.1+/- 
3.56 
B lymphocytes   
Pre LPS 
% cells 
20.42+/- 
3.13 
22.56+/- 
3.42 
24.64+/- 
3.07 
22.12+/- 
1.98 
18.83+/-
2.85 
26.53+/- 
2.97 
26.81+/-
4.15 
Post LPS 
% cells 
11.37+/-
3.74 
11.85+/-
3.22 
7.08+/- 
2.66 
4.15+/-
0.57#
7.21+/-
2.08 
10.13+/- 
0.90 
13.80+/-
3.19 
WBC 
Pre LPS 
WBCx106cells/mL 
24.18+/- 
2.04 
20.10+/- 
1.21 
23.58+/- 
1.40 
24.32+/- 
2.30 
21.12+/-
3.52 
19.26+/- 
1.69 
22.96+/-
2.24 
Post LPS 
WBCx106cells/mL 
21.74+/- 
1.57 
22.72+/- 
1.69 
23.20+/-
2.19 
23.46+/- 
2.58 
20.78+/-
2.27 
18.78+/- 
1.34 
20.28+/- 
0.88 
+ IL-1ra pre LPS vs IL-1ra post LPS p<0.05, * IL-4 pre LPS vs IL-4 post LPS p<0.05, ^ saline vs IL-4, Flunix 
p<0.05, & plasmid control vs IL-4 plasmid and IL-1ra plasmid p<0.05, # IL-4 vs saline post LPS p<0.05. 
The pigs’ whole blood from the LPS challenge model showed no difference in 
lymphocyte proliferation after Con A stimulation between the treated pigs or between 
sample times.  However the whole blood from the LPS challenge model stimulated 
with PHA showed that pigs treated with IL-1ra produced significantly greater 
(p<0.05) lymphocyte proliferation after LPS challenge as compared to the 
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proliferation produced by the same treatment group pre LPS challenge (Table 4.2).  
The whole blood from the IL-4 treated pigs at post LPS challenge, after stimulation 
with PHA had 10 fold greater lymphocyte proliferation than that of the same pigs 
prior to challenge, and the saline control-treated pigs (p<0.05). 
Neutrophil phagocytic capacity generally increased for all treatments after challenge 
with LPS (Table 4.2).  Compared to saline controls IL-4 and Flunix treated pigs had 
significantly (p<0.05) lower phagocytic capacity of neutrophils after LPS challenge. 
IL-4 plasmid and IL-1ra plasmid treated pigs had significantly less (p<0.05) 
phagocytic capacity of neutrophils after LPS challenge as compared to the plasmid 
control. 
The immunoglobulin Ig receptor found on the cell surface of B lymphocytes was 
enumerated using flow cytometry.  There was a significant decrease in B lymphocyte 
numbers in all the treatments and control group after LPS challenge (Table 4.2).  
After LPS challenge the pigs treated with IL-4 had significantly (p<0.05) less B cells 
than the blood from saline-treated pigs after LPS challenge (Table 4.2). 
The number of total white blood cells in the pigs’ whole blood was not different 
between treated pigs or between sampling time (Table 4.2). 
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plTable 4.3 mRNA production of pro-inflammatory cytokines and C reactive protein was 
established by semi-quantitative RT-PCR. Changes in pro-inflammatory cytokines were 
normalised against β-actin.  Serum production of pigs TNFα protein was also measured 
by bioassay to determine the translation, if any, of mRNA present as protein. bnd int = 
band intensity.  Data represented as mean±SEM, n=5.say  saline Plasmid 
control 
Flunix IL-4 IL-1ra IL-4 
plasmid 
IL-1ra 
plasmid 
IL-6 mRNA bnd int 
Pre LPS 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0.24+/- 
0.15@
Post LPS 0.29+/-
0.18 
0.12+/- 
0.12 
0.07+/- 
0.07 
0.38+/- 
0.16*
0+/- 
0 
0+/- 
0 
0+/- 
0 
IL-8 mRNA bnd int 
Pre LPS 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0+/- 
0 
0.12+/-
0.12 
Post LPS 0.26+/- 
0.16 
0.50+/- 
0.20 
0.53+/- 
0.21 
0.33+/-
0.20 
0.44+/- 
0.23 
0.36+/-
0.22 
0.72+/- 
0.18 
L-1β mRNA bnd int 
Pre LPS 
0+/-0 0.79+/-
0.20 
0.25+/- 
0.22 
0.71+/- 
0.21 
1.03+/-
0.03 
0.67+/- 
0.20 
0.59+/- 
0.24 
Post LPS 0.93+/- 
0.03 
0.60+/-
0.24 
0.81+/- 
0.21 
0.77+/- 
0.19 
0.39+/-
0.24+
0.49+/- 
0.25 
0.37+/- 
0.23 
CRP mRNA bnd int 
Pre LPS 
0+/- 
0 
0.70+/-
0.18 
0+/- 
0 
0.46+/-
0.19 
0.50+/- 
0.19 
0.49+/- 
0.25 
0.86+/- 
0.07 
Post LPS 0.67+/-
0.10^
0.52+/- 
0.22 
1.03+/- 
0.08 
0.80+/- 
0.20 
0.12+/-
0.12 
0.24+/-
0.15 
0.18+/- 
0.18 
NF-α mRNA bnd int 
Pre LPS 
0.42+/- 
0.25 
0.70+/- 
0.17 
0+/- 
0 
0+/- 
0 
0.24+/- 
0.21 
0.81+/- 
0.06 
0.43+/- 
0.17 
Post LPS 0.89+/- 
0.03 
0.80+/- 
0.037 
0.94+/- 
0.01 
0.55+/- 
0.22#
0.59+/-
0.24 
0.87+/- 
0.03 
0.64+/- 
0.06 
TNF protein  
Pre LPS pg/mL 
0+/-0 0+/-0 0+/-0 0+/-0 0+/-0 0+/-0 0+/-0 
Post LPS 
pg/mL 
14.06+/- 
4.50 
9.69+/- 
4.76 
14.10+/- 
2.79 
16.77+/- 
5.17 
14.77+/- 
4.53 
35.22+/-
8.51 
43.78+/- 
10.01 
* IL-4 pre LPS vs IL-4 post LPS p<0.05, + IL-1ra pre LPS vs IL-1ra post LPS p<0.05, ^ saline vs IL-1ra 
p<0.05, # saline vs IL-4 p<0.05, @ IL-1ra plasmid pre LPS vs IL-1ra plasmid post LPS p<0.05. 
e pigs treated with IL-1ra plasmid showed decreased in IL-6 mRNA production to 
ro after the LPS challenge.  The remaining treated pigs showed increased IL-6 
RNA after LPS challenge with the exception of recombinant IL-1ra and IL-4 
asmid treated pigs, which remained at an undetectable level (Table 4.3). 
72 
73 
COMMERICAL IN CONFIDENCE 
IL-8 mRNA production was significantly increased (p<0.05) after LPS challenge in 
all groups (Table 4.3).  The pigs treated with IL-4 showed the least IL-8 mRNA 
production as compared to all the treatments except for the saline-treated pigs after 
LPS challenge (not significant) (Table 4.3). 
Pigs treated with IL-1ra had significantly decreased (p<0.05) IL-1β mRNA levels 
after LPS challenge as compared to levels before challenge (Table 4.3). 
After LPS challenge saline and Flunix treated pigs showed increased C-reactive 
protein (CRP) mRNA from an undetectable level prior to challenge to a detectable 
level (Table 4.3).  The production of CRP mRNA in pigs treated with IL-4 plasmid, 
IL-1ra and IL-1ra plasmid was significantly less (p<0.05) than that of saline-treated 
pigs after challenge (Table 4.3). 
Pigs treated with IL-4 showed the least production of TNF-α mRNA (p<0.05) in 
whole blood after LPS challenge as compared to the pigs treated with saline (Table 
4.3).  After challenge Flunix and IL-4 treated pigs showed increased TNF-α mRNA 
from an undetectable level prior to LPS challenge (Table 4.3) to a detectable level. 
Protein production of TNF-α was undetectable in all treated pigs prior to LPS 
challenge however, it significantly increased (p<0.05) in the IL-4 and IL-1ra plasmid 
treated pigs (Table 4.3). 
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Table:4.4 Cluster designation (CD) lymphocyte data obtained in whole blood from pigs 
treated with saline, Flunix, recombinants or plasmid anti-inflammatory cytokines before 
and after pigs were stimulated by an LPS challenge. Data presented as mean±SEM, n=5. 
Assay saline Plasmid 
control 
Flunix IL-4 IL-1ra IL-4 
plasmid 
IL-1ra 
plasmid 
CD 3 Pre LPS 
x106 cells/mL 
6.88+/- 
1.09 
6.74+/-
0.46 
6.99+/-
0.86 
4.60+/-
0.50 
6.46+/-
0.73 
6.14+/-
1.40 
5.33+/-
1.60 
Post LPS 
x106 cells/mL 
7.80+/-
1.49 
7.75+/-
0.74 
11.10+/-
2.08 
7.23+/-
2.67 
9.28+/-
1.02 
5.33+/-
0.57 
9.03+/-
1.88 
CD 4 Pre LPS 
x106 cells/mL 
2.40+/-
0.48 
2.39+/-
0.16 
2.78+/-
0.22 
2.13+/-
0.15 
2.74+/-
0.34 
2.60+/-
0.49 
2.10+/-
0.55 
Post LPS 
x106 cells/mL 
1.86+/-
0.23 
1.38+/-
0.34 
2.24+/-
0.48 
4.24+/-
1.89#
2.07+/-
0.27 
1.68+/-
0.27 
1.60+/-
0.12 
CD 8 Pre LPS  
x106 cells/mL 
3.31+/-
0.66 
3.38+/-
0.22 
4.10+/-
0.40 
2.87+/-
0.14 
3.50+/-
0.27 
3.55+/-
0.72 
3.54+/-
1.02 
Post LPS 
x106 cells/mL 
2.41+/-
0.28 
2.22+/-
0.43 
3.20+/-
0.59 
2.09+/-
0.23 
3.12+/-
0.78 
1.87+/-
0.39 
2.45+/-
0.58 
CD 4:8 Pre LPS 
% cells 
0.77+/- 
0.14 
0.72+/- 
0.07 
0.70+/- 
0.07 
0.75+/- 
0.06 
0.78+/- 
0.07 
0.77+/- 
0.07 
0.64+/- 
0.08 
Post LPS 
% cells 
0.82+/- 
0.14 
0.62+/- 
0.16 
0.72+/- 
0.09 
1.85+/- 
0.73#
0.75+/- 
0.09 
0.92+/- 
0.05 
0.83+/- 
0.24 
 # saline vs IL-4 p<0.05. 
CD3 is the T cell receptor (TCR) on the surface of all T lymphocytes, therefore 
antibodies against CD3 can help quantify the number of total T cells present in a 
sample.  The blood from pigs that were treated with Flunix, IL-1ra or IL-1ra plasmid, 
showed increased T cells numbers after LPS challenge (p<0.05) (Table 4.4). 
T cells can be separated into two populations; those with T cell receptors 1 (TCR1) 
and those with T cell receptors 2 (TCR2).  T cells with TCR2 make up 95% of T cell 
population (Roitt, 1994).  T cells with TCR2 receptors can be further separated into T 
cells with a CD4 marker or T cells with a CD8 marker. 
T cells with a CD4 marker are T helper cells, which recognise antigens in association 
with major histocompatibity complex class II (MHC II) and T cells with a CD8 
marker are cytotoxic or suppressor cells, which recognise antigens in association with 
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MHC I (Roitt, 1994).  T cells with the CD4 receptors can be further split into T helper 
1 and T helper 2 cells (Roitt, 1994).  Pigs treated with IL-4 showed significant 
increased (p<0.05) CD4 marked cells after the LPS challenge compared with the 
number of CD4 cells the saline-treated pigs showed (Table 4.4). 
There was no difference in CD8 T cells produced by all treatments after LPS 
challenge (Table 4.4). 
When the number of cells with the CD4 receptor/marker are divided by the number of 
cells with the CD8 receptors/marker to produce a ratio, the resulting value can be a 
guide to the kind of immune response produced.  For example, it is known that viral 
infections can result in a high CD4:CD8 (Roitt 1994) (Table 4.4). 
There was an increase in the CD4:CD8 ratio after LPS challenge in the pigs treated 
with IL-4, and this was significantly higher (p<0.05) than the ratio produced by the 
pigs treated with saline (Table 4.4). 
4.4  LPS acute Challenge Model Summary  
• Growth of all the treated pigs, was not impeded by the LPS challenge  
• mRNA of pro-inflammatory cytokines mainly increased at post LPS however 
there was little distinction between the saline treated pigs and pigs treated with 
anti-inflammatory compounds. 
• Lymphocyte proliferation in whole blood from saline treated pigs showed 
variation compared to the pigs treated with IL-4 at post LPS challenge. 
• The inability of this model to induce inappetance and weight loss made it 
difficult to drawn conclusions. 
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4.5  App Challenge Model 
4.5.1  Experimental Protocol App Challenge 
 
Table 4.5: Summary of treatment groups and of treatment schedule in relation to App 
challenge. 
 
 
Treatment groups Dose rate Treatment applied 
 (days before challenge) 
Saline 50µL/kg -2days and challenge day 
Plasmid control 2µg/kg -10days 
Flunix 2mg/kg  -2days and challenge day 
recombinant IL-4 2µg/kg -2days and challenge day 
recombinant IL-1 ra 2µg/kg -2days and challenge day 
Plasmid IL-4 2µg/kg -10days  
Plasmid IL-1 ra 2µg/kg -10days  
 
This challenge was considered a chronic challenge since infection was of 2 weeks 
duration (after previous 3 week acute LPS challenge).  The App trial commenced 
when the plasmids were given to corresponding plasmid groups, 10 days prior to App 
challenge (end of week 2 of LPS challenge).  Pigs remained in their allocated pens 
from LPS challenge.  Plasmid groups were given the corresponding plasmid 10 days 
before App challenge.  The recombinant cytokine groups received the corresponding 
cytokine 2 day before App challenge and at challenge.  Weight of the animals was 
recorded at 2 days before App challenge.  The pigs weights were recorded again at 7 
days post App challenge and just before euthanasia at 13 days post App challenge.  
7.5x105 cfu/mL of App intra-tracheal was administered at App challenge (Refer to 
Section 2.3 Infection Protocol).  Pigs were observed after App challenge and 
throughout the duration of the experiment to obtain clinical scores and to check that 
the animals were not in distress.  Blood was taken 30 minutes before App challenge, 1 
day after App challenge and the day before the animals were sacrificed.  Animals 
were restrained using a nasal snare, and blood collected by venipuncture from the 
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jugular vein as per Section 2.2.  Delivery of both plasmids and cytokines were given 
in the same manner as the LPS Challenge (Section 4.2).  At 14 days the animals were 
euthanased by first sedating them with an overdose of barbiturates and then 
exsanguination. 
4.5.2  Assays performed 
As performed in Section 4.2.1. 
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4.6  Results of App Challenge Model 
4.6.1  Growth, Production and Clinical Signs of App Challenge Pig Model 
As previously stated in the App challenge experimental protocol, weight of the pigs 
were taken 2 days prior to the App challenge, 7 days after challenge and just before 
euthanasia.   Weight gain for week 1 was the weight gained in the week of challenge 
and week 2 was the weight gained after App challenge.  The growth of the IL-4 
treated pigs was significantly greater (P<0.05) than that of the saline treated pigs in 
the week during the challenge (Figure 4.1).  The remaining pigs treated with 
recombinant cytokines and plasmid delivered cytokines also increased in growth 
during this week (Figure 4.1).  Pigs treated with saline, plasmid control and Flunix 
decreased in weight during the challenge week. 
At the end of the trial the, pigs treated with recombinant IL-4 and IL-1ra gained the 
most weight (Figure 4.2b) compared to the other treatment groups and control. 
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 Figure 4.2: Average weight (kg) gain in pigs at week 1 and 2 post App challenge.  Pigs 
were treated with saline, Flunix, recombinant cytokines or plasmid cytokines during 
chronic challenge with App. * IL-4 vs saline p<0.05, # saline at week 1 vs saline week
2. Bars represent mean±SEM, n=5. 
 
 
Weight gain after 2 week showed no significant difference between the treatment 
groups when compared to their controls.  The pigs treated with IL-4 increased in 
weight after 1 week compared to the pigs treated with saline (Figure 4.2).  
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Figure 4.2b: Total weight (kg) gain at euthanasia.  Pigs were treated with 
saline, Flunix, recombinant cytokines, plasmid cytokines prior to App 
challenge. * IL-4 vs saline p<0.05, # IL-1ra vs saline p<0.05,. Bars represent 
mean±SEM, n=5. 
 
Prophylactic delivery of IL-4 and IL-1ra resulted in pigs which out-performed the 
saline controls by gaining the most weight by slaughter (Figure 4.2b).  The plasmid 
pig groups performed the poorest overall in terms of growth. 
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Figure 4.3: Clinical scores obtained by observation of pigs after infection with App. 
Clinical summary of treatment groups on a per visit basis. Total visits =30 and each pig 
was scored from 0-8 (maximum score 240) for each visit. A maximum of 8 indicating 
death of the animal. 
Scoring criteria for the Clinical assessment was as follows:- 0 = no clinical signs, 1 = 
coughing, 2 = anorexia, 3 = fever, 4 = vomiting, 5 = increased pulse rate, 6 = 
blueness, 7 = cardiac and circulatory failure and 8 = death. 
The IL-1ra treated pigs produced significantly less (p<0.05) clinical scores when 
compared to the saline control (Figure 4.3). 
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4.6.2  Immunological and Molecular Assays 
Figure 4.3 Clinical scores obtained by observation of pigs after infection with App. 
Clinical summary of treatment groups on a per visit basis. Total visits = 30 and each 
pig was scored from 0-8 (maximum score 240) for each visit. A score of 8 was given 
to a dead pig (n=5).  * IL-1ra vs saline p<0.05. Bar represent group mean±SEM. 
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Figure 4.4: Stimulation of lymphocyte proliferation by PHA in whole blood 
from pigs treated with saline, Flunix, recombinant cytokines or plasmid 
cytokines and subsequently challenged with App.  Whole blood from each pig 
cultured in media for 54 hours then pulsed with H3 and read on a β counter. 
Bars represent mean±SEM, n=5. 
The whole blood from pigs treated with IL-4 and stimulated with PHA, showed 
significantly (p<0.05) increased lymphocyte proliferation 24 hours after App 
challenge as compared to the lymphocyte proliferation in the whole blood of the same 
pig group recorded prior to App challenge (Figure 4.4).  The whole blood from pigs 
treated with IL-4 and stimulated with Con A, showed decreased lymphocyte 
proliferation compared to blood from the saline-treated pigs 13 days after App 
challenge.  There was no significant difference between treatments at pre App and 13 
days post App which was why this data was not discussed. 
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Figure 4.5: Stimulation of lymphocyte proliferation by Con A.  Whole blood 
from pigs treated with saline, Flunix, recombinants or plasmid anti-
inflammatory cytokines and exposed to App challenge.  Blood cultured in 
media for 54 hours then Pulsed with H3 and read on a β counter.  * IL-4 at 
24h post App vs IL-4 at 13d post App.  Bars represent mean±SEM, n=5. 
 
The lymphocyte proliferation in blood from IL-4 treated pigs 13 day after challenge 
was also reduced compared to blood taken from the same treated pig group at 24 
hours after App challenge (Figure 4.5). 
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ILFigure 4.6: Levels of IL-6 mRNA in peripheral whole blood, measured by RT-
PCR.  Blood from pigs treated with saline, Flunix, recombinants or plasmid 
anti-inflammatory cytokines and exposed to App challenge.  PCR products 
were migrated on an agarose gel which was photographed and quantified by 
densitometry.  Changes in IL-6 were normalised against β-actin. na indicates 
not assessable. Bars show group mean±SEM, n=5. * IL-4 13d post App vs IL-4 
24h post App p<0.05, # IL-4 24h post App vs saline 24h post App. A extracted from the blood taken 13 days after challenge from pigs treated with 
ine was degraded and therefore it was unable to be transcribed (Figure 4.6). 
e whole blood from pigs treated with IL-4 showed reduced IL-6 mRNA production 
 days after App challenge (p<0.05) (Figure 4.6).  All treatment groups showed a 
nd in the reduction of IL-6 mRNA production in whole blood sampled at 13 days 
st App (Figure 4.6) with the exception of the Flunix treated pigs (Figure 4.6).  At 24 
urs after challenge all the treated pigs produced less IL-6 mRNA compared to the 
s treated with saline.  Furthermore, the pigs treated with IL-4 reduced IL-6 mRNA 
duction significantly (p<0.05) compared to the saline control treated pigs 24 hours 
er App challenge. 
e whole blood sampled before App challenge showed no significant difference in 
-6 mRNA levels between treated pigs and control pigs.  At the conclusion of the 
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trial the pig treated with IL-4 had the least (p<0.05) IL-6 mRNA production (Figure 
4.6). 
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Wh
to, 
the
13 
betFigure 4.7: Levels of IL-8 mRNA in peripheral whole blood, measured by RT-
PCR.  Blood from pigs treated with saline, Flunix, recombinants or plasmid anti-
inflammatory cytokines and exposed to App challenge.  Products were migrated 
on an agarose gel which was photographed and quantified by densitometry. 
Changes in IL-8 were normalised against β-actin. Bars represent mean±SEM, 
n=5. ole blood from pigs treated with IL-4 and Flunix produced no IL-8 mRNA prior 
during, or after the App challenge (Figure 4.7).  The whole blood obtained from 
 pigs treated with saline produced a constant level of IL-8 mRNA, however, at day 
it reduced to an undetectable level (Figure 4.7).  Levels of IL-8 were not different 
ween treatment groups. 
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Figure 4.8 Levels of TNFα mRNA production in peripheral whole blood, 
measured by RT-PCR.  Blood from pigs treated with saline, Flunix, 
recombinants or plasmid anti-inflammatory cytokines and exposed to App 
challenge.  PCR products were migrated on an agarose gel which was 
photographed and quantified by densitometry.  Changes in TNFα were 
normalised against β-actin. Bars represent mean±SEM, n=5. 
 
The production of TNF-α mRNA in the whole blood, taken at 3 sample times from 
pigs infected with App and subsequently treated with anti-inflammatory compounds, 
showed no change between sampling time or treatment application (Figure 4.8). 
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Figure 4.9: Levels of IL-1β mRNA in peripheral whole blood, measured by 
RT-PCR. Blood from pigs treated with saline, Flunix, recombinants or plasmid 
anti-inflammatory cytokines and exposed to App challenge.  Products were 
migrated on an agarose gel which was photographed and quantified by 
densitometry.  Changes in IL-1β were normalised against β actin. * IL-4 vs 
saline 24h post App, # plasmid control 13d post App vs plasmid control 24h 
post App. Bars represent mean±SEM, n=5. 
 
The production of IL-1β in whole blood taken from the pigs treated with IL-4 showed 
a significant decline (p<0.05) at 24 hours post App challenge (Figure 4.9).  This 
reduction was significantly lower (p<0.05) than the production of IL-1β mRNA levels 
in blood from saline treated pigs 24 hours after App challenge. 
The pigs treated with plasmid IL-4 and IL-1ra had no detectable IL-1β mRNA in their 
whole blood 13 days after App challenge. 
The whole blood from the pigs treated with the plasmid control (delivery vector) also 
showed a significant reduction (p<0.05) at 13 days post challenge as compared to the 
blood taken from the same group at 24 hours post App challenge (Figure 4.9). 
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Figure 4.10 Levels of CRP mRNA in peripheral whole blood, measured by 
RT-PCR. Blood from pigs treated with saline, Flunix, recombinants or 
plasmid anti-inflammatory cytokines and exposed to App challenge.  Products 
were migrated on an agarose gel which was photographed and quantified by 
densitometry.  Changes in CRP were normalised against β-actin. Bars 
represent mean±SEM, n=5. 
 
The blood from pigs treated with IL-4 recombinant showed a trend in decreasing in C-
reactive protein mRNA (CRP) production across time to zero at euthanasia.  The 
production of CRP mRNA in the peripheral blood of pigs treated with IL-1ra reduced 
to an undetectable level 24 hours after App infection. 
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Figure 4.11: TNFα levels in serum detected by bioassay.  The serum was from 
pigs treated with saline, Flunix, recombinants or plasmid anti-inflammatory 
cytokines and exposed to App challenge.  Bars present the mean±SEM, n=5.  
* Flunix 13d post App vs Flunix 24h post App. 
 
The presence of TNF-α protein in the serum 13 days after App challenge was 
significantly higher (p<0.05) in the pigs treated with Flunix as compared to TNF-α 
produced by Flunix treated pigs at 24 hours post App challenge.  The remaining 
treatments showed inhibited TNF-α production as compared to the saline treated pigs 
at 13 days post App. 
 
 
 
 
 
89 
90 
COMMERICAL IN CONFIDENCE 
 
Table:4.6: Cluster designation (CD) lymphocyte data obtained from pigs’ whole 
blood during a 13 day challenge with App.  Blood was taken from pigs treated with 
saline, Flunix, recombinants or plasmid anti-inflammatory cytokines. na indicates not 
assessable.  Data is presented as the mean±SEM, n=5.  
 
 
CD saline Plasmid 
control 
Flunix IL-4 IL-1ra IL-4 
plasmid 
IL-1ra 
plasmid 
CD 3 Pre App 
% cells 
75.17+/- 
1.70 
71.93+/- 
2.70 
66.14+/- 
2.41 
69.16+/- 
0.61 
72.99+/- 
1.43 
70.43+/- 
2.05 
66.29+/- 
10.23 
24h Post App 
% cells 
47.62+/- 
3.45 
49.45+/- 
2.25 
52.27+/- 
6.20 
54.55+/- 
7.69 
63.65+/- 
2.81#
46.58+/- 
7.84 
58.04+/- 
5.08 
13d Post App 
% cells 
67.76+/- 
2.62 
70.37+/- 
3.40 
72.72+/- 
1.68 
52.94+/- 
17.85 
71.92+/- 
0.85 
66.10+/- 
2.38 
75.84+/- 
2.71 
CD 3 Pre App  
x106 cells/mL 
11.05+/- 
0.60 
10.50+/- 
0.32 
10.96+/- 
1.08 
10.77+/- 
1.51 
9.73+/- 
1.03 
8.55+/- 
1.42 
5.99+/- 
* 
24h Post App 
x106 cells/mL 
na na na na na na na 
13d Post App 
x106 cells/mL 
10.38+/- 
2.94 
12.47+/- 
1.78 
12.90+/- 
1.08 
10.93+/- 
1.47 
9.97+/- 
0.54 
6.96+/- 
1.90 
9.71+/- 
2.06 
CD 4 Pre App 
% cells 
19.95+/- 
2.03 
19.82+/- 
1.35 
16.93+/- 
2.17 
21.13+/-
3.79 
20.37+/- 
1.67 
23.17+/- 
3.14 
12.49+/- 
3.55 
24h Post App 
% cells 
18.21+/- 
1.51 
18.41+/-
1.71 
16.32+/- 
1.24 
20.99+/- 
5.49 
20.81+/- 
1.65 
18.83+/- 
3.01 
16.40+/- 
2.68 
13d Post App 
% cells 
19.91+/- 
1.91 
18.51+/- 
0.51 
17.59+/- 
1.55 
20.81+/- 
5.04 
18.32+/- 
1.43 
20.49+/- 
2.20 
15.97+/- 
0.94 
CD 4 Pre App  
x106 cells/mL 
2.90+/- 
0.26 
2.88+/- 
0.13 
2.72+/- 
0.21 
3.04+/- 
0.23 
2.68+/- 
0.31 
2.86+/- 
0.76 
3.18+/- 
* 
24h Post App 
x106 cells/mL 
na na na na na na na 
13d Post App 
x106 cells/mL 
2.82+/- 
0.50 
3.31+/- 
0.55 
3.14+/- 
0.45 
3.02+/- 
0.47 
2.53+/- 
0.22 
2.22+/- 
0.70 
2.03+/- 
0.41 
# IL-1ra vs saline at 24h post App, * SEM could not be calculated due to insufficient data. 
 
There was no significant difference in the production of T cells with the CD3 marker 
present in the whole blood from treated pigs collected across the 13 day challenge 
period (Table 4.6) (observed in percentage or cells/mL data). The CD3 T cells in the 
blood from pigs treated with IL-1ra remained at a high number through the 13 day 
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challenge.  Pigs treated with IL-1ra were significantly higher (p<0.05) in CD3 T cells 
at 24 hours after challenge than saline treated pigs (Table 4.6). 
There was no difference between the CD4 T helper cells in the whole blood of pigs’ 
produced by the different treatments at any time during the 13 day App challenge 
(Table 4.6).  Presenting this data as percentage cell or cells per mL produced the same 
observations (Table 4.6). 
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Table:4.7: Continuing cluster designation (CD) lymphocyte data obtained from 
pigs’ whole blood during a 13 day challenge by App. B cell numbers were obtained 
using antibody specific flow cytometry to quantify Ig receptor presence.  Blood 
from pigs treated with saline, Flunix, recombinants or plasmid anti-inflammatory 
cytokines. na indicates not assessable.  Data is presented as the mean±SEM, n=5. 
 
 
CD saline Plasmid 
control 
Flunix IL-4 IL-1ra IL-4 
plasmid 
IL-1ra 
plasmid 
CD 8 Pre App 
% cells 
22.79+/- 
2.75 
27.46+/- 
2.22 
22.58+/- 
1.79 
23.31+/- 
2.76 
27.12+/- 
1.13 
29.50+/- 
5.12 
25.32+/- 
2.27 
24h Post App 
% cells 
23.30+/- 
2.72 
29.39+/- 
1.42 
20.64+/- 
2.03 
23.25+/- 
4.08 
25.11+/- 
2.72 
20.90+/- 
5.36 
23.41+/- 
2.90 
13d Post App 
% cells 
30.82+/- 
2.53 
34.00+/- 
5.23 
36.29+/- 
3.33 # 
21.07+/- 
7.55 
27.47+/- 
1.35 
29.34+/- 
2.70 
31.29+/- 
3.70 
CD 8 x106 cells/mL 
Pre App 
3.34+/- 
0.45 
3.98+/- 
0.22 
3.72+/- 
0.43 
3.44+/- 
0.14 
3.58+/- 
0.30 
3.77+/- 
1.29 
5.01+/- 
* 
24h Post App 
x106 cells/mL 
na na na na na na na 
13d Post App 
x106 cells/mL 
4.46+/- 
0.99 
6.35+/- 
1.79 
6.49+/- 
0.98 
4.23+/- 
0.49 
3.79+/- 
0.20 
3.26+/- 
1.14 
4.19+/- 
1.19 
CD4:8 Pre App 
% cells 
0.90+/- 
0.09 
0.73+/- 
0.04 
0.74+/- 
0.06 
0.89+/- 
0.06 
0.75+/- 
0.05 
0.81+/- 
0.08 
0.47+/- 
0.13 
24h Post App 
% cells 
0.79+/- 
0.03 
0.62+/- 
0.03 
0.81+/- 
0.10 
0.86+/- 
0.11 
0.86+/- 
0.04 
1.04+/- 
0.24 
0.78+/- 
0.24 
13dPost App 
% cells 
0.65+/- 
0.03 
0.59+/- 
0.10 
0.49+/- 
0.00 
0.74+/- 
0.13 
0.66+/- 
0.03 
0.71+/- 
0.08 
0.54+/- 
0.09 
B lymphocytes 
Pre App 
% cells 
13.77+/- 
1.56 
18.46+/- 
3.24 
17.49+/- 
1.93 
18.64+/- 
4.64 
16.03+/- 
2.22 
20.95+/- 
1.76 
18.26+/- 
1.54 
24h Post App 
% cells 
10.13+/- 
2.25 
20.10+/- 
2.53 
18.70+/- 
5.91 
20.32+/- 
5.83 
11.41+/- 
2.80 
14.08+/- 
2.12 
12.05+/- 
2.92 
13d Post App 
% cells 
22.28+/- 
6.36 
23.31+/- 
4.78 
25.68+/- 
3.26 
21.03+/- 
5.02 
14.12+/- 
3.85 
23.58+/- 
3.86 
29.68+/- 
1.11 
B lymphocytes  
Pre App 
x106 cell/ml 
2.00+/- 
0.22 
2.82+/- 
0.77 
2.82+/- 
0.24 
2.90+/- 
1.04 
2.05+/- 
0.21 
2.47+/- 
0.33 
3.15+/- 
* 
24h Post App  
x106 cell/ml 
na na na na na na na 
13d Post App  
x106 cell/ml 
2.79+/- 
0.05 
3.92+/- 
0.70 
4.69+/- 
1.10 
3.15+/- 
0.83 
1.86+/- 
0.38 
2.71+/- 
1.14 
3.79+/- 
0.79 
# Flunix 24h vs Flunix 13d post App, * SEM could not be calculated due to insufficient data. 
 
The production of cytotoxic T cells in the whole blood from pigs treated with Flunix 
was significantly higher 13 days after the App challenge as compared to 24 hours 
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after the App challenge (Table 4.7) when data was presented as a percentage.  The 
whole blood from the remaining pig groups showed no difference between sampling 
time or treatment administration, when data was presented as a percentage (Table 
4.7).  However all the treated pigs’ blood revealed an increasing trend of cytotoxic 
cells at 13 days post App challenge. 
There was no significant difference in the CD4:8 ratio of cells between the sampling 
time and the treatment administration across the App challenge. 
B cells showed a decreasing trend in the blood from pigs treated with IL-1ra and its 
plasmid counterpart at 24 hours after challenge (not significant) (Table 4.7). 
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Table:4.8: Neutrophil phagocytic function and WBC counts from pigs treated with 
saline, Flunix, recombinant cytokines or plasmid cytokines and subsequently 
challenged with App. na indicates not assessable. Data is presented as the 
mean±SEM, n=5. 
 
 
 
Assay saline Plasmid 
control 
Flunix IL-4 IL-1ra IL-4 
plasmid 
IL-1ra 
plasmid 
%Phagocytosing 
neutrophils Pre App 
28.84+/- 
0.86 
32.27+/- 
4.83 
28.30+/- 
1.60 
29.41+/- 
1.62 
35.96+/- 
1.87 
29.93+/- 
1.05 
33.79+/- 
4.50 
24h Post App 
% phagocytosis 
33.00+/- 
3.57 
33.96+/- 
2.38 
34.01+/- 
4.69 
32.07+/- 
4.50 
29.33+/- 
2.83 
31.37+/- 
1.52 
26.86+/- 
2.57 
13d Post App 
% phagocytosis 
57.09+/- 
3.56 
60.93+/- 
3.59 
56.32+/- 
3.28 
64.06+/- 
5.94 
61.46+/- 
2.65 
65.70+/- 
1.86 
66.59+/- 
3.66 
WBC Pre App 
x106 cell/ml 
19.88+/- 
0.69 
19.28+/- 
1.95 
22.35+/- 
1.40 
21.10+/- 
2.28 
17.63+/- 
1.90 
17.53+/- 
1.44 
21.50+/- 
* 
24h Post App 
x106 cell/ml 
na na na na na na na 
13d Post App 
x106 cell/ml 
27.97+/- 
5.43 
29.28+/- 
3.18 
29.33+/- 
3.17 
22.70+/- 
2.21 
22.68+/- 
1.43 
22.65+/- 
2.46 
24.75+/- 
2.69 
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s* SEM could not be calculated due to insufficient data
 
he proportion of neutrophils undergoing phagocytosis increased in whole blood of 
ll the treated pigs after 13 days App challenge.  
nfortunately as earlier stated the machine which counts total whole blood cells did 
ot function to produce a result for blood taken 24 hours after App challenge.  From 
he results obtained the number of white blood cells was reduced in the blood taken at 
3 days post App challenge from pigs treated with IL-4 and IL-1ra as compared to the 
aline-treated pigs (not significant)(Table 4.8) 
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4.6.3  Pathology of the App Challenge Model 
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Pigs were euthanased at the end of the trial and their lungs were examined and scored 
by a veterinarian for severity of pleurisy and App lesions.  Pleurisy was scored from 
0-5.  Pigs treated with Flunix (p<0.05), IL-1ra, plasmid IL-4 and plasmid IL-1ra had 
less pleurisy than the saline controls, while pigs treated with the plasmid control had 
the highest levels of pleurisy (Figure 4.12). 
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Figure 4.13: Percentage of lung affected by pleuropneumonia lesion.  Pigs were 
treated with saline, Flunix, recombinant cytokines or plasmid cytokines and 
subsequently challenged with App. Bars represented as mean±SEM n=5. Figure 4.12 Degree of pleurisy at post-mortem expressed as pleurisy score (0-
5) in pigs treated with saline, Flunix, recombinant cytokines or plasmid 
cytokines and subsequently challenged with App.  Bars represented as 
mean±SEM, n=5.95 
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The percentage of the affected lung was determined by removing and weighing the 
whole lung then measuring the weight of the affected part of the lung. This showed 
degree of pleuropneumonia as a percentage of the whole lung.  Saline treated controls 
and plasmid controls had the highest affected lung weight, with greater than 40% of 
their lung weight consisting of App lesions (Figure 4.13).  Pigs treated with Flunix, 
IL-4, IL-1ra and their plasmid counterparts had considerably less affected lung than 
saline controls (Figure 4.13). 
4 7  Discussion 
Although the pigs exhibited symptoms of severe fever and lethargy after the 
administration of LPS, they showed no significant weight loss between the week prior 
to challenge and the week during challenge (Figure 4.1).  This could be due to the 
acute nature of the LPS challenge or the quick recovery of the pigs appetite.  It can be 
concluded that the LPS challenge model did not produced significant enough negative 
growth effects in large pigs to enable an accurate assessment of the efficacy of 
treatments to increase growth. 
The immunological and molecular assays utilized in the LPS acute challenge showed 
interesting responses to the challenge.  The pigs treated with IL-4 showed 
significantly more (p<0.05) lymphocyte proliferation in their whole blood compared 
to the saline treated pigs and the remaining treatment groups when stimulated with 
PHA. 
Prior to the LPS challenge the constitutive amount of IL-8 mRNA detected in the 
whole blood of all the treated pigs was zero with the exception of pigs treated with IL-
1ra plasmid. This group had minimal levels of IL-8 mRNA prior to the LPS 
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challenge.  Prior to the App challenge the pigs treated with Flunix and IL-4 levels of 
IL-8 mRNA returned to an undetectable amount. 
The pigs treated with IL-4 produced significantly less (p<0.05) phagocytosing 
neutrophils after LPS challenge (Table 4.2).  It is known that IL-8 is a neutrophil 
recruiter (Tizard 1996) and hence if there is reduced IL-8 there is usually reduced 
neutrophils.  Even though IL-8 mRNA was low in the blood of the pigs treated with 
IL-4 after LPS challenge, it was not lower than the saline treated pigs (not 
significant).  The low levels of IL-8 mRNA could be due to IL-4 administration since 
Nuntaprasert et al., (2004) also found administration of IL-4 at the same time as LPS 
inhibits the stimulation IL-8, production in pig alveolar macrophages.  The pigs 
treated with IL-4 also produced significantly less (p<0.05) TNF-α mRNA than the 
saline treated pig group.  The production of low neutrophil phagocytic capacity and 
low TNF-α mRNA in blood from pigs treated with IL-4 may be associated since 
Dubravec et al., (1990) also found that polymorphonuclear neutrophils produced 
TNF-α mRNA after LPS stimulation.  It was interesting to find that the constitutive 
levels of IL-6 mRNA were below detectable limit in all the treated pigs and controls 
except the pigs treated with IL-1ra plasmid, since human blood samples have a 
baseline constitutive level of IL-6 mRNA. However, Sipos et al., 2004 found IL-6 
mRNA weakly or not detectable in whole blood samples of some control pigs when 
carrying out a cytokine profile of pigs suffering from natural post-weaning multi-
systemic wasting syndrome. 
The analysis of the immunological and molecular assays utilized in the App chronic 
challenge showed interesting responses to the challenge as well.  The pigs treated with 
IL-4 and IL-1ra increased in weight compared to the controls over the 2 week period 
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of App challenge (Figure 4.2b).  Flunix was the poorest performing treatment in terms 
of growth (Figure 4.2). 
There was a reduction in pro-inflammatory cytokines such as IL-1β mRNA in whole 
blood taken from pigs treated with IL-4 24 hours after App challenge.  This trend in 
reduced pro-inflammatory cytokines was observed again in the reduction of IL-8 
mRNA 13 days after App challenge in the same treatment group.  Interestingly, 
Flunix did not follow this trend instead it did not inhibit the production of serum 
TNF-α, which may explain the poor growth observed in this group.  The pigs treated 
with Flunix did not reduce IL-6 mRNA production in their whole blood either (Figure 
4.6).  Morrison et al., (2000) observation that excessive TNF-α can cause massive 
lung injury in pigs.  Olsson (1995) also found that elevated levels of TNF-α play a 
role in Multiple Sclerosis (humans).  This may explain the association between poor 
growth and TNF-α, since animals in poor health rarely achieve normal growth.  
Huang et al., (1999) also recorded an elevation in TNF-α and IL-1 in the serum, 
which coincided with the onset of acute clinical disease (App) in pigs. 
Pigs treated with IL-4 had significantly less (p<0.05) IL-6 mRNA at 13 day post App 
and the most growth as total weight gain (Figure 4.2b).  Pigs treated with Flunix and 
IL-4 had an undetectable level of IL-8 mRNA in their peripheral blood prior to the 
App challenge, which was suppressed across the 13 day App challenge perhaps by the 
administration of these treatments (Figure 4.7).  Zhou et al., (1994) also found that IL-
4 administration stopped the production of IL-8 mRNA at a transcriptional level 
however, it was in a in vitro system.  The production of IL-8 mRNA 24 hours after 
App challenge was detected in the blood of pigs treated with IL-1ra (Figure 4.7) at the 
same quantity as that found in the control pig groups. 
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Pigs treated with IL-1ra had low clinical scores (Figure 4.3) and their affected lung 
was low (Figure 4.13).  Phagocytosing neutrophils in the blood gives some 
perspective of neutrophils traveling to infection site (lung).  Pigs treated with IL-1ra 
produced a similar number of phagocytosing neutrophils as the saline treated pig 
group (Table 4.8), however, the administration of IL-1ra showed an association with 
the reduction of lung damage in this group (Figure 4.13). 
The suppression of IL-8 mRNA is produced 24 hours after App challenge (Figure 4.7) 
by pigs treated with IL-4.  Perhaps IL-4 stops IL-8 at a transcriptional level (Zhou, et 
al., 1994).  IL-1ra can also influence IL-8 production since it was found by Chen et 
al., (1998) that IL-1ra inhibited IL-8 which was stimulated by IL-1α in an in vitro 
system (squamous cell carcinoma human cell line). 
The production of IL-8 mRNA by the pigs treated with saline and plasmid control, IL-
1ra and its plasmid counterpart was present prior to, and 24 hours after the App 
challenge.  This was interesting since the plasmid control and saline treated pig 
groups also produced the most lung lesions (Figure 4.13) and showed the greater 
clinical signs, yet the pigs treated with IL-1ra and IL-1ra plasmid did not show the 
same trends.  However, the pigs treated with IL-1ra and IL-1ra plasmid differed from 
the saline and plasmid control treated pigs in that each group produced higher 
numbers of T cells with CD3 (data presented as percentages) receptors 24 hours after 
App challenge (Table 4.6).  Furthermore increased TNF-α protein production showed 
this association with poor growth in pigs treated with Flunix.  The reduction in weight 
gain of Flunix treated pigs were puzzling since the group had low pleurisy, low 
affected lung, and low clinical scores. Furthermore pigs treated with Flunix at the end 
of the trial had significantly higher T cells with the CD8 marker (data as percentages) 
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in their blood, as compared to 24 hours after the App challenge.  Perhaps these 
suppressor/cytotoxic cells were compensating for the increase in TNF-α in the serum. 
The relationship between pro-inflammatory cytokines and impaired growth needs 
further study. 
The production of IL-1β mRNA in pigs treated with IL-4 was reduced 24 hours after 
App challenge (Figure 4.9).  IL-4 was found to stop the production of IL-1β mRNA at 
a transcirptional level (Zhou et al., 1994).  IL-1β is known to activate macrophages to 
produce IL-6 and IL-8 (Tizard 1996). However, there must be another inducer of IL-6 
and IL-8 production or other cells producing these cytokines such as lymphocytes, 
fibroblasts, and endothelial cells or infiltrating neutrophils (Tizard 1996), since they 
are present in the peripheral blood. 
Pigs treated with IL-1ra had suppressed TNF-α protein in serum over the 13 day App 
challenge (Figure 4.11).  Although there was IL-1β mRNA present in pigs treated 
with IL-1ra, this does not necessarily mean it had been transcribed into protein 
(Figure 4.9).  Therefore if there was no IL-1β protein in the blood of the pigs treated 
with IL-1ra then there would be reduced CRP mRNA (Figure 4.10) produced since as 
earlier stated CRP is an acute phase protein in the early stages of infection and 
mediated by IL-1 (Klein 1997).  However the acute phase response is not induced by 
a single mediator (Taylor et al 1990).  This may shed some light on the suppression of 
CRP mRNA 24 hours after App challenge in the pigs treated with IL-1ra however, the 
assumption that no IL-1β mRNA was transcribed to protein is mere speculation.  
Unfortunately time did not permit the analysis by ELISA of serum to obtain IL-1β 
protein profiles. 
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The pigs treated with IL-4 showed a reduction to zero in CRP mRNA (Figure 4.10) 
over the 13 day App challenge period, which also coincided with the suppression of 
IL-1β at 24 hours post infection (Figure 4.9). 
Even though the anti-inflammatory cytokine treatments reduced the levels of pro-
inflammatory cytokines in the circulation and increased growth in some treated pigs. 
The relationship between pro-inflammatory cytokines and impaired growth needs to 
be well defined by ongoing experiments into the role of pro-inflammatory cytokines 
and growth. 
The lymphocyte proliferation profiles of the treated pigs blood stimulated by Con A 
(Figure 4.4) in the App challenge is almost identical to the lymphocyte proliferation 
profile stimulated by PHA (Figure 4.3) therefore, either can be used in the next 
experiment. 
The production of TNF-α protein in the serum of pigs treated with Flunix may be 
secreted by the T cells with CD4 markers however, it seems unlikely since they are at 
the same numbers of cells as the remaining treated pig groups.  Macrophages and 
other cells may also be producing the TNF-α in the serum of these pigs.  As stated 
earlier the pigs treated with IL-1ra produced the most T cells with a CD3 marker 
present (Table 4.6) at 24 hour after App challenge. This large production does not 
mean all these T cells are active since IL-1ra binds to T helper 2 cells and inactivates 
the cell from producing IL-1, which is a precursor to other pro-inflammatory 
cytokines like IL-6 and IL-8 (Figure 4.6-4.7) (Arend et al., 1993). 
Since IL-1ra can stops IL-1β by binding to receptors on T helper 2 cells and blocking 
IL-1 from signal transduction (Arend et al., 1993) therefore stopping the secretion of 
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IL-5 or IL-4 which stimulate B cells proliferation and growth perhaps could give an 
explanation to the low number of B cells.  The fact that pigs treated with IL-1ra did 
not produce a large amount of B cells demonstrates that this treated pig group 
displayed better health.  The decrease in clinical signs (Figure 4.3) and increase in 
weight gain in the pigs treated with IL-1ra reflected the improved health of this group 
(Figure 4.2b). 
Pigs treated with IL-4 and IL-1ra performed better than the remaining treatment 
groups in terms of their clinical scores (Figure 4.3) and affected lung (Figure 4.13). 
There was no significant difference between the treatment groups in terms of pleurisy, 
with the exception of the pigs treated with Flunix which produced less pleurisy scores 
than the pigs treated with plasmid control (Figure 4.12). 
IL-1ra plasmid reduced the amount of lung lesions caused by App as compared to the 
saline and plasmid controls. Nevertheless recombinant IL-1ra dramatically improved 
the pathology of the pigs’ lung.  IL-1 is a precursor to pro-inflammatory cytokines 
like TNF-α which are implicated in lung damage (Morris et al., 2000), along with IL-
8 which causes acute lung inflammation (Huang et al., 1999).  TNF-α is not totally 
inhibited since this can also affect the pig negatively.  Pigs treated with saline and 
plasmid controls had a similar amount of lung lesions and affected lung (Figure 4.13). 
The pigs treated with IL-1ra produced significantly less (p<0.05) clinical scores 
(Figure 4.3) with saline and Flunix produced the most. Thus it can be said that in 
addition to improving the growth of pigs, some cytokines also improve the health of 
pigs especially those at risk to disease. Similarly Muller (1998), Mosmann (1994) 
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observed that IL-4 inhibited the synthesis of pro-inflammatory cytokines and 
therefore reduced rheumatoid arthritis in humans. 
Some cytokines in addition to improving growth can boost the health of pigs exposed 
to disease such as App.  For example IL-4 and IL-1ra treated pigs had reduced 
affected lungs was similar to the reduced IL-6 and IL-8 mRNA (Figure 4.13, 4.6, 4.7), 
(Zhou, et al., 1994). 
 
It may be concluded that plasmids are not useful as a delivery system for anti-
inflammatory cytokines like IL-4, and IL-1 receptor antagonist since they did not 
differ in growth or health from the pigs treated with saline.   
The NSAID (Flunix) performed as well as IL-4 and IL-1ra however, Flunix in large 
doses can be toxic. The prophylactic delivery of the cytokines and the non-steriodal 
drugs had a positive affect on pathological stress and hence on growth. 
4.8   App chronic Challenge Model Summary  
• During the first week of App challenge recombinant IL-4 and IL-1ra increased 
the growth of pigs compared to the saline control group.  The pigs treated with 
Flunix had the lowest growth over the 13 day challenge period. 
• At euthanasia the pigs treated with recombinant IL-4 and IL-1ra were 4kg 
heavier than their saline counterparts 
• The pigs treated with Flunix, IL-1ra and IL-4 had the reduced pleurisy at post-
mortem.  These treatments and their plasmid counterparts reduced the 
percentage of lung affected by App lesions. 
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• The pigs treated with Flunix and IL-4 suppressed IL-8 mRNA production 
across the 13 day App challenge. 
• Delievery of anti-inflammatory compounds through plasmids proved to be 
ineffective as a delivery system. 
• IL-1ra and IL-4 administered as a prophylactic has demonstrated an ability to 
improve growth however, do these anti-inflammatory cytokines have the 
ability to improve growth when given as a therapeutic.  This will be 
investigated in the next Chapter.
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CHAPTER 5 
THERAPEUTIC DELIVERY OF IL-4 AND IL-1RA FOR 
THE TREATMENT OF SYMPTOMS ASSOCIATED 
WITH APP IN PIGS 
5.1  Introduction 
Since the prophylactic use of IL-4 and IL-1ra showed promising results in the 
previous Chapter, the therapeutic potential of IL-4 and IL-1ra required investigation.  
The prophylactic characteristics of IL-4 and IL-1ra for reducing the production of pro-
inflammatory cytokines such as IL-6, IL-8 and increasing weight gain was dramatic.  
Furthermore, the ability of IL-4 and IL-1ra to reduce App associated pathology in 
lungs of the pigs showed that these substances may also have use as therapeutics.  A 
large trial examining therapeutic (ie, post-challenge) delivery of IL-4 and IL-1ra, was 
therefore conducted with a multitude of assays (including whole blood counts, T cell 
counts using CD markers, lymphocyte proliferations and RT-PCR). 
The overall aim of this experiment was to observe if IL-4 and IL-1ra had a therapeutic 
affect to treat App infection.  A commercially available medication (Excenel) for pigs 
suffering App infection was also included for comparison with IL-4 and IL-1ra. 
Excenel is a broad spectrum antibiotic which has been shown to inhibit the cell wall 
synthesis of bacteria in vitro (IVS annual).  It binds to inflammatory proteins in the 
lung and also works in extracellular fluid where pathogens (e.g. pneumonia) live. 
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5.2  Materials and Methods 
5.2.1  Experimental Protocol 
As in the previous experiment the pigs were weighed and randomly allocated into 5 
treatment groups and 1 control group.  Fifty four pigs at a mean weight of 34kg were 
introduced into the Elizabeth Macarthur Agricultural Institute (EMAI).  
Each pen consisted of 6 pigs 1 from each of the 6 treatment groups.  This pen design 
was replicated 3 times, in 3 separate rooms.  The treatments included IIL 4 low 
concentration, IL-4 high concentration, IL-1ra low concentration, IL-1ra high 
concentration, Excenel (Pfizer AH, NY, USA) and saline. 
Table 5.1: Summary of the treatment groups and of the treatment schedule in relation 
to challenge 
 
Treatment groups Dose rate Treatment applied 
 (post challenge) 
Saline 10mg/pig 24h, 48h,1week 
IL-4 low 2mg/kg 24h, 48h,1week 
IL-4 high 10mg/kg 24h, 48h,1week 
IL-1ra low 2mg/kg 24h, 48h,1week 
IL-1 ra high 10mg/kg 24h, 48h,1week 
Excenel 3mg/kg Daily for 3 days according to 
manufacturer’s instructions. 
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The pigs were challenged with 7.5x105cfu/mL App intra-tracheal at day zero(as 
described in Chapter 4 and section 2.3) and starting weights were recorded. Pigs were 
observed for 24 hours after App inoculation and then examined daily for clinical signs 
such as fever, apathy, lethargy and labored breathing.  Weights were measured at 24 
hours, 7 days and 2 weeks. Jugular blood samples were taken at 0 hour, 24 hours, 48 
hours, 7 days and 2 weeks after infection for immunological and molecular analyses..  
At 2 weeks after infection the animals were euthanasied and the blood and lungs were 
examined for analysis of pathological change due to pleuropneumonia. 
5.2.3  Immunoassays Performed 
Lymphocyte proliferation, neutrophil function, T and B lymphocyte number, 
immunoglobulin levels, TNFa levels, differential and whole blood counts were 
determined according to the methods outlined in, Sections 2.6-2.10 and 2.12. 
Antibodies in the serum of treated pigs such as IgA and IgG were quantified using 
sandwich ELISA.  The limit of detection was 15pg/mL, and data was expressed as 
mg/mL of immunoglulin present.  IgG is a major immunoglobulin synthesized in the 
body (Roitt 1994). 
Cluster designation (CD) receptor data, obtained by flow cytometry, was supplied as 
both percentages and cells/mL (Table 5.5-5.6).  Chapter 4 has an incomplete set of 
data presented as cells/mL due to a machine breakdown.  Therefore a full set of 
percentage lymphocyte stimulation data in this Chapter can be used to compare to the 
percentage CD cell count data in Chapter 4 (Table 4.6-4.7). 
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5.2.4  Measurement of Pro-inflammatory Cytokines by RT-PCR 
RNA was extracted from whole blood samples as outlined in Section 2.4.1.  RT-PCR 
was performed as described in Sections 2.4.2 and 2.4.3, using mRNA primers for b-
act, IL-8, IL-6, TNFa, IL-1b and CRP (refer to the table in Appendix 1 for 
sequences). Minor modifications to the methods described previously included cDNA 
template changes and additives used with some primers which is documented in 
Appendix 3. 
5.2.5  Paraffin Tissue Sections 
Lung samples measuring <1cm3 were fixed in 10% formalin overnight. The tissue 
samples were then trimmed to a smaller size for embedding and placed in a transfer 
cassette and stored in 70% alcohol overnight. The cassettes were placed in an 
automatic processor which passed through an alcohol gradient, and were then 
infiltrated with molten paraffin. The samples were embedded in wax paraffin blocks 
and cut to 5mm sections. Sections were attached to clean glass slides from water bath 
and placed in an oven at 37oC until dry. 
Prior to use, sections were dewaxed in two changes of xylol for 3 minutes each, and 
then rehydrated through an ethanol gradient (twice 100%, 95%, and 70%) for 3 
minutes each.  Slides were soaked in picric acid for 15 minutes to remove excess 
blood, and then washed under running tap water for 15 minutes.  The slides were 
counter stained in haematoxylin (Sigma-Aldrich, St Louis, USA) for 3 minutes and 
washed for 2 minutes in running water, and stained in Scott’s blueing solution for 2 
minutes. Slides were washed again in running tap water and stained with eosin 
(Sigma-Aldrich, St Louis, USA) for 30 seconds. Slides were then passed through an 
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ethanol gradient (twice 70%, 95%, 100% and 100%). The slides were passed through 
a solution of 50% ethanol in xylol three times and once in 100% xylol. Sections were 
mounted in Depex and coverslip placed on top, and left to dry. 
5.2.6  In situ Hybridization 
5.2.6.1  Sample Collection and Cutting Frozen Sections 
Tissue samples from pig lungs measuring approximately 1cm3 were placed in 
cryotubes and snap frozen in liquid nitrogen. Tissues were embededed in O.C.T 
compound (Tissue-Tek, Bayer, Leverkusen, Germany) and frozen. Sections of 8mm 
were cut using a cryomicrotome (International Equipment Company, CA, USA) and 
were mounted on silane-coated slides (Sigma-Aldrich , St Louis, USA).  
5.2.6.2  IL-8 Probe 
Cloned IL-8 cDNA was prepared as described in Section 2.4.  PCR was performed on 
known IL-8 positive sample and the resulting PCR product was used to make the IL-8 
probe following the manufacturer’s instructions for the DIG-label kit (Roche, 
Postfach, Switzerland). A positive RNA probe (IL-8 anti-sense probe) and a negative 
RNA probe (IL-8 sense probe) were made, and 5ml of each was run on a 1.2% agarose 
gel to confirm probe production. Probes were purified by alcohol precipitation and the 
purity of the probe was confirmed by reading at 260nm on a Spectromax 250 
(Molecular Devices, Sunnyvale, CA, USA) spectrophotometer. Alcohol precipitation 
was performed by adding 1:10 volume 3M C2H3O2Na and 2 volumes of ethanol to the 
probe volume and incubated at -20oC overnight. This solution was then centrifuged at 
15000g for 10 minutes at 4oC.  Supernatant was decanted and the pellet was washed 
with 200mL 70% ethanol and centrifuged again at 15,000g for 10 minutes at 4oC.  
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Supernatant was decanted and the pellet air dried.  The probes were diluted to 
200hg/mL, aliquoted and stored at -20oC prior to use. 
5.2.6.3  Pre-Hybridization 
Slides were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) pH 10, 
containing 0.1% active diethyl pyrocarbonate (DEPC) for 30 minutes. The slides were 
then soaked twice for 15 minutes in PBS containing 0.1% active DEPC.  A volume of 
150ml of 5x SSC (0.75M NaCl and 0.075M Na3C6H5O7 in DEPC water) was 
dispensed onto each tissue and the slides were placed in a hybridizing chamber at 
room temperature for 15 minutes. The SSC was removed by tilting the slides.  Pre-
hybridization solution (50% formide, 5x SSC and 40mg/mL unlabled cDNA), 150ml, 
was dispensed onto each tissue and the slides were returned to the hybridizing 
chamber. Parafilm was used as a coverslip to stop evaporation and the chamber was 
set at 58oC for 2 hours. 
5.2.6.4  Hybridization 
Slides were again tilted to removed pre-hybridization solution and either 400hg/mL 
of positive probe or negative probe in fresh hybridization solution was added to each 
tissue. The slides were heated to 95oC for 2 minutes to denature the probes. Slides 
were then returned to the hybridization chamber at 58oC with parafilm coverslip 
attached and left to hybridize overnight. 
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5.2.6.5  Blocking 
Slides were soaked in two changes of TB-S (0.1M Tris-HCL and 0.15M NaCl with 
0.1% TritonX-100, pH 7.6) at 65oC for 1 hour each.  The slides were returned to the 
chamber with 150 ml of blocking solution (10% heat inactivated foetal calf serum and 
3% bovin serum albumin into TB-S) on each tissue and kept at room temperature for 
30 minutes.  Buffer was removed by tilting the slides, alkaline phosphatase-
conjugated anti-DIG (Roche, Postfach, Switzerland) antibodies was diluted to 1:500 
in blocking buffer and added to tissues. Slides were placed back into the chamber at a 
temperature of 37oC for 2 hours. 
5.2.6.6  Staining 
Alkaline phosphatase substrate buffer (APSB) 0.1M Tris-HCL pH9.5, (0.1M NaCl, 
50mM MgCl2) was used to wash slides in a container with constant stirring. Slides 
were washed twice for 30 minutes at room temperature. Slides were removed and 
stained for 20 minutes at room temperature with alkaline phosphatase substrate 
containing 0.33mg/mL nitroblue tetrazolium, 0.175mg/mL bromochloroindolyl 
phosphate and 3 mM levamisole in APSB.  Colour development was stopped using 
distilled water.  Slides were air-dried and coverslipped with Kaiser Jelly (gelatin w/v 
7.7%, glycerol v/v 53.8%, sodium azide w/v 0.13%, phenol w/v 7.7% in distilled 
water. 
5.2.6.7  Statistics 
Data from all assays were analysed using ANOVA. 
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5.3.Results 
5.3.1  Growth, Production and Clinical Signs 
Change in weight was considered to be the most important parameter in determining 
treatment efficacy; however, there were no significant differences between groups at 
the end of the trial (Figures 5.2).  Unlike the previous experiment in Chapter 4 all 
groups gained weight in the 2 weeks after App infection (Figure 5.1).  IL-4 lo, IL-4 hi 
and IL-1ra lo treatment groups experienced similar weight gain after 2 weeks; the 
dramatic increase in weight of the IL-4 and IL-1ra treated pig groups observed in 
Chapter 4 (Figure 4.2) did not occur in this current experiment.  After the first week 
the weight gain of the saline treated groups increased by 6.3kg. 
 
 
 
 
 
 
Figure 5.1: Weight gain of pigs challenged with App and subsequently treated 
with saline, Excenel, or recombinant cytokines at high and low concentrations at 
1 and 2 weeks after challenge. Bars represent mean±SEM, n=9. 
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Regardless of the treatment administered there was no difference between treatment 
groups in the amount of weight gained at the conclusion of the trial (Figure 5.2). 
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Figure 5.2: Mean total weight gain of pigs challenged with App and 
subsequently treated with saline, Excenel, or recombinant cytokines at high 
and low concentrations, at the conclusion of the trial.  Bars represent 
Mean±SEM, n=9. 
Figure 5.3: Clinical summary of pigs challenged with App and subsequently 
treated with saline, Excenel, or recombinant cytokines at high and low 
concentrations on a per visit basis. The pigs had 30 visits and each pig was 
scored from 0-8 (maximum score 240) for each visit.  Bars represent mean 
±SEM, n=9. * = IL-1ra hi vs excenel treated groups p<0.05. 
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There were significantly less clinical signs observed in the pigs treated with Excenel 
as compared to the pigs treated with IL-1ra at a high dose.  Other than that there were 
no differences between the groups as far as clinical signs were concerned. 
5.3.3  Immunological and Molecular Techniques 
5.3.3.1  Lymphocyte Proliferation and Neutrophil phagocytosis 
Whole blood from pigs treated with IL-4 lo had significantly increased lymphocyte 
proliferation in response to Con A, 48 hours after App infection as compared to the 
blood from pigs treated with saline at the same sample time (Table 5.2).  All of the 
treatment groups slightly increased lymphocyte proliferation after stimulation with 
Con A at 48 hours post-infection compared to pre-challenge samples (Table 5.2).  KB 
were also used to stimulate lymphocyte proliferation as outlined in Section 2.10.1, 
which caused an increase in proliferative response in the whole blood from all the 
treated pig groups (Table 5.2).  The whole blood sampled at 24 hours and stimulated 
with KB showed decreased lymphocyte proliferation responses in all the treatment 
groups.  Blood sampled at 48 hours post App from pigs treated with IL-1ra lo and 
stimulated with KB, showed an significant increase in lymphocyte proliferation 
compared to the blood from the pigs treated with IL-1ra hi however, there was no 
significant difference between these groups and saline-treated pigs (Table 5.2).  
Generally, the proliferation of lymphocytes stimulated by Con A and KB showed no 
significant differences between treatments or sample time. 
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Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
KB Lymphocyte 
proliferation 0h  
% stimulated cells 
 
38.29+/- 
5.51 
 
40.31+/- 
4.46 
 
26.59+/- 
6.86 
 
41.96+/- 
4.87 
 
44.44+/- 
6.54 
 
33.71+/- 
7.05 
24h  
% stimulated cells 
22.87+/- 
4.46 
24.75+/- 
4.52 
24.73+/- 
4.07 
30.37+/- 
8.81 
33.24+/- 
6.65 
21.24+/- 
4.38 
48h 
% stimulated cells 
27.78+/- 
8.71 
28.28+/- 
8.18 
24.53+/- 
8.88 
41.90+/- 
8.66# 
19.72+/- 
4.17 
31.77+/- 
5.50 
1 week 
% stimulated cells 
31.95+/- 
4.46 
22.49+/- 
3.65 
22.55+/- 
3.33 
25.56+/- 
8.55 
28.23+/- 
6.75 
22.89+/- 
5.32 
2 weeks 
% stimulated cells 
35.59+/- 
5.20 
24.33+/- 
4.98 
28.94+/- 
5.53 
22.45+/- 
5.78 
31.49+/- 
7.47 
29.74+/- 
5.22 
ConA Lymphocyte 
proliferation 0h 
% stimulated cells 
 
0.93+/- 
0.09 
 
0.97+/- 
0.14 
 
0.92+/- 
0.17 
 
1.12+/- 
0.13 
 
1.10+/- 
0.16 
 
1.07+/- 
0.20 
24h 
% stimulated cells 
1.03+/- 
0.12 
1.10+/- 
0.06 
1.05+/- 
0.07 
1.03+/- 
0.12 
1.04+/- 
0.05 
1.22+/- 
0.07 
48h 
% stimulated cells 
1.21+/- 
0.13 
1.76+/- 
0.28* 
1.41+/- 
0.14 
1.31+/- 
0.08 
1.47+/- 
0.08 
1.33+/- 
0.09 
1 week 
% stimulated cells 
0.86+/- 
0.08 
0.71+/- 
0.09 
1.03+/- 
0.09 
1.05+/- 
0.08 
1.06+/- 
0.08 
0.83+/- 
0.15 
2 weeks 
% stimulated cells 
1.24+/- 
0.12 
1.03+/- 
0.18 
1.63+/- 
0.26 
1.15+/- 
0.12 
1.17+/- 
0.19 
1.30+/- 
0.19 
 
There was no difference between treatment groups in the ability of neutrophils  to 
phagocytose zymosan or KB (Table 5.3). with the exception of the pigs treated with 
IL-1ra lo, which had a significantly higher proportion of phagocytosing neutrophils 
compared to IL-1ra hi treated pigs 48 hours after App challenge. 
Table:5.2 Lymphocyte proliferative responses to KB or ConA in whole blood 
from pigs infected with App and subsequently treated with saline, Excenel, or 
recombinant cytokines at high and low concentrations. Data presented as 
mean±SEM, n=9. 
 
* IL-4 lo vs saline at 48h, # IL-1ra lo vs IL-1ra hi at 48h 
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Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
Phagocytosis zymosan 
stimulated neutrophil 0h 
 % phagocytosis 
 
46.24+/- 
2.80 
 
50.24+/- 
3.63 
 
55.96+/- 
2.10 
 
56.27+/- 
4.72 
 
51.74+/- 
4.67 
 
56.91+/- 
3.06 
24h 
% phagocytosis 
55.90+/- 
3.29 
55.58+/- 
2.36 
57.67+/- 
3.86 
61.42+/- 
1.87 
57.66+/- 
3.51 
58.88+/- 
2.81 
48h 
% phagocytosis 
41.70+/- 
3.34 
42.15+/- 
4.38 
45.03+/- 
3.84 
52.68+/- 
4.91# 
37.59+/- 
4.22 
48.06+/- 
2.40 
1 week 
% phagocytosis 
50.02+/- 
3.93 
51.03+/- 
2.64 
42.59+/- 
4.29 
47.23+/- 
3.10 
47.11+/- 
3.89 
52.10+/- 
1.90 
2 weeks 
% phagocytosis 
65.36+/- 
3.66 
62.56+/- 
2.69 
59.62+/- 
3.82 
61.81+/- 
3.65 
61.15+/- 
2.27 
69.79+/- 
2.64 
Phagocytosis KB stimulated 
neutrophils 0h 
% phagocytosis 
 
70.75+/- 
3.18 
 
74.89+/- 
1.94 
 
76.72+/- 
2.01 
 
76.11+/- 
2.13 
 
65.16+/- 
8.24 
 
75.07+/- 
2.62 
24h 
% phagocytosis 
60.55+/- 
3.20 
59.08+/- 
3.66 
61.47+/- 
4.03 
59.75+/- 
0.94 
56.92+/- 
2.96 
57.06+/- 
2.32 
48h 
% phagocytosis 
60.79+/- 
5.39 
61.04+/- 
5.45 
61.44+/- 
3.14 
72.23+/- 
5.06 
60.73+/- 
4.59 
73.01+/- 
6.87 
1 week 
% phagocytosis 
84.53+/- 
1.23 
80.72+/- 
2.82 
80.34+/- 
1.93 
82.20+/- 
2.52 
81.98+/- 
2.41 
83.16+/- 
1.51 
2 weeks 
% phagocytosis 
72.86+/- 
2.92 
71.98+/-
3.21 
74.23 
2.19 
69.11+/-
4.23 
60.50+/- 
3.42 
57.24+/-
11.31 
 
5.3.3.2  Semi-quantitative RT-PCR 
IL-8 mRNA production in peripheral blood in all the treated pigs varied little between 
sample times (Table 5.4).  However, 24 hours after the App challenge a significantly 
larger level of IL-8 mRNA was found in the pigs treated with IL-4 hi as compared to 
the pigs treated with IL-1ra lo.  IL-8 mRNA production decreased to an undetectable 
amount between 48 hours and 1 week post-infection in the pigs treated with IL-4 hi 
but not in other treatments (Table 5.4). 
IL-8 mRNA production in the peripheral blood of pigs treated with IL-4 hi is 
significantly higher than that produced by pigs treated with saline.  In all treatment 
Table:5.3 Proportion of neutrophils phagocytosing zymosan or KB from pigs 
infected with App and subsequently treated with saline, Excenel, or recombinant 
cytokines at high and low concentrations. Data presented as mean±SEM, n=9. 
# IL-1ra lo vs IL-1ra hi at 48h p<0.05 
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groups the amount of TNFa mRNA in peripheral blood was high before the App 
infection was administered (Table 5.4).  The saline treated pig group had a reduction 
in TNFa mRNA at 24h post App infection which increased slightly until euthanasia.  
TNFa mRNA levels decreased in pigs treated with IL-4 hi by more than half, 24 
hours after App challenge and subsequently decreased to an undetectable amount 
followed by a slight increase at 2 weeks post App infection.  Similar trends were seen 
for pigs treated with IL-1ra lo. 
Pigs treated with IL-4 lo had decreased TNFa mRNA 24 hours after App after which 
the TNFa mRNA levels remained constant till euthanasia (Table 5.4).  TNFa mRNA 
was reduced in Excenel treated pigs 24h post App further reduced to undetectable 
until the end of the trial. TNF-a mRNA from pigs treated with saline was reduced 
across time less than the pigs treated with IL-1ra and IL-4 (Table 5.4).Interestingly 
there was an elevation of IL-1b mRNA with a corresponding TNFa mRNA decrease 
(Table 5.4) 
With the exception of the pigs treated with IL-1ra hi and Excenel, all the treated pigs 
had undetectable levels of IL-1b mRNA at the time of App challenge.  There was 
significantly less IL-1b mRNA in the IL-1ra lo treated pigs as compared to the IL-4 hi 
and IL-4 lo treated pigs at 24 hours post App (Table 5.4).  The production of IL-1b 
mRNA in all the blood of all the treated pigs increased with App challenge and was 
greater at the end of the trial.  IL-6 mRNA production was undetectable in the blood 
of all treated pigs at all sample times over the 13 day challenge. the variability in 
cytokine production is due to individual difference among pigs and the difference in 
IL-6 mRNA baseline between experiments in Chapter 4 and 5 may be due to the 
previous LPS challenge pigs were exposed to the first experiment in Chapter 4.
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Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
IL-8 mRNA bnd int 
0h 
0.14 +/- 
0.14 
0.33+/-
0.21 
0.19+/- 
0.19 
0.25+/- 
0.16 
0.07+/- 
0.07 
0.37+/- 
0.17 
bnd int 
24h 
0.56+/-
0.18 
0.85+/- 
0.11 
0.88+/- 
0.18* 
0.36+/- 
0.18 
0.41+/- 
0.19 
0.39+/- 
0.19 
bnd int  
48h 
0.45+/- 
0.17 
0.38+/- 
0.18 
0.00+/- 
0.00 
0.42+/- 
0.16 
0.70+/- 
0.15 
0.48+/-
0.15 
bnd int  
1 week 
0.37+/- 
0.23 
0.25+/- 
0.17 
0.00+/- 
0.00 
0.63+/- 
0.20 
0.43+/- 
0.25 
0.57+/- 
0.15 
bnd int  
2 weeks 
0.18+/- 
0.18 
0.29+/- 
0.19 
0.74+/- 
0.13# 
0.20+/- 
0.13 
0.38+/- 
0.12 
0.00+/- 
0.00 
IL-1b mRNA bnd int 
0h 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.17+/- 
0.11 
0.43+/- 
0.20 
bnd int  
24h 
0.28+/- 
0.14 
0.59+/- 
0.15 
0.57+/- 
0.18 
0.09+/- 
0.09^ 
0.36+/- 
0.17 
0.34+/- 
0.17 
bnd int  
48h 
0.72+/- 
0.16 
0.30+/- 
0.19 
0.23+/- 
0.15 
0.47+/- 
0.18 
0.73+/- 
0.16 
0.62+/- 
0.20 
bnd int  
1 week 
0.36+/- 
0.22 
0.36+/- 
0.17 
0.56+/- 
0.23 
0.46+/- 
0.20 
0.71+/- 
0.24 
0.46+/- 
0.18 
bnd int  
2 weeks 
0.47+/-
0.21 
0.28+/- 
0.18 
0.53+/- 
0.19 
0.11+/- 
0.11 
0.17+/- 
0.12 
0.13+/- 
0.13 
IL-6 mRNA bnd int 
0h 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
bnd int  
24h 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
bnd int  
48h 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
bnd int  
1 week 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
bnd int  
2 weeks 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
TNFa mRNA bnd int 
0h 
1.30+/- 
0.09 
0.53+/- 
0.24 
1.44+/- 
0.08 
0.90+/- 
0.20 
0.95+/- 
0.21 
1.14+/- 
0.23 
bnd int  
24h 
0.35+/- 
0.18 
0.22+/- 
0.14 
0.56+/- 
0.25 
0.56+/- 
0.18 
0.68+/- 
0.24 
0.41+/- 
0.20 
bnd int  
48h 
0.49+/- 
0.24 
0.20+/- 
0.20 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.16+/- 
0.16 
0.00+/- 
0.00 
bnd int  
1 week 
0.61+/- 
0.38 
0.22+/- 
0.14 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
0.00+/- 
0.00 
bnd int  
2 weeks 
0.60+/- 
0.27 
0.17+/- 
0.17 
0.15+/- 
0.15 
0.11+/- 
0.11 
0.13+/- 
0.13 
0.00+/- 
0.00 
 
 
Table:5.4 mRNA levels for pro-inflammatory cytokines was established by semi-
quantitative RT-PCR. Changes in pro-inflammatory cytokine mRNA were 
normalised against b-actin.  Whole blood from pigs infected with App and 
subsequently treated with saline, Excenel, or recombinant cytokines at high and 
low concentrations. Data presented as mean±SEM, n=9, bnd int = band intensity. 
^ IL-1ra lo vs IL-4 hi and IL-4 lo at 24h p<0.05, * IL-4 hi vs IL-1ra lo at 24hp<0.05,#IL-4 hi vs sline  p<0.05 
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5.3.3.3 Cell Counts and Differential White Cell Counts  
 
 
Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
WBC 0h 
cell/ml 
19.29+/- 
1.03 
17.46+/- 
0.59 
18.00+/- 
0.94 
17.73+/- 
1.38 
20.68+/- 
2.02 
18.30+/- 
0.82 
24h cell/ml 30.28+/-
2.35* 
30.70+/- 
2.61 
30.09+/-
2.00 
28.80+/- 
2.47 
34.11+/- 
3.59 
30.59+/- 
1.61 
48h cell/ml 22.92+/-
1.68 
23.54+/- 
1.69 
22.67+/- 
1.75 
17.56+/- 
1.96 
25.57+/- 
2.75 
18.94+/- 
1.44 
1 week cell/ml 24.57+/- 
2.71 
24.14+/- 
1.62 
26.31+/- 
1.42 
24.14+/- 
1.12 
26.47+/- 
2.59 
22.02+/- 
1.30 
2 weeks cell/ml 14.50+/- 1.46 
16.79+/- 
1.83 
16.76+/- 
2.00 
16.14+/- 
0.95 
20.17+/- 
3.02 
14.76+/- 
1.04 
Neutrophil count 
0h cell/mL 
6.33+/- 
0.45 
6.47+/- 
0.59 
6.70+/- 
0.60 
6.01+/- 
0.56 
7.12+/- 
1.07 
4.91+/- 
0.66 
24h cell/mL 15.53+/- 
1.74 
19.04+/- 
2.47 
16.96+/- 
1.72 
18.88+/- 
2.13 
21.59+/- 
2.24 
19.26+/- 
0.94 
48h cell/mL 12.31+/- 
1.52 
14.66+/- 
1.55 
13.17+/- 
1.48 
7.26+/- 
0.89* 
14.97+/-
2.52 
9.41+/- 
1.66 
1 week cell/mL 10.53+/- 
1.75 
13.17+/- 
1.19 
11.92+/- 
2.21 
10.15+/-
1.42 
13.89+/- 
2.31 
8.13+/- 
1.29 
2 weeks 3.04+/- 
0.60 
3.76+/- 
0.53 
4.66+/- 
0.63 
5.00+/- 
0.62 
6.28+/- 
1.79 
3.00+/- 
0.43 
Lymphocyte count 
0h cell/mL 
10.45+/- 
0.85 
8.32+/- 
0.22 
8.85+/- 
0.76 
9.23+/- 
0.79 
10.69+/- 
1.52 
11.19+/- 
0.37 
24h cell/mL 11.58+/- 
1.57 
9.29+/- 
0.75 
10.62+/- 
1.69 
8.21+/- 
0.49 
9.74+/- 
1.32 
9.37+/- 
1.04 
48h cell/mL 8.64+/-
0.64 
7.17+/- 
0.60 
7.70+/- 
0.97 
6.67+/- 
0.78 
8.43+/- 
0.91 
9.89+/- 
0.97 
1 week cell/mL 11.97+/- 
1.64 
9.26+/- 
0.56 
12.83+/- 
1.43 
11.94+/- 
0.46 
10.51+/- 
1.00 
12.20+/- 
0.97 
2 weeks cell/mL 10.44+/- 
1.08 
11.64+/- 
1.81 
10.52+/- 
1.54 
9.87+/- 
0.43 
12.47+/- 
1.21 
10.61+/- 
0.81 
 
There was an increase in WBC 24 hours after App challenge in all the treatment 
groups which subsequently decreased over time (Table 5.5). 
Lymphocyte population in whole blood of treated pigs were relatively constant across 
time (Table 5.5).  Neutrophils in all the treatment groups increased markedly 24 hours 
after App challenge then decreased across time.  IL-1ra lo treated pigs produced the 
Table:5.5 Total white blood cell and differential counts of blood smears from 
pigs’ infected with App and subsequently treated with saline, Excenel, or 
recombinant cytokines at high and low concentrations. Data presented as 
mean±SEM, n=9. 
* IL-1ra lo vs saline at 48h p<0.05 
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least amount of circulating neutrophils at 48 hours post infection (Table 5.5) and this 
level was significantly lower than the saline treated pigs (p<0.05). 
 
 
Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
Monocyte count cell/mL 0h 2.40+/- 
0.24 
2.51+/- 
0.28 
2.12+/- 
0.38 
2.21+/- 
0.34 
2.58+/- 
0.46 
1.98+/- 
0.19 
24h 2.58+/- 
0.53 
2.05+/- 
0.27 
2.12+/- 
0.31 
1.35+/- 
0.23 
2.32+/- 
0.37 
1.64+/- 
0.12 
48h 1.57+/- 
0.18 
1.57+/- 
0.21 
1.55+/- 
0.20 
1.22+/- 
0.13 
1.69+/- 
0.25 
1.29+/- 
0.17 
1 week 1.71+/- 
0.27 
1.42+/- 
0.13 
1.32+/- 
0.14 
1.69+/- 
0.14 
1.48+/- 
0.29 
1.49+/- 
0.20 
2 weeks 0.92+/- 
0.11 
1.09+/- 
0.14 
1.04+/- 
0.10 
0.92+/- 
0.06 
1.17+/- 
0.16 
0.94+/- 
0.07 
Eosinophil count cell/mL 0h 0.11+/- 
0.03 
0.16+/- 
0.04 
0.33+/- 
0.05 
0.27+/- 
0.07 
0.29+/- 
0.07 
0.21+/- 
0.08 
24h 0.59+/- 
0.10 
0.31+/- 
0.09 
0.39+/- 
0.20 
0.36+/- 
0.13 
0.46+/- 
0.18 
0.33+/- 
0.17 
48h 0.40+/- 
0.05 
0.15+/- 
0.07 
0.24+/- 
0.08 
0.47+/- 
0.12 
0.26+/- 
0.11 
0.50+/- 
0.09 
1 week 0.37+/- 
0.10 
0.30+/- 
0.08 
0.24+/- 
0.06 
0.37+/- 
0.07 
0.58+/- 
0.09 
0.21+/- 
0.05 
2 weeks 0.09+/- 
0.03* 
0.30+/- 
0.07 
0.36+/- 
0.10 
0.53+/- 
0.16 
0.24+/- 
0.04 
0.20+/- 
0.06 
 
Even though there was not a significant difference between the treatment groups, 
there was a trend of reduction in monocytes across time in the whole blood of all 
treated pig groups.  Pigs treated with IL-1ra lo, saline and Excenel showed increased 
eosinophil numbers (not significant) as compared to the remaining treatments 48 
hours after App infection (Table 5.7).  Eosinophil numbers in whole blood of all the 
treated pigs were significantly higher (p<0.05) 2 weeks after App challenge than that 
of the saline treated pigs with the exception of the Excenel treated pigs. 
 
Table:5.6 Differential counts from blood smears of pigs’ infected with App and 
subsequently treated with saline, Excenel, or recombinant cytokines at high and 
low concentrations. Data presented as mean±SEM. n=9, * saline vs all treatments 
except Excenel at 2 weeks p<0.05. 
No basophils were found (results not shown) , ^ Excenel vs saline at 48h p<0.05 
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In all the treated pigs’ blood the number of B cells expressing IgG remained relatively 
constant 24 hours after App challenge, with the exception of the pigs treated with IL-
1ra lo which had significantly reduced B cells (p<0.05).  The pigs treated with IL-1ra 
lo had B cell numbers reduced by almost half that of the B cells produced by pigs 
treated with IL-1ra hi, saline and Excenel 48 hours after App challenge (Table 5.7).  
Cells expressing IgG decreased 2 weeks after App challenge in all treatment groups.  
There was little difference between B cells treatment groups for expressing IgG1 at 
most sample times, with the exception of the pigs treated with IL-4 lo and IL-4 hi, 
Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
B cell  IgG  
0h cell/mL 
2.77+/-
0.54 
1.92+/- 
0.23 
1.85+/- 
0.27 
1.90+/- 
0.23 
2.19+/- 
0.24 
2.18+/- 
0.31 
24h cell/mL 
 
2.86+/- 
0.74 
2.21+/- 
0.28 
2.52+/- 
0.39 
1.29+/- 
0.19* 
2.01+/- 
0.30 
1.87+/- 
0.35 
48h cell/mL 
 
3.56+/-
0.44 
2.19+/- 
0.38 
2.51+/- 
0.23 
1.63+/- 
0.34^#* 
3.48+/- 
0.61 
3.00+/- 
0.34 
1 week cell/mL 
 
3.21+/- 
0.87 
2.32+/- 
0.39 
3.28+/- 
0.27 
2.67+/- 
0.39 
2.63+/- 
0.37 
2.92+/- 
0.28 
2 weeks cell/mL 
 
1.76+/- 
0.30 
1.52+/- 
0.17 
1.57+/- 
0.41 
1.55+/- 
0.33 
1.64+/- 
0.31 
1.73+/- 
0.19 
B cells IgG1 
0h cell/mL 
0.45+/- 
0.09 
0.30+/- 
0.09 
0.40+/- 
0.10 
0.48+/- 
0.15 
0.38+/- 
0.08 
0.40+/- 
0.12 
24h cell/mL 
 
0.36+/- 
0.09 
0.38+/- 
0.09 
0.34+/- 
0.09 
0.17+/- 
0.03 
0.29+/- 
0.08 
0.22+/- 
0.09 
48h cell/mL 
 
1.79+/- 
0.46& 
0.81+/- 
0.17 
0.89+/- 
0.21 
1.10+/- 
0.23 
1.24+/- 
0.26 
1.47+/- 
0.34 
1 week cell/mL 
 
0.60+/- 
0.18 
0.33+/-
0.08 
0.72+/- 
0.18 
0.64+/- 
0.12 
0.63+/- 
0.17 
0.53+/- 
0.09 
2 weeks cell/mL 
 
0.11+/-
0.04 
0.17+/-
0.04 
0.16 
0.06 
0.29+/- 
0.11 
0.20+/- 
0.06 
0.14+/- 
0.03 
Table:5.7 Quantity of cells with IgG and IgG1 receptors present in whole blood 
from pigs infected with App and subsequently treated with saline, Excenel, or 
recombinant cytokines at high and low concentrations. Data presented as 
mean±SEM. n=9.  
* saline vs IL-1ra lo p<0.05, & saline vs IL-4 lo and IL-4 hi at 48h p<0.05, ^ IL-1ra hi vs IL-1ra lo 
p<0.05, # Excenel vs IL-1ra lo at 48h p<0.05.  
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who had the lowest numbers of IgG1 producing B cells 48 hours after App challenge 
(p<0.05) (Table 5.7). 
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5.3.3.5  T cells counts 
 
 
 
Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
CD 3 % 0h 72.89+/- 
1.91 
73.63+/- 
2.52 
69.87+/- 
1.92 
72.37+/- 
1.04 
74.41+/- 
2.15 
74.94+/- 
0.49 
24h 69.11+/- 
1.94 
69.37+/- 
1.65 
63.50+/- 
2.40 
71.13+/- 
1.34 
70.83+/- 
2.24 
69.48+/- 
2.48 
48h 67.24+/- 
1.25 
65.02+/- 
1.39 
59.92+/- 
1.35 
64.43+/- 
2.13 
66.91+/- 
1.34 
62.29+/- 
8.15 
1 week 67.42+/- 
1.73 
69.85+/- 
1.69 
64.55+/- 
2.66 
58.44+/- 
7.89 
67.85+/- 
2.27 
71.07+/- 
2.53 
2 weeks 46.90+/- 
8.91 
56.17+/- 
7.44 
57.59+/- 
2.86 
48.52+/- 
9.31 
64.93+/- 
3.06 
64.08+/- 
2.93 
CD 3cells/mL 0h 7.60+/- 
0.64 
6.00+/- 
0.29 
6.25+/- 
0.65 
6.77+/- 
0.56 
8.06+/- 
1.27 
8.22+/- 
0.29 
24h 7.90+/- 
1.02 
6.44+/- 
0.55* 
6.81+/- 
1.18 
5.80+/- 
0.27 
6.96+/- 
1.10 
6.57+/- 
0.83 
48h 5.68+/- 
0.43 
4.68+/- 
0.41 
4.66+/- 
0.66 
4.26+/- 
0.49 
5.64+/- 
0.62 
6.39+/- 
1.14 
1 week 7.97+/- 
1.02 
6.52+/- 
0.53 
8.39+/- 
1.16 
7.81+/- 
0.40 
7.16+/- 
0.78 
8.80+/- 
0.94 
2 weeks 4.60+/- 
1.00 
7.61+/- 
1.50 
6.05+/- 
0.87 
6.15+/- 
0.32 
8.09+/- 
0.86* 
6.92+/- 
0.77 
CD4 % 
0h 
28.28+/- 
1.74 
28.69+/- 
1.69 
31.92+/- 
1.56 
31.67+/- 
2.11 
31.21+/- 
2.19 
26.36+/- 
1.70 
24h 26.54+/- 
1.94 
29.60+/- 
1.80 
30.24+/- 
1.73 
28.79+/- 
1.79 
29.54+/- 
2.57 
26.12+/- 
1.35 
48h 22.01+/- 
3.29 
25.77+/- 
1.24 
26.82+/- 
1.43 
26.13+/- 
1.07 
27.66+/- 
2.03 
23.62+/- 
1.12 
1 week 27.19+/-
1.35 
27.11+/-
1.86 
28.61+/- 
1.23 
24.43+/- 
3.25 
27.14+/- 
1.89 
24.64+/- 
1.90 
2 weeks 11.39+/-
1.92 
13.10+/-
2.52 
14.60+/-
2.56 
15.54+/-
3.23 
16.11+/-
2.04 
9.30+/-
2.27 
CD4 cells/mL 
0h 
2.89+/-
0.23 
2.51+/-
0.15 
2.78+/-
0.21 
2.82+/-
0.16 
3.53+/-
0.82 
2.93+/-
0.15 
24h 2.87+/-
0.26 
2.71+/-
0.22 
3.31+/-
0.66 
2.33+/-
0.14 
3.07+/-
0.79 
2.45+/-
0.30 
48h 1.82+/-
0.31 
1.83+/-
0.15 
2.01+/-
0.21 
1.72+/-
0.18 
2.37+/-
0.35 
2.31+/- 
0.22 
1 week 3.17+/-
0.36 
2.47+/-
0.17 
3.65+/-
0.39 
3.28+/-
0.20 
2.92+/-
0.43 
2.92+/- 
0.24 
2 weeks 1.14+/-
0.25^ 
1.81+/-
0.57 
1.71+/-
0.51 
1.98+/-
0.20 
2.03+/-
0.37 
0.94+/- 
0.19# 
 
 
Table:5.8: T cell counts enumerated by flow cytometry on whole blood from pigs 
infected with App and subsequently treated with saline, Excenel, or recombinant 
cytokines at high and low concentrations.  Data is presented as the mean±SEM, 
n=9. 
* saline vs IL-1ra hi p<0.05, # excenel vs all treatment except saline p<0.05, ^ saline vs IL-4 lo and hi 
p<0.05. 
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The results for T cell counts are presented as percentages as well as cells per mL so 
that comparisons could be made between this data and that described in the previous 
Chapter (Table 5.8-5.9). 
Pigs treated with IL-1ra hi had significantly higher numbers of T cells 2 weeks after 
challenge compared with saline-treated pigs (Table 5.8).  When described as 
percentages, T cells decreased 48 hours after App challenge in all treatment groups.  
This trend was also seen in the T cells with the CD4 and CD8 receptors (data as 
percentages) in the whole blood of all the treated pigs (Table 5.8-5.9).  The decreasing 
trend of T cells with the CD4 receptor, 48 hours after App infection which occurred in 
all the treatment groups (presented as percentages in Table 5.8) is also observed in the 
data presented as cells/mL.  At the conclusion of the trial the saline control and 
Excenel treated pigs produced the least (data as cell/mL) T helper cells (Table 5.8). 
T cells expressing CD8 markers, were reduced 48 hours after challenge (data 
presented as cell/mL) as compared to 24 hours post App with the exclusion of the 
groups treated with IL-1ra hi (Table 5.9). 
The T cell counts by flow cytometry is a method for determining the percentages of 
different subpopulations of cells in whole blood using the technique of flow 
cytometry”. The raw data is given as % of cells gated which is then multiplied by the 
total Lymphocytes counted (which is obtained by using a haemocytometer to count 
Lymphocyte in a 200 total of cells then multiply by WBC) which then gives you a 
value of cells per mL.  The data was presented as both % and cells per mL to allow 
comparison between experiments and Chapters due to a machine error the WBC 
(Table 4.8) for the App challenge model at 24 hours was not obtained, therefore 
cells/mL for this sample time was not calculated.
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Prior to App challenge and until 1 week after challenge, there was no difference in 
CD4:8 ratio across all treatment groups.  However, 2 weeks after challenge, pigs 
treated with IL-1ra lo still had a significantly higher CD4:8 ratio (p<0.05) while this 
ratio decreased in all other groups (Table 5.9).  At the 2 week time point the saline 
and Excenel treated pigs had the lowest CD4:8 ratio. 
Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
CD 8 % 0h 
 
37.80+/- 
2.25 
39.25+/-
4.44 
42.15+/-
2.34 
41.73+/-
3.19 
42.37+/-
2.59 
38.56+/-
2.51 
24h 36.76+/- 
3.09 
 
39.91+/- 
2.14 
 
42.90+/- 
3.81 
 
43.13+/- 
4.16 
 
39.89+/-
4.15 
 
35.97+/-
2.84 
 48h 30.56+/-
1.82 
 
30.96+/- 
1.34 
 
31.97+/- 
2.36 
 
33.84+/-
2.47 
 
32.44+/-
1.67 
 
30.18+/-
1.68 
 1 week 31.74+/-
1.66 
 
33.05+/-
1.61 
 
35.68+/-
0.75 
 
33.36+/-
4.93 
 
33.26+/-
1.98 
 
32.40+/-
1.29 
 2 weeks 30.11+/-
5.06 
 
29.52+/-
5.88 
 
28.86+/-
5.82 
 
22.02+/-
5.20 
 
29.83+/-
3.64 
 
24.47+/- 
1.68 
1.68 
CD 8 cells/mL 
0h 
3.88+/- 
0.32 
3.20+/- 
0.44 
3.76+/-
0.41 
3.82+/-
0.34 
4.54+/-
0.74 
4.19+/-
0.24 
24h 3.94+/-
0.33 
3.78+/-
0.43 
4.44+/-
0.70 
3.54+/-
0.44 
4.13+/-
1.06 
3.47+/-
0.56 
48h 2.66+/-
0.26 
2.25+/-
0.27 
2.45+/-
0.34 
2.28+/-
0.30 
2.80+/-
0.37 
2.86+/-
0.32 
1 week 3.73+/-
0.51 
3.05+/-
0.22 
4.57+/-
0.52 
4.45+/-
0.34 
3.57+/- 
0.52 
3.91+/-
0.29 
2 weeks 3.21+/- 
0.82 
4.37+/-
1.41 
3.48+/-
1.23 
2.82+/-
0.48 
4.00+/-
0.92 
2.58+/-
0.26 
CD 4:8 % 
0h 
0.76+/-
0.04 
0.87+/-
0.19 
0.78+/-
0.07 
0.77+/-
0.05 
0.75+/-
0.05 
0.69+/-
0.04 
24h 0.74+/- 
0.05 
0.76+/-
0.07 
0.80+/-
0.14 
0.70+/-
0.06 
0.77+/-
0.07 
0.76+/-
0.07 
48h 0.73+/-
0.10 
0.85+/-
0.06 
0.89+/-
0.10 
0.79+/-
0.05 
0.87+/-
0.07 
0.80+/-
0.04 
1 week 0.87+/- 
0.06 
0.82+/-
0.05 
0.80+/-
0.04 
0.75+/-
0.05 
0.83+/-
0.06 
0.75+/-
0.05 
2 weeks 0.41+/-
0.07 
0.48+/-
0.07 
0.49+/-
0.08 
0.77+/-
0.09* 
0.51+/-
0.09 
0.37+/- 
0.08 
Table 5.9: Cluster designation (CD) lymphocyte data obtained from whole blood  
from pigs’ infected with App and subsequently treated with saline, Excenel, or 
recombinant cytokines at high and low concentrations.  Data is presented as the 
mean±SEM, n=9. 
126 
COMMERICAL IN CONFIDENCE 
 
5.3.3.4  ELISA 
 
 
Assay saline IL-4 lo IL-4 hi IL-1ra lo IL-1ra hi Excenel 
serum IgA 0h mg/mL 1316+/- 
269 
945+/- 
209 
1515+/- 
207 
1289+/- 
305 
1626+/- 
463 
836+/- 
176 
24h mg/mL 
 
1015+/- 
282 
 
1104+/- 
278 
 
1912+/- 
331@ 
 
982+/- 
265 
 
1666+/- 
463 
 
785+/- 
175 
 48h mg/mL 1711+/- 
477 
1402+/- 
463 
1812+/- 
221 
1243+/- 
227.16 
1410+/- 
275 
1421+/- 
194 
1 week mg/mL 2156+/- 
233 
1477.67+/- 
92.00 
1391.96+/- 
193.53 
1607.48 
358.58 
1542.74+/- 
153.06 
1924+/- 
344 
2 weeks mg/mL 774+/- 
285 
328+/- 
42& 
1446+/- 
293@ 
687+/- 
164 
604+/- 
155 
1249.05+/- 
317.41 
serum IgG 0h mg/mL 
0h 
4995+/- 
880 
5387+/- 
1608 
5876+/- 
1223 
5389+/- 
1119 
7417+/- 
896 
7018+/- 
1693 
24h mg/mL 1964+/- 
726 
958+/- 
354 
1861+/- 
871 
423+/- 
177 
920+/- 
621 
2859 
1077 
48h mg/mL 3559+/- 
1023 
3648+/- 
1331 
3904+/- 
1046 
1295+/- 
649* 
1552+/- 
851 
3993+/- 
1168 
1 week mg/mL 2203.16+/- 
858.72 
1300.76+/-
772.46 
2705.13+/- 
1015.98 
991.20+/- 
315.50 
1321+/- 
439 
1973+/- 
393 
2 weeks mg/mL 1514+/- 
359 
938+/- 
256 
2303+/- 
456 
1106+/- 
373 
1862+/- 
1053 
1148+/- 
277 
 
The amount of serum IgA found in the IL-4 hi treated pigs was significantly greater 
(p<0.05) at 24 hours post infection than that found in the saline treated pigs (Table 
5.10).  Pigs treated with IL-4 hi also had the largest level of serum IgA at 2 weeks 
post infection as compared to the saline-treated group, while the low dose IL-4 treated 
pigs had the lowest serum IgA (p<0.05) (Table 5.10) 2 weeks after App challenge.  
Pigs treated with IL-1ra lo produced the least amount of serum IgG protein 48 hours 
after App challenge as compared to the IgG produced by the saline control pigs.  At 2 
week post App all the treatment groups showed decreased serum IgG (Table 5.10) 
compared to baseline levels prior to App challenge. 
Table:5.10 Immunoglobulin G and Immunoglobulin A concentration in serum 
from pigs’ infected with App and subsequently treated with saline, Excenel, or 
recombinant cytokines at high and low concentrations. Data presented as 
mean±SEM. n=9. 
@ saline vs IL-4 hi p<0.05, & saline vs IL-4 lo at 2wks p<0.05 
127 
COMMERICAL IN CONFIDENCE 
 
5.3.4  Pathology 
Figure 5.4: Degree of pleuropneumonia expressed as the percentage of affected lung 
by weight. Lungs obtained after euthanasia of pigs infected with App and 
subsequently treated with saline, Excenel, or recombinant cytokines at high and low 
concentrations.  Bars show group mean±SEM, n=9, * IL-1ra lo vs Excenel p<0.05. 
 
The Excenel treated pigs had a significantly lower percentage of affected lung as 
compared to IL-1ra low (p<0.05) and comparatively less than the other treatment 
groups and the saline control group (Figure 5.4). 
There appeared to be a positive relationship between the percentage affected lung and 
clinical scores (Figure 5.5).  Pigs that had higher clinical scores during the challenge 
period tended to have a greater proportion of their lung affected by App lesions. 
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Figure 5.5: Affected lung plotted against clinical scores from pigs infected with 
App and subsequently treated with saline, Excenel, or recombinant cytokines at 
high and low concentrations. 
Figure 5.6: Degree of pleurisy expressed as pleurisy score (0-5) in pigs infected 
with App and subsequently treated with saline, Excenel, or recombinant cytokines 
at high and low concentrations.  Bars show group mean±SEM, n=9, * Excenel vs 
IL-4 hi p<0.05. 
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Pigs treated with Excenel had the lowest mean pleurisy scores compared to the saline 
control group (Figure 5.6).  Excenel treated pigs showed the lower pleurisy than the 
pigs treated with IL-4 high,IL-1ra lo and IL-1ra hi. 
Figure 5.7 compares the appearance of App-affected lungs and clean lungs apparently 
free of obvious App lesions.  Figure 5.7a is from a pig treated with saline while the 
healthy lung in Figure 5.7b was from a pig treated with IL-1ra hi. 
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a 
b
Figure 5.7 Lung from pigs challenged with App and subsequently treated with 
saline (a) and IL-1ra hi (b). Post-mortem was performed 2 weeks after challenge. 
The arrow indicates a gross App lesion. 
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RT-PCR performed on lung and lymph node tissue confirmed the presence of 
localised IL-8 mRNA (Figure 5.8).  IL-8 mRNA was detected in all the lung and 
lymph tissue at a similar level regardless of the treatment administered. The pigs 
treated with IL-4 lo and IL-1ra lo produced slightly less IL-8 mRNA than the saline 
control treated pigs (not significant). 
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Figure 5.8: Levels of mRNA for pro-inflammatory cytokine IL-8 determined by 
RT-PCR in lung and lymph node tissue post-mortem. Tissue taken from pigs 
infected with App and subsequently treated with saline, Excenel, or recombinant 
cytokines at high and low concentrations. The results were normalised by 
presenting results as a ratio of the cytokine over b actin mRNA expression.  Bars 
show group mean±SEM. 
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There was no IL-6 mRNA found in the lungs of pigs treated with IL-1ra hi and 
Excenel (Figure 5.9).  Pigs treated with IL-4 hi produced slightly more IL-6 mRNA 
than the other treatments (not significant).  However, IL-6 mRNA was not detected in 
the lymph nodes of pigs treated with IL-4 hi (Figure 5.9). 
The in situ hybridization was performed 3 times on 5 sections of each treatment 
group. 
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Figure 5.9: Levels of mRNA for pro-inflammatory cytokine IL-6 determined 
by RT-PCR in lung and lymph node tissue post-mortem. Tissue taken from 
pigs infected with App and subsequently treated with saline, Excenel, or 
recombinant cytokines at high and low concentrations. The results were 
normalised by presenting results as a ratio of the cytokine over b actin mRNA 
expression.  Bars show group mean±SEM. 
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Figure 5.10: In situ hybridisation of IL-8 antisense oligonucleotide probe 
(positive probe) on lung tissue sections from pigs challenged with App and 
subsequently treated with saline, Excenel, or recombinant cytokines at high and 
low concentrations. 
The dark spots indicate cells producing IL-8 mRNA. Bar represents 80mm. 
(Magnification x 400). BR – bronchus. 
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Figure 5.11: In situ hybridisation of IL-8 sense oligonucleotide probe (negative 
probe) on lung tissue sections from pigs challenged with App and subsequently 
treated with saline, Excenel, or recombinant cytokines at high and low 
concentrations. Bar represents 80mm. (Magnification x 400). BR – bronchus. 
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The expression of IL-8 mRNA was investigated using in situ hybridization in order to 
localise cytokine production in the lung (Figure 5.10).  The lung tissue at post-mortem 
showed IL-8 mRNA near the lung lesions in some treatment groups. The spotting 
seen in Figure 5.10 appeared to be associated with macrophages and neutrophils.  The 
bronchiolus of pigs treated with Excenel were found to contain large amounts of IL-8 
mRNA since they stained heavily by in situ hybridization, while only a scattering of 
the cells in the saline control treated pigs were stained.  Lungs from pigs treated with 
IL-4 hi and IL-1ra hi showed positive staining for IL-8.  There was little or no IL-8 
mRNA detected in lungs of pigs treated with IL-4 lo or IL-1ra lo.  The trends in IL-8 
mRNA levels detected by in situ hybridization (Figure 5.10) reflect those seen in RT-
PCR on lung tissue (Figure 5.8).  The IL-8 mRNA sense probe (negative control 
probe) did not hybridize to any lung tissue of any group (Figure 5.11). 
A haematoxylin and eosin (H and E) stain was performed on a selection of lung tissue 
from each treatment group and a representative is shown (Figure 5.12).  There is an 
increase in polymorphonuclear cells around the broncholi of lung tissue from pigs 
treated with IL-1ra lo (Figure5.12).  The pigs treated with IL-4 hi also showed large 
numbers of polymorphonuclear cells in its lung tissue. Lung tissue from the saline, 
IL-4 lo and IL-1ra hi treatment pigs had normal morphology (Figure 5.12). 
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Figure 5.12. Sections of lungs from pigs challenged with App and 
subsequently treated with saline, Excenel, or recombinant cytokines at high 
and low concentrations; stained with H&E (Magnification x 400). A) Saline 
treatment.  B) Excenel treatment.  C) IL-4 treatment, low dose.  D) IL-4 
treatment, high dose. E) IL-1ra treatment, low dose.  F) IL-1ra treatment, high 
dose.  PM - lesions of abnormal morphology made up of polymorphonuclear 
cells.  BR – bronchus.  The bar represented 80mm. 
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5.4. Discussion 
The dramatic weight increase of pigs prophylactically treated with IL-4 and IL-1ra as 
compared to the saline treated pigs reported in Chapter 4 unfortunately was not 
observed in this experimental trial examining therapeutic delivery of these treatments.  
No real weight difference was observed between the treatment groups in this trial.  
Clinical scores showed no difference between the pigs treated with saline and the 
remaining treated pigs with the exception of pigs treated with Excenel, which were 
significantly lower (p<0.05) in clinical scores compared to IL-1ra lo treated pigs 
(Figure 5.3).  This trend was also observed in the percentage of affected lung (Figure 
5.4). 
The App infection was given at the same dosage of 7.5x105cfu/mL in both the 
prophylactic trial (Chapter 4) and the therapeutic trail (Chapter 5).  Even so, the pigs 
treated with saline in the prophylactic trial had approximately 3 times greater clinical 
symptoms and lung damage compared to the pigs treated with saline in the therapeutic 
trial. 
Perhaps in the therapeutic trial the lack of weight variation between control treated 
pigs and cytokine-treated pigs may be due to the timing of infection and treatments, or 
the inability of treatments to deal with an already established infection (Figure 5.2).  
As the saline-treated pigs in the therapeutic trial failed to exhibit as severe an 
infection as they did in the prophylactic trial, it may be possible that the virulence of 
the inoculating bacteria was not maintained between trials.  sub-culturing was done 
PPLO agar then transferred to PPLO broth and frozen at -80oC in 70% glycerol. The 
preparation of the inoculum was done by research staff at EMAI since we were 
working in collaboration. Retrospective enumeration of the inoculum would have 
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stopped questions like viability of the inoculums in Chapter 4 and 5.  The pigs 
immunity or resistance to App may have come into question since they may have 
been exposed to this very bacteria before participating in this trial.  
When comparing the cluster designation data (data as percentages) between the two 
trials, there is a decreasing trend in both trials in terms of T cell data.  The therapeutic 
trail (Chapter 5) shows a decreasing trend 48 hour after App challenge in all the 
treated pigs T cells with the CD3, CD4 and CD8 receptor.  The decreasing trend in the 
prophylactic trial (Chapter 4) however, occurred 24 hours after App challenge in all 
the treated pigs T cells with CD3, CD8 receptors.  This may be related to the 
virulence of the bacteria between the trials.  The T-lymphocytes may be mobilized to 
other areas such as the lung and leave the blood steam in response to infection. Since 
the prophylactic trial produced a decrease in peripheral T cells earlier in the infection 
perhaps the virulence of the bacteria used in this challenge was higher than that given 
to the pigs in the therapeutic trial. 
Immunological and molecular biological assays showed an interesting perspective of 
the therapeutic App infection.  The reduction in IL-8 mRNA in peripheral blood at 24 
to 48 hours post infection found in the IL-4 hi treated pigs (Table 5.4) could be due to 
the ability of IL-4 to stop IL-8 production at a transcriptional level (Zhou et al., 1994).   
This reduction did not take place in the pigs treated with a low dose of IL-4.  Perhaps 
the dose of IL-4 lo was too low.  A similar dose given in the LPS prophylactic trial 
did not reduce the levels of IL-8 mRNA 24 hours post challenge, however the time 
lapse between the LPS challenge in Chapter 4 and the administration of IL-4 two days 
before App challenge reduced the production of IL-8 mRNA to an undetectable 
amount. 
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It is interesting to compare between the two trials.  However it must be taken into 
consideration that there are many variables such as the virulence of bacterial 
challenge, number of pigs per group, blood sampling time and mainly the  timing of 
administration of treatments, that differ between the 2 trials. 
The absence of TNFa mRNA in the peripheral blood of pigs treated with IL-1ra lo, 
IL-4 hi and Excenel 48 hours and 1 week after App challenge (Table 5.4) could be 
associated with pathology of App, since these 3 treated pig groups exhibited the 
highest amount of affected lung and pleurisy.  Interestingly, in support of this, 
Morrison et al., (2000) found TNFa and IL-1b in moderate levels effectively controls 
lung infection of pigs. It was also found that lack of TNFa or the neutralization of 
TNFa can impair bacterial clearance from the lung of mice infected with a bacterial 
pneumonia infection (Laichalk et al., 1996 and Standford et al., 1999). 
Pigs treated with IL-1ra lo produced lower levels of IL-1b mRNA in their peripheral 
blood at 24 hours post infection (Table 5.4) and also had high levels of App-
associated pathology (Figure 5.4), which further support the argument that the 
absence of IL-1b and TNFa may contribute to pathology in the lung. 
IL-6 mRNA was not detected in the lung of the pigs treated with IL-1ra hi and 
Excenel (Figure 5.9).  IL-6 mRNA production is very difficult to detect as this 
cytokine is short-lived in the tissue and localized (Mire-Sluis and Thorpe 1998) which 
may have contributed to the absence of IL-6 in the lung of IL-1ra hi and Excenel 
treated pigs. 
Neutrophil chemoattractant IL-8 was the major factor associated with of acute lung 
inflammation rather than App bacterial components (Huang et al., 1999).  The over 
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production of IL-8 may exacerbate disease caused by bacterial infection.  Slocombe et 
al., (1985) found from his research that animals with depleted neutrophils had normal 
lungs, whereas those that did not, suffered lung lesions after infection with 
Pseudomonas haemolytica.  IL-8 recruits neutrophils to inflammatory sites (reviewed 
by Standiford et al., 2000 and Murtaugh et al., 1996) and lesions found in the 
respiratory tract of pigs suffering App infection are made up largely of neutrophils, 
macrophages and platelets (Liggett et al., 1987). The IL-8 mRNA was probably 
produced by the alveoli macrophage and infiltrating neutrophils (Strieter 1992) in the 
lung.  Therefore, IL-8 may be a significant player in inflammatory lung disease such 
as App infection. 
Excenel, a commercially available broad spectrum antibiotic used for pigs suffering 
App infection is thought to bind to App-produced protein in the lung.  The Excenel 
treated pigs produced a large amount of IL-8 mRNA in the lung (Figure 5.8).  Excenel 
compound lyse the cell walls of the App bacteria.  Pigs treated with Excenel had 
undetectable amounts of IL-8 mRNA in their peripheral blood at euthanasia.  Pigs 
treated with Excenel did not produce any IL-6 mRNA in their lungs or lymph nodes at 
post-mortem or in their peripheral blood at any time. 
In situ hybridization detected no IL-8 mRNA in the lung tissue of pigs treated with 
IL-1ra lo (Figure 5.10).  However, it was detected at low levels when RT-PCR was 
performed (Figure 5.8). This could be due to the fact that PCR only required one 
signal to amplify while in situ hybridization needs more copies for detection.  In situ 
hybridization showed (Figure 5.10) that IL-8 mRNA was being produced by alveolar 
macrophages as expected (Hakansson et al., 1996; Khair et al., 1996) and that 
infiltrating neutrophils were also producing IL-8 mRNA (Strieter 1992).  
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Inflammatory cells such as neutrophils and macrophages were found within alveoli 
interlobular spaces and the airway of animals in the IL-1ra lo treated group.  The 
association between App lung infection and inflammatory cytokines such as IL-8 
seems to suggest IL-8 is a direct cause of the pathology of the lung infection (Huang 
et al., 1999; Baarsh et al., 1995).  IL-1ra and IL-4 given as a prophylactic (Chapter 4) 
reduced IL-8 mRNA production in the lung, however when given as a therapeutic did 
not have the same effect. 
Pigs treated with IL-1ra hi produced significantly (p<0.05) more T lymphocytes (with 
the CD3 receptor) as compared to the saline control treated pigs.  This suggest an 
elevated immune response is occurring with this treatment.  Interestingly, this 
treatment group had no Polymorphonuclear Cells (PMN) present in the lung tissue at 
post-mortem despite IL-8 mRNA being present in the lung tissue and peripheral 
blood. 
The lack of IL-6 in the lung tissue in this study could be explained in the findings of 
Scamurra et al., (1996) who showed alveolar macrophages from pigs produced 
differing amounts of IL-6 which was stimulated by LPS.  Scamurra et al., (1996) 
found different pigs had different IL-6 (stimulated by LPS) ranging from low to high.  
Perhaps IL-1ra hi-treated pigs just produced an undetectable amount of IL-6 in the 
lungs as compared to the other treatment groups. 
Pigs treated with saline and Excenel produced least T helper cells (CD4 receptor 
present) at conclusion of the trial. 
IgG is the major immunoglobulin synthesized in the body. It diffuses into the 
extravascular body space where it neutralizes bacterial toxins (Roitt 1994). This 
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immunoglobulin is produced by B cells and therefore the more Ig protein present the 
more antigens from the infection are present. IgG1 is a subclass of IgG, it makes up 
the largest class at 65% component of all the IgG1-IgG4.  Significantly less B cells 
with IgG1 were present in pigs treated with IL-4hi and IL-4 lo 48 hours after App as 
compared to the saline treated pig group.  It is known that the growth and 
differentiation of B cells is stimulated by the secretion of IL-4 and IL-5 by Th2 
lymphocytes (Tizard et al., 1996).  Perhaps IL-4 is stimulating Th 1 cytokine 
production instead of Th 2 lymphocyes cytokines.  Nuntaprasert et al., (2004) found 
that depending on administration of the IL-4 , it can cause either stimulate or inhibit 
pro-inflammatory cytokines like IL-8, TNFa, IL-6and  IL-1a in pigs challenged with 
LPS. 
IgG and IgA were detected by ELISA in the serum of treated pigs. IgA defends the 
exposed external surfaces eg. lung, gut, and nasal area from micro-organisms attack. 
It is synthesized locally and is in abundance in times of infection. Therefore it can be 
used as a tool to detect infection (Roitt 1994) serum levels of IgA may be indicative 
of IgA levels present in the lung. 
As earlier stated IL-5 and IL-4 produced by Th 2 lymphocytes which stimulate B cells 
to grow and differentiate which then in turn produce IgG, IgA, IgM and Ig E (Tizard 
1996).  However in this study IgA production was significantly less in the serum of 
pigs treated with IL-4 lo as compared to the serum from saline control treated pigs 2 
weeks after challenge (Table 5.10). 
PMN are needed to isolate infection, however, too many neutrophils can cause even 
more lung damage in App infection such as necrosis (Liggett 1987).  Pigs treated with 
IL-1ra lo had significantly less neutrophils at 48 hour post App and a reduced 
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numbers at 1 week which could contribute to the lung damage (Table 5.5).  Pigs 
treated with IL-1ra lo also had the highest T lymphocyte CD4:8 ratio at the conclusion 
of the trial.  Since PMN were found in the lung of IL-1ra lo treated pigs, neutrophils 
may have already crossed the blood tissue barrier and proceeded to the lung resulting 
in depleted neutrophils in the periphery.  IL-8 mRNA in the peripheral blood was low 
and IL-8 mRNA was undetected in the lung tissue, in situ, of treated pigs treated with 
IL-1ra lo, since IL-8 is thought to recruit neutrophils (Standiford et al., 2000) perhaps 
the PMN found in the lungs of this group were not made up of neutrophils but rather 
eosinophils and basophils.  Eosinophils are known to produce tissue damage in the 
lung of asthmatics through its major protein eosinophil derived neurotoxin (Nicola 
1997). 
Another explanation is that PMN have neutrophils present in the lung of the pig 
treated with IL-1ra lo which could be recruited through by Leukotriene B4 (LTB4) 
through a different pathway (arachadonic pathway) (Taki, Iwata et al., 1988; Atkins, 
Valenzano et al., 1989; Pace, Profita et al., 2004; VanderMeer, Menconi et al., 1995).  
None of the treatments delivered therapeutically after App infection increased weight 
gain. It is apparent in this study that clinical scores were considerably lower than 
those from the previous Chapter and the animals did not get as ill as the previous trial 
in Chapter 4.  Due to infection already being established when treatments were given 
or differences in bacterial virulence between the trials. 
5.5  Experiment  Summary 
· There was no difference in growth found between the treated pigs and saline 
(control) treated pigs. 
144 
COMMERICAL IN CONFIDENCE 
 
· Saline and Excenel treated pigs had significantly less clinical signs and 
suffered less lung damage compared to the remaining treated pigs. 
· Pigs treated with IL-1ra at a low dose suffered the most lung damage 
compared to the remaining treated pigs.  
· IL-1ra lo, IL-4 hi and Excenel treated pigs produced no TNFa mRNA at 48 
hours post infection.  
· Polymorphonuclear cells were found in lung tissue from pigs treated with IL-
1ra lo, IL-4 hi and Excenel treated pigs. 
· The lung tissue of saline, Excenel, IL-4 hi and IL-1ra hi treated pig showed 
presence of IL-8 mRNA. 
· IL-8 mRNA in pigs treated IL-4 hi reduced to an undetectable level at 24 and 
48 hours post infection.  
· In the lymphocyte proliferation assay killed bacteria (KB) was a better stimuli 
in whole blood than ConA, increasing lymphocyte proliferation (Table 5.2). 
· IL-6 was not detected in the peripheral. 
· IL-1ra and IL-4 administrated therapeutically did not have the ability to 
improve growth 
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CHAPTER 6 
GENERAL DISCUSSION 
 6.1 Discussion 
Immunological mechanisms of infection associated with the inhibition of growth in pigs 
were examined in a series of in vivo studies in which App was the infection model.  Both 
local and systemic effects of infection were examined. 
The lung, along with the stomach, urinogenital tract and eye are mucosal surfaces with 
little if any natural bacterial flora, yet on infection these surfaces develop a cytokine 
response to bacterial pathogens (Svanborg et al., 1993).  Svanborg et al., (1993) went on 
to state that stimulation of cytokines is influenced by the amount of interaction between 
bacteria and epithelium.  Agace et al., (1993), Cubitt et al., (1995) and Eckmann et al., 
(1993) found epithelial cells of mucosal surfaces can express and secrete pro-
inflammatory and chemotatic cytokines in response to bacterial infection. 
Epithelial cells in the respiratory tract produce cytokines such as IL-8, IL-6, TNF-α and 
GM-CSF (Khair et al., 1996; Levine 1995) in response to bacterial challenge.  In the 
therapeutic experimental trial (Chapter 5) IL-8 and IL-6 were found in the lung tissue at 
post-mortem. 
Pro-inflammatory cytokines such as TNF-α, IL-1β, IL-8 and IL-6 have been identified as 
being associated with poor growth of pigs (Morrison et al., 2000; Baarsch et al., 1995). 
Other studies have found an association with lung damage in pigs and over-production of 
cytokines (TNF-α and IL-1β) which leads to poor health (Morrison et al., 2000) and 
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growth.  It has also been noted that IL-1β and IL-8 were associated with 
pleuropneumonia severity in pigs (Baarsch et al., 1995). The chemoattractant IL-8 has 
been linked to acute lung inflammation in pigs by Huang et al., (1999). IL-1β and IL-6 
were also found by Arend et al., (1990) to be elevated in systemic juvenile chronic 
arthritis in humans.  For all of the above reasons these pro-inflammatory cytokines were 
of interest and were measured in this study. 
There are several examples of IL-6 and IL-8 production after infection with bacteria. 
Hakansson et al., (1996) showed IL-6 and IL-8 are produced by airway epithelial cells 
due to the attachment of Haemophilus influenzae.  Increased cytokine secretion has been 
shown by bronchial epithelia exposed to Pseudomonas aeruginosa in vitro (Dimango et 
al., 1995; Massion et al., 1994). 
Over production of pro-inflammatory cytokines has been associated with the 
exacerbation of infection and reduced growth.  To gain greater understanding of the 
relevant immune responses in vitro, it was necessary to find a mitogen which produced 
maximal stimulation of pro-inflammatory cytokines.  This would help identify potential 
targets of interest and to test potential therapeutics to treat their effects. 
Small in vitro trials were run (Chapter 3) and once the best inflammatory agent was 
determined, anti-inflammatory cytokines, receptor antagonists and anti-inflammatory 
drugs were tested for their ability to inhibit the production of pro-inflammatory 
cytokines. 
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The mitogens used were PMA, PHA, Con A and LPS and the optimal concentrations of 
these mitogens for maximum stimulation of pro-inflammatory cytokine mRNA were 
determined to be 10µg/mL, while 1x 107cfu/mL of KB was found to be the optimum 
concentration to use for further experiments. 
In vitro experiments in Chapter 3 showed that blood taken from different pigs had 
varying amounts of baseline cytokines. Constitutive amounts of cytokines in the blood 
and tissue have long been established (Mayringer et al., 2000).  The experiments in 
Chapter 3 showed that of the mitogens tested PMA, LPS and KB performed the best by 
stimulating the most pro-inflammatory cytokines. Thus, if an anti-inflammatory cytokine 
or another substance inhibits or reduces the production of pro-inflammatory cytokines in 
blood stimulated by any of these mitogens, then it has potential as a therapeutic or 
prophylactic.  The inhibitory properties demonstrated by anti-inflammatory cytokine IL-4 
and the cytokine receptor antagonist IL-1 (IL-1ra) on the production of IL-8 mRNA in 
Chapter 3 Experiment 3 showed promise. 
In Experiment 3 Flunix or IL-1ra or IL-4 were added to un-stimulated whole blood to 
check if these anti-inflammatory substances inhibited constitutive baseline levels of IL-8 
mRNA.  Flunix and IL-1ra were found to inhibit constitutive levels, interestingly IL-4 
was found to up-regulate IL-8 mRNA production.  This was interesting since the 
stimulation of IL-8 mRNA in whole blood by PMA and LPS was inhibited by IL-4 (low 
dose) to zero.  The medium and high concentrations of IL-4 however, did not inhibit the 
stimulation of IL-8 mRNA by PMA and LPS.  This up-regulation of IL-8 without 
mitogen stimulation by IL-4 can be explained by Nuntaprasert et al., (2005) who found 
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that IL-4 when given with LPS to alveolar macrophages suppressed the secretion of TNF-
α, IL-1α, IL-6 and IL-8.  However when IL-4 was administered before LPS challenge in 
pigs, it increased the severity of respiratory failure and endotoxic shock and increased 
pro-inflammatory cytokines (Nuntaprasert et al., 2005).  Thus IL-4 has the ability of to 
activate or suppress pro-inflammatory cytokines depending on the concentration and time 
of administration. 
The in vitro experiments performed in Chapter 3 and the above studies showed that IL-4 
and IL-1ra needed further in vivo exploration. 
The therapeutic treatments, high dose of IL-4, low dose of IL-1ra and Excenel reduced 
TNF-α mRNA to an undetectable level after 48 hours of App challenge (Chapter 5) 
which may be associated with increased pleurisy and lung damage from 
polymorphonuclear cells aggregating in lung tissue. The increase in pleurisy and lung 
damage may in turn be associated with the reduced growth performance of the pigs 
treated with the above mentioned treatments. 
In contrast, prophylactic delivery of IL-4 and IL-1ra treatment (Chapter 4) did not reduce 
TNF-α mRNA production in pigs challenged with App, yet pleurisy and lung damage 
were reduced greatly below the saline control.  Morrison et al., (2000) found that the over 
production of IL-1β and TNF-α by macrophages in the lung of pigs suffering from an 
App infection was the main factor associated with massive lung injury.  Lung damage 
and clinical scores in pigs treated prophylactically with IL-4 and IL-1ra were greatly 
reduced (Chapter 4).  Pigs treated prophylactically with IL-4 and IL-1ra also produced 
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the fewest cytotoxic cells (CD8) and had reduced mRNA pro-inflammatory cytokines IL-
8 and IL-6.  Baarsch, et al., (1995) found that pro-inflammatory cytokines, particularly 
IL-1 and IL-8, were associated with the development of pleuropneumonia and may 
contribute to disease severity.  A reduction in IL-8 mRNA levels could explain why pigs 
prophylactically treated with IL-4 or IL-1ra had reduced in lung damage and increased 
growth.  IL-8 is known to be a neutrophil recruiter to inflammatory sites (reviewed by 
Standiford et al., 2000; Murtaugh et al., 1996). Lesions in the respiratory tract of pig 
suffering App are made up of neutrophils, macrophages and platelets (Liggett et al., 
1987).This study found white blood cells in the lung and around bronchus of infected 
pigs suffering lesions.  The reduction in IL-8 mRNA by IL-4 or IL-1ra may suppress the 
neutrophil influx into the lung and hence decrease lung damage. However the magnitude 
of IL-4 and IL-1ra must be accurate to produce this affect.  Especially since pigs given a 
high concentration of IL-4 showed presence of IL-8 mRNA producing white cells in their 
lungs.  Lung damage and clinical scores in pigs treated prophylactically with IL-1ra were 
reduced (Chapter 4).  This could be due to the reduction in IL-8 mRNA exhibited in this 
group.  It is known that IL-1ra can inhibit IL-1β by binding to receptor sites on the Th 2 
lymphocytes, thereby stopping signal transduction (Arend et al., 1993).  In view of the 
fact that IL-1β and IL-8 are associated with the severity pleuropneumonia (Baarsch et al., 
1995), and IL-1β and α also stimulate the production of IL-8 by macrophages (Tizard 
1996). Hence IL-1ra may be able to not only reduce IL-1β, but also IL-8.  IL-1ra can also 
directly influence the production of IL-8 since it was found by Chen et al., 1998 that IL-
1ra inhibited IL-8 in an in vitro system (squamous cell carcinoma human cell line). 
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Prophylactically delivered IL-1ra and IL-4 not only reduced the production of IL-1β 
mRNA in the pigs peripheral blood, they also inhibited or reduced the production of 
TNF-α mRNA in peripheral blood.  Lee et al., 1995 also observed IL-4 ability to down 
regulate the amount of IL-1β, TNF-α and IL-6 mRNA expression by human peripheral 
blood mononuclear cells (PBMC) stimulated with LPS and IL-2.  Prophylactic delivery 
of IL-4 to pigs similarly showed a reduction in TNF-α mRNA after LPS challenge 
(Chapter 4).  Pigs treated prophylactically with IL-4 and IL-1ra also reduced IL-8 and IL-
6 mRNA in peripheral blood in response to the App challenge (Chapter 4).  Similarly Lee 
et al., (1995) found that IL-4 stimulates IL-4ra while inhibiting the production of IL-1 
and TNF-α by monocytes.  In Chapter 4, both IL-1ra and IL-4 reduced the production of 
IL-1β mRNA 24 hours after LPS challenge as compared to the saline control.  Although 
it appeared that the LPS challenge did not produce an effect on growth, it did have an 
affect on cytokine levels.  
Prophylactic delivery of IL-4 and IL-1ra resulted in pigs which out-performed the saline 
controls by gaining the most weight by slaughter (Chapter 4).  The plasmid pig groups 
performed the poorest overall in terms of growth and it would seem that this delivery 
system is not suited to this animal model. 
Pigs with App, when treated therapeutically did not increase in weight compared to the 
saline controls (Chapter 5).  This could be due to the App infection being established 
before the recombinant cytokine (IL-4) and receptor antagonist (IL-1ra) could produce 
their effect.  By giving these treatments at a later stage, the pro-inflammatory cytokines 
were stimulated before they could be suppressed.   
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Even though there were no differences between the therapeutically treated pig groups in 
terms of weight gain there were differences in the leucocyte numbers, pro-inflammatory 
cytokine production and secreted immunoglobulins (Chapter 5). 
The pig group given therapeutic IL-1ra at a low dose performed the worst and these 
animals had low IL-8 mRNA in their peripheral blood as compared to the other pig 
groups by 2 weeks post-App challenge.  Very small amounts of TNF-α and IL-1β mRNA 
were found in IL-1ra (low dose) treated pigs’ peripheral blood as compared to all other 
treatment groups including the saline control.  A review by Standiford et al., 2000 found 
the inhibition of TNF-α can stop bacterial clearing thus presence of TNF-α is essential in 
the control of bacterial pneumonia in mice.  The reduction in IL-8 and TNF-α mRNA 
occurred concurrently with this groups’ lung tissue and lymph nodes producing IL-6 and 
IL-8 mRNA which may have resulted in the very high mean affected lung and pleurisy 
(Chapter 5).  
In response to the App infection undetectable to small amount of TNF-α mRNA were 
produced by pigs treated with IL-1ra (low dose) over time of (48 hours to 2 weeks). The 
production of IL-8 mRNA also reduced 2 weeks after App challenge (Chapter 5).  It 
would be expected that this group (low dose IL-1ra) would perform well and increase in 
health and therefore growth since a reduction in IL-8 (neutrophil chemotactic) implies a 
reduction in neutrophil infiltration to inflamed site (reviewed by Standiford et al., 2000).   
A reduction in TNF-α has been shown to reduce lung damage (Morrison et al., 2000).  
However, too little cytokines can be as damaging as too much.  Standiford et al., 1999 
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found that bacterial clearance and improved survival of Klebsiella pneumoniae 
challenged mice depended on the dose of TNF-α given to the animals. TNF-α is critical 
to antibacterial host defences of mice suffering Klebsiella pneumoniae infection 
(Laichalk et al., 1996).  Therefore the reduction in IL-8 and TNF-α may have been 
associated with the poor health and thus growth performance observed in the current 
studies. 
Immunological stress such as disease cause partitioning of dietary nutrients away from 
growth and skeletal muscle accretion in favor of metabolic processes that support 
immune response and disease resistance (Solomons et al., 1993). By increasing health of 
pigs using IL-4 and IL-1ra as done in these studies, dietary nutrients from feed in-take 
may be directed to growth as seen in Chapter 4.  The negative effects of App infection 
were reduced by IL-4 and IL-1ra and growth was increased. However this was only 
successful if the pigs were given these substances as a prophylactic.  Therefore it can be 
said that these substances delivered as prophylactics reduced the negative effect of 
disease on growth and health and have potential as alternatives to antibiotics. 
The potential for anti-inflammatory treatments to address the deleterious effects of App 
on pig growth were successfully explored.  The data provided in this thesis have 
implications for the future in the development of a product which could be delivered prior 
to housing animals.  The potential also exist for the development of a viral delivery 
system for future application. 
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APPENDIX  
APPENDIX 1- PRIMER SEQUENCES 
 
Primer Gene/Accession Product 
size 
(bp) 
Sequence 5’→3’ CDNA 
Cycles & 
concentration 
IL-1β upper IL-1β M86725 285 aaaggggacttgaagagag 29cycles 
IL-1β lower IL-1β X74568 285 ctgcttgagaggtgctgatgt 2µl cDNA 
IL-6 240 IL-6 M86722 760 catcctcggcaaaatctctg 29cycles 
IL-6 980 IL-6 M86722 760 cctggctctgaaacaacaag 2µl cDNA 
IL-8 U2 IL-8 M86923 565 caccccaaatttatcaaggaactg 29cycles 
IL-8 L2 IL-8 M86923 565 ttggggataaagaagaaactgagg 2µl cDNA 
β-actin upper U07786 233 ggacttcgagcaggagatgg 29cycles 
β-actin lower U07786 233 gcaccgtgttggcgtagagg 1µl cDNA 
TNFα upper M29079  351 atcggcccccagaaggaagag 29cycles 
TNFα lower X54857  351 gatggcagagaggaggttgac 1µl cDNA 
CRP upper c-reactive protein 420 ctcccgccatrrwctcaccaca 29cycles 
CRP lower c-reactive protein 420 actgccvgcrtcrccatag 3µl cDNA 
 
 
R=a+g 
V=a+c+g 
W=a+t 
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APPENDIX 2-Synthesis of cDNA (RT) 
 
Using the Reverse Transcription System by Promega 
1.  Prepare reactions on ice. 
2.  Prepare 10 µl reactions by adding following components (can be scaled up or 
down, but maintain the concentrations). 
 
MASTER MIX for 10ul reaction 
 
Component Amount/sample Final 
concentration 
MgCl2 (25 mM) 2 µl 5 mM 
Reverse transcription 10X buffer 1 µl 1X 
10 mM dNTP mixture 1 µl 1 mM dNTP 
RNase Inhibitor 0.25 µl 1 U/µl 
AMV reverse transcriptase 0.3 µl (15 U) 15 U/µg 
Oligo(dT) primer 0.5 µl (0.5 µg) 0.5µg/µg RNA 
   
RNA  0.5 µg  
Nuclease Free Water to a final volume of 10 µl. 
 
Everything is constant – regardless of RNA concentration, every sample receives 
5.05ul MasterMix.  The only components that vary are RNA and water.  Water is 
required to make up the final volume to 10ul. 
 
3.  Use Excel table to determine RNA concentration as ug/ul.  The ul RNA 
required for RT reaction = 0.5ug x1ul/RNA concentration (the excel table will 
calculate it for you) 
4.  Incubate reactions at 42 °C for 1 hr, followed by  5 min at 95 °C. (program 18 
on the Omnigene thermal cycler) 
5.  Remove tubes/plate to 20oC. 
6.  Once cool, dilute the reaction  1/5 in Nuclease Free Water.  We do 10ul 
reactions, so add 40ul water. Eg: 
7.  Store tubes in –20 until used in PCR. 
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APPENDIX 3-PCR COMPONENTS 
Perform this procedure on ice in the PCR hood. 
 
Make mastermix: 
For a 25 µl reaction place the following components per tube (use PCR 
omnistrips or 384 well plate): 
Component Amount per reaction Final concentration 
RedTaq 10Xbuffer/ 
MgCl2 (15 mM) 
2.5 µl 1.5 mM 
PCR mix (10 mM dNTP) 0.5 µl 100 µM 
RedTaq Polymerase  1.25ul  
Upper primer* 1 µl 50 pmol total 
Lower primer* 1 µl 50 pmol total 
H2O     Add to make up to 25ul 
   
cDNA approx 1 µl  
*When using CRP, add primers at 0.5ul/reaction and thus, increase water by 1ul. 
 
Additives: 
Certain PCR reactions require the following additives (to adjust for this the 
amount of water added is changed).  
 
Primers Additive Amount Percentage 
in reaction 
Amount of 
water in 
reaction 
IL-1β 4% Glycerol 1.56µl 0.0624% 
HAP DMSO 2.5 µl 10% 
change 
accordingly 
 
cDNA: 
Primer name Primer volume (µL) cDNA volume (µL) 
β-act 1 1 
IL-8 1 3 
IL-6 1 2 
IL-1β 1 2 
TNFα 1 3 
CRP 1 2 
Water was adjusted to have a final volume of 25µL  
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APPENDIX 4-RNA Isolation 
Using the SV RNA Isoation kit by Promega 
 
Before you start, turn water bath to 70°C. 
 
1. Add 500µl blood to 1.5ml eppendorf tube 
2. Add 900µl red blood cell lysis solution (RBC Lysis) and mix by inverting. 
3. Incubate at room temp for 10 mins (invert tubes at 5 mins) 
4. Centrifuge at 20,000 g for 20 seconds; discard supernatant by tipping the 
tube. You should see a white spot in the middle of a red pellet. 
5. Add 175µl of SV RNA lysis buffer and mix 
6. Add 350µl SV RNA dilution buffer (blue) and mix 3-4 times.  
7. Put into water bath for exactly 3 mins (exceeding this time causes RNA 
degradation). 
8. Put tubes on ice for 1 min. 
9. Centrifuge at 20,000 g for 10 mins.  Transfer the supernatant to a new 1.5m 
eppendorf using a P200.  Pipette slowly and carefully so that you do not 
disturb the protein pellet.  The supernatant may be yellow at this stage which 
is OK. 
10. Add 200µl cold 95% ethanol to each tube (containing supernatant).  Mix by 
inverting. 
11. Remove a ‘column assembly’ from the packet and add to the column (the 
top bit) the supernatant from step 11. 
12. Centrifuge at 13,000 g for 1min. 
13. Disconnect column from collection tube – discard the liquid in the collection 
tube. 
14. Reattach the column to the collection tube.  Add 600µl SV RNA wash 
solution to the column. 
15. Centrifuge at 13,000 g for 1 min. 
16. Make up DNase solution fresh: (per sample requirements)  
40µl of Yellow Core Buffer,  
5µl 0.09M MnCl2
5µl DNase-1 enzyme 
17.  Remove columns from centrifuge.  Discard the liquid in the collection tube. 
18. Add 50µl DNase solution to each column. 
19. Incubate at room temp for 15 mins. 
20. Add 200µl DNase stop solution. 
21. Centrifuge at 13,000 g for 1 min.  (do not empty collection tube) 
22. Add 600µl SV RNA wash solution to the column and centrifuge at 13,000 g 
for 1 min. 
23. Discard the liquid in the collection tube. 
24. To the column, add 250µl SV RNA wash solution. 
25. Centrifuge at 15,000g for 2 min. 
26. Attach the column to a labelled 1.5ml eppendorf (elution tube in the kit).  
You can now discard the original collection tube. 
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27. Add 100µl DEPC water to the column.  Spin at 20,000 g for 1 min. 
28. Remove the column and throw it away.  Your RNA is in the eppendorf. 
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APPENDIX 5-PCR product purification  
Using Wizard PCR prep from Promega 
 
This method is to purify PCR products for sequencing, or to create pure PCR 
positive controls for running on gels. 
 
Perform the PCR in room 220 wearing gloves and coat.  Then, perform the 
purification in the main lab, wearing gloves and coat.  Use baked/autoclaved 
labwear. 
 
Use at least 30µl of a PCR reaction for purification (generally use a 50 µl 
reaction, ie., double the volume of a normal PCR). 
 
1.  Run PCR. 
2.  Transfer the PCR reaction to a 1.5 ml eppendorf tube.  Add 100 µl Direct 
Purification Buffer and vortex briefly. 
3.  Add 1 ml of Resin and vortex briefly 3 time over a period of 1 min. 
4.  Prepare a Wizard PCR prep column/Syringe barrel assembly (from the 
Wizard Miniprep kit).  Insert column into the vacuum manifold (the blue pig).   
 
 
blue pig
to vacuum
column
syringe
Reminder!! 
Don’t forget to take 
your tips and 
pipettes! 
5.  Pipette the resin/PCR mix into the syringe barrel.  Apply vacuum to draw the 
resin/PCR mix into the Minicolumn. 
6.  Break the vacuum to the Minicolumn by separating the tube connection to the 
vacuum pump.  Pipette 2 mls of 80% isopropanol to the syringe barrel and 
reapply the vacuum until the isopropanol has been drawn through the 
Minicolumn.  Continue to apply vacuum for exactly 30 seconds (use a 
timer!!!) after the isopropanol has been drawn though. 
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7.  Transfer the Minicolumn to a clean 1.5 ml eppendorf tube (you will need to 
snip off the lid of the epp).  Centrifuge at 10 000 G for 2 mins.  Discard the 
tube. 
8.  Elution:  Transfer the Minicolumn to a clean 1.5 ml eppendorf tube with lid.  
Add 50 µl of DEPC water to the top of the column.  Wait for at least 1 min (not 
longer then 30 mins) and then centrifuge at 10 000 G for 20 secs to elute the 
DNA.  DNA is left in the tube. 
9.  Store the DNA at -20°C. 
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APPENDIX 6-DNA ligation 
using the pGEM-T easy Vector System II by Promega  
 
This is a method to stick PCR products (or other sources of DNA) into plasmids. 
 
1. Set up ligation reaction as follows  
 
T4 DNA Ligase 10X buffer 1 µl 
Vector DNA (Plasmid) 50 ng (1 µl pGEM®-T Easy Vector) 
Insert DNA (eg PCR product) X µl 
T4 DNA Ligase  1 µl 
DEPC Water To a final volume of 10 µl 
 
2. Mix reaction by pipetting up and down and incubate overnight at 4°C. 
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APPENDIX 7-Transformation 
 
Transformation refers to inserting the plasmid vector into a cell for replication. 
 
Perform this method in the molecular lab (room 220).  Ensure the plates are 
prepared beforehand. 
 
Before you start:  
1. Equilibrate 3 LB/ampicillin plates to room temperature per ligation. (if pGEM®-
T Easy ligation then the plates are LB/ampicillin/IPTG/X-gal.  Add 100µl IPTG 
and 20µl X-gal to each plate.)  If using pQE vector, you don’t need to add 
IPTG/X-gal).  Leave to absorb at 37°C for 30mins. 
2. Remove JM109 cells from -70°C and thaw on ice (about 5 mins).  Flick tube 
to mix cells.  Heat water bath to 42°C. 
 
Transformation: 
3. Centrifuge the tube containing the ligation reaction.  Add 2µl of the reaction to 
a 1.5µl eppendorf tube on ice.  
4. Add 50µl of JM109 cells to the eppendorf.  
5. Flick the tube and place on ice for 20 mins. 
6. Heat shock the cells by placing at exactly 42°C for 40-50 seconds in water 
bath. 
7. Return tubes to ice for 2 mins. 
8. Add 900µls of SOC medium. 
9. Incubate for 1.5 hrs at 37°C with shaking (150 g). 
10. Plate out 5 µl, 100 µl and the rest of the transformation on the plates prepared 
in step 1. 
11. Incubate plates at 37°C overnight. (if using pGEM®-T Easy vector the white 
colonies contain the vector with the insert). 
12. Pick up a colony (using a loop/toothpick) and grow up overnight in 10 ml of LB 
broth containing 20µl of 50 mg/ml ampicillin (final concentration =100ug/ml). 
 
Screen for the presence of insert by PCR: 
• add 5 µl of culture to a 50 µl PCR reaction.   
 
Alternative: 
• Purify the plasmid by running the culture through a Miniprep. 
• Restriction digest the plasmid with enzyme/s that cut out the insert. 
• Run on an agarose gel. 
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• If the insert is cut out, you will get more than 1 band in the gel.  The 
target should occur around its usual PCR product size. 
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APPENDIX 8-Buffer Recipes - Transformation 
 
IPTG stock solution 
1.2g IPTG, made up to 50ml with sterile milliQ water. 
Filter sterilise. 
Store at 4°C. 
 
LB Medium (1L) 
10g bacto-tryptone 
5g bacto-yeast extract 
5g NaCl 
pH 7.0 and autoclave 
 
LB plates with Ampicillin 
Add 15g agar to 1L LB medium.  Allow the medium to cool to 50°C. 
Add ampicillin to a final concentration of 100µg/ml. 
Pour 30-35ml of medium per 85mm petri dish and allow to set. 
Store at 4°C up to 1 month. 
 
2M Mg2+ stock 
MgSO4.7H20  2.46g 
MgCl2.6 H20  2.033g 
make up to 10ml with sterile water and filter 
 
SOC medium 
• 2g bacto-tryptone 
• 0.5g bacto-yeast extract 
• 1ml 1M NaCl 
• 0.25ml 1M KCl 
Add to 97ml distilled water.  Stir, autoclave and return to room temp. 
 
• 1ml 2M Mg2+ stock 
• 1ml 2M glucose 
make up to 100ml with autoclaved water 
check that pH = 7.0 
sterile filter through 0.2µm filter 
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APPENDIX 9- Zymosan - FITC labeling and serum opsonization 
 
 
FITC-labelling zymosan 
 
100mg zymosan 
10ml carbonate buffer, pH 9.5 (30ml 1M Na2CO3, 70mls 1M NaHCO3, 900mls 
dH2O) 
300µg FITC (ie 30µg FITC/ml) 
 
Mix zymosan and buffer on vortex.  Check pH with litmus paper.  Add FITC and 
roll/mix for 2hrs. 
Wash 2x in buffer, 1200rpm , 5mins, room temp. 
Wash 2x in PBS. 
Dilute to 200ml in PBS. 
Check fluorescence under the fluorescent microscope. 
Aliquot into 20ml lots in 50ml centrifuge tubes wrapped in foil. 
 
(0.5mg zymosan/ml is approximately 1500 X106 particles/ml) 
 
 
 
 
Opsonising FITC-labelled Zymosan 
 
NB:  Maximum amount of zymosan opsonised is 5mg/ml of serum 
 
20 ml tube of FITC-zymosan at 0.5mg/ml 
Add 10ml serum 
Roll/agitate for 45 min at 37oC.  Keep dark/in foil. 
Spin at 800g (2000 rpm) for 10 min at room temperature.  Discard the 
supernatant. 
Resuspend the pellet to 20 ml in PBS.  Retain as serum opsonised FITC-
zymosan and aliquot in 5ml and 1ml lots.  Store at -20oC.
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